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GWAS Genome wide association studies 
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HDL-C High-density lipoprotein cholesterol 
HEARTS Heart-disease Evidence-based Audit & Research 
Tayside Scotland 
HIC Health Informatics Centre 
HMM Hidden Markov model 
HPC high performance cluster  
HWE Hardy-Weinberg equilibrium 
IBD Identical by descent 
ICD International Classification of Diseases 
IFN-ƴ Interferon gamma 
IGF-1 Insulin like growth factor 
IL-1 Interleukin 1 
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IMI Innovative medicines initiative 
IS Ischaemic stroke 
ISGC The international stroke genetics consortium  
LDL-C Low density lipoprotein cholesterol 
LEAD Lower extremity arterial disease 
MCP-1 Monocyte chemo attractant protein 1 
MGP Matrix Gla protein  
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PDGF Platelet derived growth factor 
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(SUMMIT) 
T1DM Type 1 diabetes 
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TGF-ß Transforming growth factor beta 
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Summary 
The aim of this thesis was to identify genetic determinants associated with 
cardiovascular disease. We developed and verified algorithms to identify Coronary 
artery disease (CAD) , ischaemic stroke (IS) and lower extremity arterial disease (LEAD) 
cases and controls from electronic medical record data linked to Genetics of Diabetes 
and Audit Research Tayside Scotland cohort. We showed that these could be used in 
the discovery of novel genetic variants by replicating known signals in the LPA and the 
9p21 region. We also identified unique associations of genetic scores for type 1 
diabetes and triglycerides with the derived cardiovascular phenotypes. We used the 
derived CAD phenotype to contribute towards a large scale meta-analysis of CAD that 
led to the discovery of 15 new loci for CAD. A genetic score, that combined all the SNPs 
that passed a false discovery rate of 0.5% in the CAD meta-analysis, was not more 
predictive of CAD low density lipoprotein and high-density lipoprotein cholesterol. We 
found that a genetic score for decreasing 25-hydroxy vitamin D was associated with an 
increased risk of CAD. The effects of the genetic score suggested that there is a causal 
relationship between low 25OHD levels and increased CAD risk. A meta-analysis of CAD 
in patients with type 2 diabetes identified two independent signals in ADAMTS7 
associated with CAD at genome wide significance. Tests for heterogeneity of allelic 
effects for known CAD loci showed significant heterogeneity for signals in the 9p21 
region, ADAMTS7, ABO, and VEGFA. A meta-analysis of LEAD replicated known 
associations in the 9p21 region and a known locus for nicotine dependence CHRNA3. A 
smoking interaction analysis identified signals in ADAMTS17 that interact with smoking 
status to increase the risk of LEAD in non-smokers. We identified novel loci for CAD 
and putative loci for CAD in patients with T2D and LEAD with further analysis and 
replication required to establish these loci. 
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Chapter 1: Introduction 
1.1 Cardiovascular disease 
Cardiovascular disease (CVD) has many underlying aetiologies which include 
atherosclerosis, aortic stenosis, left ventricular hypertrophy and cardiomyopathy. The 
most common cause of CVD in the Western world is atherosclerosis of blood vessels in 
different parts of the vascular system. Cardiovascular diseases caused by 
atherosclerosis encompass coronary artery disease (CAD), ischaemic stroke (IS) and 
lower extremity arterial disease (LEAD). IS is caused by occlusion of blood vessels that 
supply the brain with blood; CAD in most cases results in myocardial infarction (MI) 
that occurs as the result of a coronary artery becoming blocked following the rupture 
of an atherosclerotic plaque8 and LEAD is a chronic disease where the major vessels of 
the lower extremities become lined with atherosclerotic plaques and become 
progressively occluded9.  
Type 2 diabetes (T2D) increases the risk of CAD 2-3 fold in the general population10 and 
is even higher in individuals who have T2D. T2D individuals are at much greater risk of 
CAD, LEAD and IS10, 11 where CVD complications account for half the deaths in patients 
with T2D12. It has been reported that the incidence of atherosclerosis is 3-4 fold higher 
in the T2D population compared to non-diabetic individuals13, which is largely 
attributed to insulin resistance. Hyperinsulinemia causes natural metabolic processes 
to become imbalanced which has a knock on effect in other pathways. Circulating 
levels of glucose and triglycerides increase which leads in time to dyslipidaemia14, 15. 
This places a large amount of stress on the endothelium and eventually the 
endothelium becomes dysfunctional and the atherosclerotic process begins14, 15. 
1.2 Atherosclerosis 
Atherosclerosis is a progressive multifactorial disease characterised by the 
accumulation of lipids and fibrous elements in the large arteries16, 17. Early 
atherosclerosis is characterised by the development of atherosclerotic lesions and four 
main processes are involved their formation: accumulation of lipids, free cholesterol 
and esterified cholesterol in the matrix of the intima; proliferation and chemo-
attraction of smooth muscle cells (SMC), macrophages which leads to the formation of 
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foam cells; the release of inflammatory markers and synthesis of a connective tissue 
matrix by SMCs18, 19; and finally SMC proliferation to form a fibrous cap.  
 
Figure 1-1: Structure of artery and vein walls where the endothelium is the barrier between 
blood and tissue. 
1.2.1 Accumulation of lipid particles 
The first step in atherosclerosis is the accumulation of lipid particles in the media 
(Figure 1-1). Two main theories have been proposed to explain the initiating step of 
atherosclerosis: the “response-to-injury” hypothesis proposed by Ross et al., 1977 and 
the “response-to-retention” hypothesis proposed by Williams et al., 1995. Both 
theories indicate that forces acting on the endothelium (Figure 1-1) are responsible for 
the initiation of atherosclerosis.  
1.2.1.1 Response-to-injury 
The Response-to-injury hypothesis proposes that the development of atherosclerotic 
lesions is a result of injury to the endothelium. Injury to the endothelium may be 
caused by shear stress caused by the flow of blood through the vessel or may be 
caused by biochemical agents in the blood such as lipids, Homocysteine and uraemia. 
Infections and immunologic injury have also play a role in endothelial injury20. Injury to 
the endothelium causes changes in the morphology of the endothelial cells, which 
prevents the cells from forming a continuous layer. Injury may result in the loss of 
endothelial cells from the endothelial layer and subsequent exposure of the underlying 
collagen that is then bound by platelets.  
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The endothelium becomes permeable to platelet derived factors and lipoproteins and 
these infiltrate the endothelium and migrate through to the media. This invasion of 
particles causes the vascular SMCs to migrate into the media and to proliferate. The 
SMCs also produce new connective tissue which increases the deposition of extra 
cellular lipids causing the lesion to enlarge. Repeated injury leads to larger 
atherosclerotic plaques that may hinder blood flow20.  
1.2.1.2 Response-to-Retention  
The “response-to-injury” theory has been superseded by the “response-to-retention” 
hypothesis which proposes the retention of lipids as the first step of atherosclerosis. 
This theory is a plausible explanation as atherosclerotic plaques are often covered by 
an intact endothelial layer21. 
Transport of low density lipoprotein cholesterol (LDL-C) into and out of the media 
takes place naturally across a healthy endothelium. Some of the LDL-C is retained in 
the media while some is released back into the blood stream. When there are normal 
serum levels of LDL-C in the blood stream the rate of LDL-C influx does not exceed the 
rate of efflux and only small amounts of LDL-C are retained. When serum levels of LDL-
C are high more LDL-C particles are retained in the extra-cellular matrix than are 
released back into the blood stream. The LDL-C particles are bound to proteoglycans22 
by apoB which is found in both LDL-C and lipoprotein (a) 21. LDL-C retention is also 
increased by lipoprotein lipase which is produced by the endothelial cells increases the 
uptake of lipoproteins from the blood stream.  
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Figure 1-2: Schematic of atherogenesis and an unstable atherosclerotic plaque23 
1.2.2 Foam cell formation 
Once lipids are bound to the extra cellular matrix either through retention or as a 
response to injury it stimulates a number of biological pathways to produce an 
atherosclerotic lesion. Retained LDL-C is oxidised by oxidising species that are naturally 
produced by healthy cells surrounding the media. The oxidation of LDL-C causes the 
endothelial cells and the vascular SMCs to express monocyte, T-lymphocyte and SMC 
chemoattractants21 such as colony stimulating factors (CSF), monocyte chemo 
attractant protein 1 (MCP-1) and transforming growth factor beta (TGF-β). 
The oxidised LDL-C (oxLDL) is taken up by macrophages and by vascular SMCs (Figure 1-
2). The oxLDL is mainly bound by two scavenger receptors, SR-A and CD36, expressed 
on the surface of macrophages. The oxLDL is ingested by the macrophages and they 
become foam cells. The foam cells stimulate proliferation, migration of vascular SMCs 
and release of proteoglycans and lipoprotein lipase from the SMCs21. This increases the 
amount of LDL-C that is retained in the media. As the amount of retained LDL-C 
increases the diseased area expands into an atherosclerotic lesion22.  
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1.2.3 Inflammation 
LDL oxidation stimulates the endothelium to produce a number of pro-inflammatory 
markers like interleukin 1(IL-1), tumour necrosis factor alpha (TNF-α), interferon 
gamma (IFN-γ) and interleukin 2 (IL-2) with the CSF as well as adhesion molecules and 
growth factors24. The pro-inflammatory markers attract monocytes and leukocytes to 
the lesion (Figure 1-2). Adhesion molecules expressed by the endothelial cells allow the 
monocytes to bind the endothelium and invade the media21. As well as initiating the 
release of pro-inflammatory markers, oxidised LDL can also inhibit the production of 
nitric oxide by the endothelial cells that causes endothelial dysfunction. 
1.2.4 Endothelial dysfunction 
The endothelium plays an important role in maintaining vascular health as it function 
as a selective barrier to the diffusion of macromolecules from the lumen to the 
interstitial space; and through the production of nitrous oxide (NO), regulates vascular 
tone; modulates inflammation; promotes and inhibits of vascular growth and 
modulates platelet aggregation25. Any process which causes endothelial dysfunction 
has a large impact on the health of the blood vessel and plays a role in the 
development or acceleration of atherosclerosis. Oxidised LDL-C and the production of 
reactive oxygen species contribute to endothelial dysfunction. 
NO has many anti-atherosclerotic properties and acts on the endothelium and SMCs to 
prevent atherosclerosis. NO interacts with prostacyclin to inhibit platelet aggregation 
and inhibits the adhesion of neutrophils to the endothelium. NO in high concentrations 
also inhibits the proliferation of smooth muscle cells. So under conditions of 
endothelial dysfunction atherosclerotic processes are accelerated (Figure 1-2). 
Inflammatory cells such as macrophages, monocytes, neutrophils and lymphocytes can 
infiltrate into the media and the proliferation of SMCs is not regulated25.  
1.2.4.1 Measuring endothelial dysfunction 
Endothelial dysfunction can be clinically assessed in coronary or peripheral arteries 
and or arterioles via intracoronary or intrabrachial infusion of the endothelium with 
acetylcholine. Non-invasive techniques can also be used such as flow mediated dilation 
of the brachial artery, finger-pulse plethysmography or by pulse curve analysis25.  
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1.2.5 Fibrous cap formation 
The final stages of atherosclerotic plaque maturation is characterised by the formation 
of a thin fibrous cap that covers the atherosclerotic plaque. Fibrous plaques are 
characterised by a growing mass of extracellular lipid, by the accumulation of SMC’s 
and SMC derived extracellular matrix. SMCs are stimulated to migrate into the 
atherosclerotic lesion by platelet derived growth factor (PDGF) and insulin like growth 
factor (IGF-1). The migration and proliferation of SMCs causes the fatty streak to 
expand into a plaque. The plaque is stabilised by a fibrous cap made up of SMCs24 
(Figure 1-2).  
The expanding plaque convolutes the luminal surface of the artery26, 27 and hinders 
blood flow. During the advanced stages of atherogenesis the lesions become 
vascularised. Fissuring, cracking or ulceration of the plaque can lead to a haemorrhage 
from the lumen or from small vessels26, which may manifest as an MI or an IS.  
1.2.6 Atherosclerosis and type 2 diabetes 
Atherosclerosis is accelerated in patients with insulin resistance, metabolic syndrome 
and T2D28, 29. The main causes are A-FLIGHT toxicity (Table 1-1) which cause injury to 
the vascular wall or where atherosclerosis is already present accelerate plaque 
formation. Individuals who suffer from insulin resistance, metabolic syndrome and T2D 
have increased levels of circulating reactive oxygen species which decreases the half-
life of nitric oxide 25. Patients with T2D have higher levels of circulating lipids which 
leads to increased retention of these particles in the media. They also have higher level 
of advanced glycation end products and may also suffer from hypertension increasing 
the chances of injury to the endothelium. which can cause the oxidation of lipids16. 
These factors combine with already present chronic inflammation to increase the 
amount of atherosclerosis present in the blood vessels28, 29. 
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Table 1-1: The manifold toxicities of insulin resistance, metabolic syndrome and type 2 
diabetes mellitus28, 29. 
A-FLIGHT toxicities
A 
Antioxidant reserve compromised 
Absence of antioxidant network 
Ageing 
F Free fatty acid toxicity 
L 
I 
Inflammation toxicity 
G 
H Hypertension toxicity 
T Triglyceride toxicity 
Amylin  (hyperamylinemia)/amyloid toxicity 
Ang II (also induces PKC)
AGEs/AFEs (advanced glycosylation/fructosylation endproducts)
Angiogenesis (induced redox stress) Arteriogenesis (impaired PAI-1)
Atherosclerosis – Atheroscleropathy. [ROS beget ROS] 
Lipotoxicity 
Insulin toxicity (hyperinsulinemia-hyperproinsulinemia) (endogenous)
Glucotoxicity (compounds peripheral insulin resistance) reductive
stress Sorbitol / polyol pathway
Pseudohypoxia (NADH/NAD increased) PKC
t homocysteine toxicity 
 
1.3 Genetics of Cardiovascular disease 
1.3.1 Coronary artery disease 
CAD occurs when the coronary arteries become narrowed or blocked by 
atherosclerotic plaques causing a lack of blood flow to the heart. This process can 
manifest itself as clinical symptoms in the form of shortness of breath, fatigue and 
general weakness as the heart is not pumping enough blood around the body. 
Narrowing of the blood vessels can cause angina pectoris that manifests as chest pain; 
blockage of the coronary arteries can result in an MI. An MI is irreversible necrosis of 
the heart muscle where lack of blood flow deprives part of the heart muscle of 
nutrients and oxygen resulting in damage and apoptosis of the heart muscle cells. 
Stenosis of the coronary arteries can be treated with different drugs or by 
interventions in the form of percutaneous coronary intervention (PTCA), where a stent 
is inserted at the site of the stenosis. The stenosis can also be bypassed by coronary 
artery bypass grafting (CABG) where blood vessels are harvested from other parts of 
the body and grafted onto the affected artery to bypass the blocked section of the 
coronary artery. 
CAD is the leading cause of death worldwide and is the main macrovascular 
complication of T2D30. According to the British Heart Foundation, coronary artery 
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disease is the cause of premature death of 1 in 5 men and 1 in 7 women in the United 
Kingdom with the highest death rate in Scotland. The American Heart Association 
reports similar results in the United States of America where it is the main cause of 
death for 1/3 of deaths that occur. T2D is thought to affect 8.5% of the world 
population and more than 50% of individuals suffering from diabetes will succumb to a 
vascular complication of which the majority are cardiovascular. The heritable 
component of CAD has been estimated at between 40 and 50 % in twin and family 
studies31 but large-scale genetic studies have only explained a small amount of the 
heritability.  
1.3.2 The genetics of coronary artery disease 
Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis32 32 is a 
consortium that has been formed to investigate the genetic determinants of CAD and 
myocardial infarction33. CARDIoGRAM incorporates published and unpublished 
genome wide association studies (GWAS) studies from Atherosclerotic Disease 
VAscular functioN and genetiC Epidemiology study34-37, CADomics38, Cohorts for Heart 
and Aging Research in Genomic Epidemiology39, deCODE 40, the German Myocardial 
Infarction Family Studies I, II, and III 41, Ludwigshafen Risk and Cardiovascular Health 
Study/AtheroRemo42, MedStar43, Myocardial Infarction Genetics Consortium44, Ottawa 
Heart Genomics Study45, PennCath46, and the Wellcome Trust Case Control 
Consortium47 amounting to data on over 22000 CAD cases and 60000 CAD free 
controls33.  
There are 25 loci that have been reported at genome wide significance for CAD by 
Schunkert et al., 2011 for CARDIoGRAM and another six by other consortia38, 44, 48-52. 12 
of the loci had been published in previous studies by members of CARDIoGRAM, 13 
loci were identified by combining the data across CARDIoGRAM (Figure 1-3) and 6 by 
other consortia which include the IBC CAD consortium. The 25 loci identified in the 
CARDIoGRAM study48 explain about 10% of the total heritability of CAD48. The CAD 
associated SNPs are found in genes that also contain signals for associated risk factors 
such lipid metabolism, blood pressure, glucose homeostasis, chemotaxis and in other 
genes that are involved in regulating cell growth and cycle(Table 1-2). The genetic 
determinants have clear roles in atherosclerosis: OxLDL is the main component of 
atherosclerotic plaques26 as many of the genes associated with CAD also play a role in 
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the metabolism of LDL-C and other signals are found in genes that affect cell adhesion, 
migration, cell death and cellular matrix formation may have roles in the formation 
and stability of atherosclerotic plaques (Table 1-2).  
Figure 1-3: A Manhattan plot taken from Schunkert et al., 2011 annotated for 
previously described CAD loci (red) and those that were reported as new loci (blue). 
Data from the discovery phase are shown in circles, and data from the combined 
discovery and replication phases are shown in stars48. 
32 
 
 
Table 1-2: Thirty one loci have been identified by the CARDIoGRAM consortium, the 
IBC CAD consortium and in other smaller studies have a number of different biological 
functions and the genes contained signals for other phenotypes32, 38, 44, 48, 50-52. 
 
Locus SNP Closest Gene 
Biological 
function 
Other 
phenotypes 
1p32.3 rs11206510 PCSK9 
Lipid 
homeostasis 
LDL- C levels53 
1p13.3 rs599839 SORT1 
Lipid 
homeostasis 
LDL-C and 
TC54 
1q41 rs17465637 MIA3   
2q33.1 rs6725887 WDR12 
Ribosome 
biogenesis and 
cell 
proliferation55 
 
3q22.3 rs2306374 MRAS 
Cell growth and 
differentiation56 
 
6p24.1 rs12526453 PHACTR1 
Endothelial cell 
death and tube 
formation57 
 
6q25.3 rs3798220 LPA 
Lipoprotein A 
levels58 
 
7q22 s10953541 Gene desert   
9p21.3 rs4977574 CDKN2A, CDKN2B  Glioma59 
10q11.21 rs1746048 CXCL12 
Lymphocyte 
activation 
Cancer60 
12q24.12 rs3184504 SH2B3 Cell signalling61 
Type 1 
diabetes62; 
Blood 
pressure63 
19p13.2 rs1122608 LDLR 
Lipid 
homeostasis 
LDL-C levels64 
21q22.11 rs9982601 MRPS6 Mitochondrion 
ribosome 
Respiratory 
function65 
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Locus SNP Closest Gene 
Biological 
function 
Other 
phenotypes 
protein 
1p32.2 rs17114036 PPAP2B 
Cell migration 
and adhesion66 
 
6p21.31 rs17609940 ANKS1A   
6q23.2 rs12190287 TCF21 
Transcription 
factor 
Lung cancer67 
7q32.2 rs11556924 ZC3HC1   
9q34.2 rs579459 ABO  
E-selectin68; 
Depression69; 
Erythrocyte 
indices70 
10q24.32 rs12413409 CYP17A1,CNNM2, NT5C2 
Epithelial 
transport, 
purine 
metabolism. 
Blood 
pressure71; 
Schizophrenia 
11q23.3 rs964184 ZNF259, APOA5-A4-C3-A1 
Lipid 
homeostasis54 
Metabolic 
syndrome73; 
Triglycerides64 
13q34 rs4773144 COL4A1, COL4A2 
Stability of 
basement 
membranes74 
Cerebral small 
vessel 
disease74 
14q32.2 rs2895811 HHIPL1   
15q25.1 rs3825807 ADAMTS7 Degrades 
cartilage matrix 
protein75 
 
15q25.1 Rs4380028 ADAMTS7  
17p13.3 rs216172 SMG6, SRR 
Telomerase 
stability 
Aorta76; Type 
2 diabetes77 
17p11.2 rs12936587 RASD1, SMCR3,PEMT 
Cell 
morphology 
and growth 
 
17q21.32 rs46522 UBE2Z, GIP, ATP5G1, SNF8 
Glucose 
homeostasis 
 
10q23.2 rs1412444 LIPA 
Lipid 
homeostasis 
 
11q22.3 rs974819 PDGFD Cell migration78  
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Locus SNP Closest Gene 
Biological 
function 
Other 
phenotypes 
10p11.23 rs2506083 KIAA1462 Cell adhesion79  
19q13.2 rs2075650 ApoE-ApoC1 
Lipid 
homeostasis 
C-reactive 
protein80 
 
Large studies need to be conducted to identify variants that explain the missing 
heritability of CAD. Although diabetes is a large predictor of CAD risk13 the two 
diseases do not share any common genetic determinants48. Analyses to identify genes 
that specifically determine CAD in T2D individuals and in non-diabetic individuals 
separately may provide insights into the role of T2D in CAD.  
1.3.3 Ischaemic stroke 
Ischaemic stroke is a broad description of a number of stroke subtypes that have 
different underlying aetiologies. Blockages in the blood supply to the brain cause a 
rapid loss of brain function manifesting in clinical symptoms that include a loss of 
eyesight, motor function and speech. Acute IS can be divided into 5 subtypes: large 
artery atherosclerosis, cardioembolism, small-vessel occlusion, stroke of other 
determined aetiology and stroke of undetermined aetiology. Individuals who suffer a 
large-artery stroke have stenosis (>50%) or occlusion of the main brain artery and 
usually have a history of atherosclerotic disease81. Cardioembolic stroke is due to 
arterial occlusions caused by an embolus arising in the heart. Individuals who suffer 
from atrial fibrillation, sick sinus syndrome, myocardial infarction (less than 4 weeks), 
and left ventricular thrombus are at higher risk of cardioembolic stroke82. Small-vessel 
stroke occurs due to occlusions of the small arteries of the brain. Individuals who 
suffer from small-vessel stroke are usually hypertensive and have diabetes mellitus82. 
Strokes with other determined aetiology do not fit into the above categories but have 
an identifiable reason for the stroke such as haematological disorders and 
hypercoagulable states82. Stroke of undetermined aetiology have no known cause of 
the stroke83.  
1.3.4 The genetics of ischaemic stroke 
The international stroke genetics consortium (ISGC, http://www.strokegenetics.org/) is 
a consortium similar to CARDIoGRAM which combines data from published and 
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unpublished GWAS on stroke. Since the stroke subtypes have such distinct aetiologies 
large genetic studies on ischaemic stroke have been unsuccessful in identifying 
common genetic determinants of ischaemic stroke. Studies that have been targeted at 
identifying variants associated with stroke subtypes have identified the 9p21 region 
associates with large artery stroke84 and variants on 4q22 and 16q22 with 
cardioembolic stroke85, 86. Atherosclerosis of the carotid arteries has also been 
associated with the 9p21 region and is the underlying cause of large artery stroke. PITX 
is known to cause atrial fibrillation87 the underlying cause of cardioembolic stroke , as 
is ZFHX388 (Table 1-3).  
Candidate gene studies have identified loci that correlate with risk factors for IS. APOE, 
LPA and eNOS are associated with atherosclerotic disease48, 89, 90, the major underlying 
cause of IS91, 92. Other loci that influence blood pressure like ACE and MTHFR are likely 
candidates as one of the predictors of IS is hypertension92. The candidate gene loci also 
include loci that could be linked to drug metabolism like the cytochrome p loci (Table 
1-3). VCKOR1A explains a large proportion of the variation of Warfarin dose an 
anticoagulant commonly prescribed to treat IS93 (Table 1-3).  
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Table 1-3: Candidate gene loci and genome wide association study loci for ischaemic 
stroke 
Study 
Locus 
Gene SNP 
Biological 
function 
Other phenotypes 
Candidate 
genes 
17q23.3 
ACE 94 
Blood 
pressure  
homeostasis 
Response to ACE 
 inhibitors95 
 
13q12 
ALOX5A
P 
rs17216473 
Inflammator
y 
Response 
Asthma96 
 
8q23.1 ANGPT1 rs250780097, 98 Angiogenesis  
 
6q26 
APOA 99 75, 76 
Lipoprotein 
A 
Coronary artery 
disease48 
 
19q13.2 
APOE 100 
Triglyceride  
Metabolism 
C-reactive protein80 
and atherosclerosis90 
 
1q21-23 
CRP 
rs2794521101, 
102 
Host defence C-reactive protein103 
 
1p33 
CYP4AII 104 
Drug and 
lipid 
metabolism 
 
 
19q13.12 
CYP4F2 rs2108622104 
Drug and 
lipid 
metabolism 
Vitamin E105 
 
8q21-q22 
CYPIIB2 
rs1799998106, 
107 
Drug and 
lipid 
metabolism 
 
 
1p22 
DDAH1 108 
Nitric oxide 
Metabolism 
 
 
7q36 
eNOS Rs1799983109 Vasodilation 
Atrial fibrillation110 
and coronary artery 
disease89 
 
1q23 
F5 
LEIDEN 
94
 
Blood 
coagulation 
Venous 
thrombosis111, D-
Dimer112 and P-
selectin69 
 
4q28 
FGB 113 
Blood 
coagulation 
Fibrinogen114, 115 
 
17p3-12 
GP1BA 116 
Blood  
Coagulation 
Platelet 
count70 
 
17q21.32 
ITGB3 117 
Cell adhesion 
and 
signalling 
Glanzmann 
thrombasthenia118 
 
7p21 IL6 119, 120 Inflammation  
 
5q35 
LTC4S rs730012121, 122 
Production 
of 
leukotrienes 
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Study 
Locus 
Gene SNP 
Biological 
function 
Other phenotypes 
 
1p36.3 
MTHFR rs227497694 
Homocystein
e 
methylation 
Homocysteine123 and 
blood pressure63 
 
7p15.1 
NPY rs16147124 
Cardiovascul
ar function 
 
 
7q22.1 PAI-1 125   
 
7q21.3 PAROXO
NASE -1 
rs662126 
Lipid 
homeostasis 
Prevents oxidation of 
HDL in the liver 
 
1p32.3 
PCSK9 rs11206510127 
Lipid 
homeostasis 
Low density 
lipoprotein 
cholesterol53 
 
5q12 
PDE4D 
rs12188950128, 
129 
Signal 
transduction 
Asthma130, sleep131 
and oesophageal 
carcinoma132 
 
11p11 PROTHR
OMBIN 
94
 
Blood  
Coagulation 
 
 
6q23 
SGK1 rs1057293133 
Stress 
response 
 
 
6p21.3 TNF-α 134, 135  Type 2 diabetes136 
 
16p11.2 
VKORC1 rs9923231137 
Blood  
Coagulation 
Warfarin93 
GWAS 
 
9p21 rs4977574126 Cell cycle 
Coronary artery 
disease40 
 
12p13 
NINJ2 
rs11833579138, 
139 
Cell adhesion  
 
14q23.1 
PRKCH 
rs2230500140, 
141 
Cell 
signalling 
 
 
4q25 
PITX2 rs2200733142 
Transcription 
factors 
cardioembolic 
stroke143 
 
16q22.3 
ZFHX3 
rs7193343144 
Cell cycle 
Atrial fibrillation144; 
cardioembolic 
stroke143 
 
7p21.1 
HDAC9 
rs11984041145 Chromosome 
structure 
Body weight146 and 
electrocardiography14
7 
  
 
Candidate gene studies have only included a few hundred IS cases and are 
comparatively smaller than large genome wide association studies. Thus these 
candidate genes need to be confirmed in larger genetic studies. Currently, only 5 loci 
have been identified by genome wide association studies (Table 1-3). This may indicate 
that larger sample sizes are required to identify more variants. It is pertinent to 
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consider that IS is made up of 5 subtypes three of which have well defined and distinct 
aetiologies so GWAS may be more successful if they were focused on the subtypes 
rather than the broader IS phenotype.  
1.3.5 Lower extremity arterial disease 
It has been estimated that lower extremity arterial disease affects between 4.5 and 
12% of the population148,149-151. Prevalence increases with age where it is up to 20% in 
people over 70. The underlying atherosclerotic disease increases the chances of 
mortality from other cardiovascular diseases by six fold152 making it an important 
indicator of CVD death. Coronary artery disease is the main cause of death in 
individuals with LEAD followed by cerebrovascular disease and to a lesser extent by 
other cardiovascular disease such as ruptured aneurysms153-155. The disease is 
characterised by atherosclerotic occlusions of the larger arteries of the lower limbs.  
The most common method of diagnosis is an abnormal ankle brachial index (ABI) 
measurement of less than 0.9 or greater than 1.3. A low ABI usually indicates limb 
ischaemia while an abnormally high ABI is characteristic of vessel stiffening by 
calcification of the media156. Partial stenosis of the large arteries results in intermittent 
claudication and may be exacerbated by exercise. In extreme cases complete stenosis 
of the large arteries completely blocks blood flow, sores and ulcers develop and 
eventually gangrene156. Gangrenous infections are treated by amputating the affected 
limb, while intermittent claudication can be treated using drugs like pentoxifyline and 
cilostazol156. Vascular intervention surgeries can also be used to remove or bypass 
blocked vessels156, 157.  
1.3.6 The genetics of lower extremity arterial disease 
The heritability of ABI has been estimated from family studies to be between 21 and 
30%158. Currently there are only two genome wide association studies that have been 
published for LEAD159, 160. Two signals were identified at genome wide significance: in 
CHRNA3, which is an established locus for nicotine dependence and in the well-
established atherosclerosis locus 9p21 which is associated with CAD and IS48, 160, 161. 
Rs3798220 and rs10455872 in the LPA have also been associated with LEAD in the 
Heart Protection Study162.  
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There are 19 loci which were reported in candidate gene studies; these are listed in 
Table 1-4. The SNPs are found in genes which are linked to blood pressure, blood 
coagulation, cell signalling, lipid metabolism, calcification, inflammation and heart 
disease. ACE, AGT and MTHFR have been associated with blood pressure and 
hypertension63, 95, 163, known risk factors for LEAD164. Vessel calcification is well 
characterised for LEAD so signals in ENPP1, which has been associated with plaque and 
vessel calcification165, 166, are also good candidates. CSMD1 is an established CAD locus 
a risk factor for LEAD164. These associations have not been replicated in large 
populations so their association with LEAD still needs to be confirmed.  
An international consortium of all the GWAS available for LEAD has not been 
established and the meta-analysis published by Murabito et al., 2011, which includes 
3409 LEAD cases from 21 population based cohorts, is the largest collection of GWAS 
data for LEAD to date160. 
 
40 
 
Table 1-4: Nineteen candidate SNPs have been associated with lower extremity arterial 
disease. 
SNP Gene/ Mutation 
Biological 
function 
Other phenotypes 
rs4340 ACE indel167 
Blood pressure  
homeostasis 
Response to ACE 
 inhibitors95 
rs5051 /rs699 AGT 168 C/T169 
Blood pressure  
Homeostasis 
Hypertension163 
rs2554503  CSMD1170 
Carcinogenesis 
171 
Coronary artery disease172 
rs1044498 ENPP1 K121Q173 Calcification 
Plaque and vessel 
calcification165 
166 
rs1801020 F12174 Blood coagulation  
rs6025 F5 1691 G/A169 Blood coagulation 
Venous thrombosis111, D-
Dimer112 and P-selectin69 
rs1800790 FGB -455G/A175 Blood coagulation Fibrinogen114, 115 
rs1800795 IL6 (174 G/C)169 Inflammation  
rs5918 ITGB3169  
Cell adhesion and 
signalling 
Glanzmann 
thrombasthenia118 
rs3918242 MMP9 (-1562 C/T)169 
Extracellular matrix  
Metabolism 
 
rs1801133 MTHFR C677T176 
Homocysteine 
methylation 
Homocysteine123 and blood 
pressure63 
rs1800591  MTTP177 Lipid metabolism 
Non-alcoholic fatty liver 
disease178 
rs2070744 NOS3179 
Vasodilation 
Atrial fibrillation110 
and coronary artery 
disease89 
rs891512 NOS3180 
rs1902341  OSBPL10170 Lipid receptor  
rs11591147  PCSK9 R46L181 Lipid homeostasis 
Low density lipoprotein 
cholesterol53 
rs1805182 Pro12Ala PPARG182 Transcription 
Obesity183, diabetes184 and 
atherosclerosis185 
rs1799963 PT G20210A186 Blood coagulation  
rs235243  VPS13D170 
Vacuolar-protein-
sorting 
 
1.4 Risk factors for cardiovascular disease 
CAD, IS and LEAD share several risk factors which include elevated blood pressure, 
diabetes, fasting glucose, total cholesterol, low density lipoprotein cholesterol, high-
density lipoprotein cholesterol (HDL-C), triglycerides and smoking164, 187-189. These risk 
factors are well established in epidemiology and recently variants that predict 
cardiovascular risk factors have been identified in large genetic association studies. 
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Several of the studies have published genetic risk scores for traits and associated with 
outcomes such as CAD. These studies provide additional evidence that may be used to 
predict disease outcomes from genetic data.  
1.4.1 Genetics of the risk factors for cardiovascular diseases 
Ehret et al., 2011 identified 16 novel loci associated with systolic (SBP) and diastolic 
blood pressure (DBP) in addition to the 13 established SNPs31. The authors calculated a 
composite risk score for increasing SBP and DBP and found that it was associated with 
increased left ventricular wall thickness and increased risk of IS and CAD31. While CAD 
and T2D do not share any genetic signals, fasting glucose is correlated with 
cardiovascular risk190, and both type 1 and type 2 diabetes are established 
cardiovascular risk factors. 
GWAS for diabetes and glycaemic related traits have identified loci that are associated 
with type 1 diabetes, type 2 diabetes and fasting glucose. Dupuis et al., 2010 identified 
17 loci that had a replicated allelic effect on fasting glucose. There are 42 loci that have 
been identified for type 1 diabetes which include the HLA locus identified in linkage 
studies, 5 genes from candidate gene studies and 36 signals identified by GWAS191. 
There are 48 established loci for T2D31, 77, 192, 193 which have been identified in multi-
ethnic populations. The relationship between genetic risk scores calculated from these 
variants and cardiovascular outcomes has not been established.  
Lipid levels are the largest predictor of cardiovascular disease and play an important 
role in how cardiovascular disease is treated. 95 loci have been reported for lipid traits, 
59 novel loci that were identified by Teslovich et al., (2010) and 36 previously 
established loci. Of the novel loci: 39 were associated with total cholesterol; 22 with 
LDL-C; 31 with HDL-C and 16 with triglycerides. The majority of previously identified 
loci associated with more than one lipid trait54. Teslovich et al, found that 14 of the 95 
loci were associated with CAD after correcting for multiple testing, 12 of the SNPs had 
associations with other lipid traits and 4 of the lipid effect alleles had an opposite 
effect on CAD risk54. The findings of Teslovich et al 2010 indicate that despite an 
increase or decrease in a corresponding lipid trait the allelic effect does not always 
translate to increased risk of CAD. These findings need to be investigated further. 
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Smoking status is the biggest predictor of LEAD and is associated to a lesser extent 
with IS and CAD. Several loci have been associated with smoking behaviour in large 
genetic association studies. The Tobacco and Genetics consortium identified the 
following loci which were associated with the number of cigarettes smoked per day: 
CHRNA3, LOC100188947, CYP2A6/EGLN3, BDNF and DBH194. Thorgeirsson et al 
identified CYP2A6/RAB4D, CHRNB3/CHRNA6, 7p14.3 and CYP2B6195. CHRNA3 is an 
established locus for LEAD but the effect of the other smoking loci on LEAD has not 
been assessed159. 
1.5 Vitamin D deficiency and cardiovascular disease 
In addition to the conventional risk factors many other traits have been indicated as 
risk factors for CVD. Vitamin D deficiency has been identified as a risk factor for CAD 
and supplementation trials show that there is a decrease in overall mortality with 
vitamin D supplementation but this is not specific to CVD outcomes6, 196, 197. The causal 
relationship between vitamin D levels and CAD outcomes is unclear as vitamin D levels 
can be affected by many factors such as poor diet and lack of sunlight196, therefore low 
vitamin D levels could be due to the illness rather than a cause. 
1.5.1 Serum vitamin D concentrations decrease with increasing latitude 
Healthy concentrations of serum vitamin D are accepted as between 70 and 
250nmol/L198, insufficiency at between 25-50nmol/L, deficiency at less than 25nmol/L 
and toxicity at greater than 250nmol/L. Insufficiency and deficiency have serious 
health consequences including myopathy, reduced bone mineral density, rickets and 
hyperparathyroidism199-201. Vitamin D insufficiency and deficiency increases with 
increasing distance from the equator198 (Figure 1-4) where individuals from countries 
40° North or South of the equator have vitamin D insufficiency or deficiency (Figure 1-
4). 
43 
 
  
Figure 1-4: Mean circulating 25-hydroxyvitamin D levels in children, adolescents, and 
adults according to geographic latitude (r2 0·68; P, 0·01). 191 Children; (2) male adults; 
(3) male adolescents and adults; (4) female adolescents and adults; 52 male adults; 168 
adolescents and adults; (7) adults; (8) children; (9) adolescents; (10) children; (11) 
adults; (12) adults (13) children; (14) adults; (15) adolescents; (16) adults198. 
Interestingly, the same trend is true for increasing death rates from ischaemic heart 
disease (IHD) where the death rate increases with increasing latitude (Figure 1-5)198. 
Although this may be due to other factors there is evidence that the risk of CAD 
increases with decreasing vitamin D levels202 and biological evidence that vitamin D in 
the form of calcitriol has vaso-protective properties. 
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Figure 1-5: Association between geographic latitude and ischaemic heart disease (IHD) 
death rates in (a) females (r =0.49; P< 0·01) and (b) males (r=0.51; P<0·01) of different 
European countries. A, Austria; AL, Albania; B, Belgium; BG, Bulgaria; BY, Belarus; CZ, 
Czech; D, Germany; DK, Denmark; E, Spain; EST, Estonia; F, France; FIN, Finland; GR, 
Greece; H, Hungary; I, Italy; L, Luxembourg; LT, Lithuania; LV, Latvia; M, Malta; N, 
Norway; NL, Netherlands; P, Portugal; PL, Poland; S, Sweden; SLO, Slovenia; RUS, 
Russia; UKR, Ukraine198. 
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1.5.2 Vitamin D metabolism 
Vitamin D is a broad term which describes a group of fat soluble vitamins that are 
responsible for the intestinal absorption of calcium and phosphate. Vitamin D can be 
absorbed as cholecalciferol or ergocalciferol from the gut or can be synthesised from 
cholesterol in the skin with adequate sun exposure. Many different forms of vitamin D 
are found in different organs of the body: in the liver vitamin D is converted to calcidiol 
(25 hydroxyvitamin D) then part of the calcidiol is converted to calcitriol in the kidneys 
(Figure 1-6). Calcitriol is the biologically active form of vitamin D203 which acts as a 
hormone to regulate serum concentrations of calcium and phosphate. Outside the 
kidneys calcitriol affects the cell cycle, inflammation and neuromuscular function204-206.  
1.5.3 Biological mechanism of vitamin D 
Vitamin D plays a crucial role in maintaining healthy bones by maintaining calcium and 
phosphate homeostasis. Calcium and phosphate homeostasis is essential for the 
deposition of bone mineral and an imbalance will affect skeletal integrity. Vitamin D 
stimulates the absorption of calcium and phosphate in the intestines and is also 
responsible for the reabsorption of bone calcium and phosphate as well as 
reabsorption of renal calcium and phosphate. Vitamin D deficiency can lead to 
nutritional rickets207 
1.5.4 Vitamin D as a vaso-protective agent 
25-hydroxyvitamin D (25OHD) otherwise known as calcitriol has been shown to protect 
the body against atherosclerotic lesions and vascular calcification. A key step in 
atherosclerotic lesion development is the proliferation of SMCs and calcitriol prevents 
the proliferation of vascular SMCs by allowing large amounts of calcium into the 
cytoplasm of these cells208. Vascular calcification occurs in mature atherosclerotic 
lesions and is inhibited by calcitriol. Calcitriol increases the production of matrix Gla 
protein (MGP)209 in vascular SMCs210, 211 where MGP is known to inhibit vascular 
calcification210, 212. 
Chronic inflammation is also associated with the development of atherosclerosis and 
vitamin D has anti-inflammatory properties. IL-6 and TNF- α are chief physiological 
stimulants of C-reactive protein (CRP), which can serve as an indicator of inflammatory 
processes. Increasing levels of vitamin D suppresses the release of TNF-α and IL-6 in a 
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dose dependent manner213. Vitamin D also increases the synthesis of IL10, an anti-
inflammatory cytokine214. IL-10 deficiency has been associated with severe 
atherosclerosis in experimental animals215. 
Calcitriol levels inversely correlate with serum parathyroid hormone (PTH) (Figure 1-6), 
which has been linked to CAD risk. Individuals with vitamin D deficiency have elevated 
levels of PTH that are toxic to the vascular system. PTH has been linked to elevated 
cardiac contractility, vascular calcification and has been linked to chronic 
atherosclerosis via insulin resistance216. 
There is also evidence that vitamin D reduces blood pressure which in turn reduces the 
risk of CAD. Vitamin D acts on blood pressure through the renin-angiotensin system217 
therefore playing a central role in the regulation of blood pressure and electrolyte 
homeostasis218. Supplementation with Calcitriol reduces blood pressure, plasma renin 
activity, and angiotensin II levels219, 220. UVB radiation, key in the synthesis of 25(OH) D-
serum in the skin, was shown to lower blood pressure in patients with mild essential 
hypertension221, 222. 
With so much evidence to support the role of increased vitamin D levels with improved 
vascular health it follows that decreased vitamin D levels are likely to increase risk of 
CAD through their action on a variety of cells in the vasculature and organs. The 
relationship between vitamin D and CAD could be confounded by the lack of outdoor 
activity observed in patients with CAD. Randomised control trials (RCT) are used to 
assess causal relationships between an environmental exposure and a disease 
outcome. In RCTs it is possible to account for the majority of confounding factors and 
to identify a causal relationship if one exists223.  
The results of observational studies don’t always reflect what is observed in RCTs and 
this is often due to confounding by unobserved lifestyle factors or may be due to 
reverse causation. The participants in RCTs don’t always represent the general 
population and are not powered to detect exposure that takes years to develop. Large 
observational studies are able to include enough people to represent the general 
population and observational studies run for long periods of time223 thus allowing for 
adequate exposure. Another approach that can be used to mimic RCTs in observational 
data is Mendelian randomisation. This approach uses variants known to be predictive 
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of the exposure to determine the causal relationship between the exposure and the 
outcome.  
1.5.5 The genetics of Vitamin D 
Recent genome wide association studies have identified 4 variants that were 
associated with decreased vitamin D levels. The single nucleotide polymorphisms are 
located within or near 4 genes related to vitamin D metabolism: rs2282679 in vitamin 
D binding protein (GC); rs12785878 in 7-dehydrocholesterol reductase (DHCR7); 
rs10741657 in cytochrome P450 2R1 (CYP2R1) and rs6013897 in CYP24A1 were 
associated with differences in 25OHD levels2, 6. GC is responsible for binding vitamin D 
and transporting it through the blood stream; DHCR7 metabolises 7-
Dehydrocholesterol to cholesterol reducing the vitamin D precursor levels in the skin, 
CYP2R1 metabolises cholecalciferol to calcidiol in the liver and CYP24A1 is responsible 
for inactivating vitamin D from the kidneys (Figure 1-6). These SNPs may be used in a 
Mendelian randomisation study design to assess the relationship between decreasing 
vitamin D levels and CAD. 
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rs12785878 
Figure 1-6: Vitamin D synthesis pathway1-7. This figure was generated using WikiPathways. 
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1.6 Mendelian Randomisation 
Mendelian randomisation is an instrumental variable approach that is well suited to 
inferring causality when unobserved confounding is believed to be likely. It uses a well 
understood genetic variant known to be associated with the exposure but without a direct 
effect on the disease as the instrument223. Genotypes are assigned randomly at birth due to 
meiosis so the genotypes are assigned independent of disease status or the unobserved 
confounder. Essentially this is a randomised control trial that runs for the life time of the 
individual223.  
The genetic variants are used as the instrumental variable in this case would be SNPs 
associated with vitamin D deficiency. The association between the SNPs and CAD would 
provide evidence for or against a causal relationship between low vitamin D exposure and 
the increased risk of CAD (Figure 1-7).  
 
 
 
 
 
 
 
 
1.7 Rationale for the thesis 
This thesis encompasses 5 specific studies with the broad aim of identifying genetic variants 
associated with CVD. At present, only 10% of the total heritability of CAD is explained by the 
known variants, which indicates that there are additional genetic variants that have not yet 
Figure 1-7: Mendelian randomisation is an instrumental variable approach which uses 
genes to determine the relationship between an exposure and a disease. 
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been identified. To date only two genome significant variants have been identified for LEAD 
and no stratified analyses have been carried out leaving this phenotype largely under 
investigated in large scale genetic studies. None of the current CAD or LEAD associated 
variants overlaps with T2D associated loci, which is interesting as diabetes is a large 
predictor of CAD and LEAD. The Genetics of Diabetes and Audit research in Tayside Scotland 
(GoDARTS) is a partner in a large EU funded innovative medicines initiative (IMI) known as 
SUMMIT. The SUrrogate markers for Micro- and Macro-vascular hard endpoints for 
Innovative diabetes Tools (SUMMIT) study (http://www.imi-summit.eu/) includes 19 
academic and 6 industry partners across Europe with the main purpose of identifying 
genetic risk factors for chronic diabetic complications such as CAD and LEAD.  
While investigating determinants of CVD in T2D populations may explain some of the 
missing heritability for CAD and LEAD, it is still useful to identify loci that may be globally 
associated with CVD. Variants identified from large genetic studies can also be used to 
determine causal relationships in observational studies. The causal relationship between 
vitamin D and CAD has not been analysed in a way that is free from confounding and the 
true relationship remains unexplained. 
We hypothesised that there are genetic determinants that are associated with 
cardiovascular disease in patients with diabetes and in non-diabetic individuals. Therefore 
the main aims of this thesis are: 
 To develop methods to identify individuals with CAD, IS and LEAD from the 
electronic medical record linked to GoDARTS for genetic association studies 
 To identify new variants associated with CAD through large scale genetic studies 
 To identify variants associated with CAD in T2D populations 
 To determine the causal relationship between vitamin D and CAD 
 To identify new variants associated with LEAD 
51 
 
Chapter 2: Methods 
2.1 Description of databases 
The Health Informatics Centre (HIC) in partnership with the University of Dundee, National 
Health Service Tayside and the information services division of national services 128 provides 
researchers and others with information derived from person-specific datasets. These 
datasets are mainly derived from data held by University of Dundee and the National Health 
Service and are anonymized in accordance with the Standard Operating Procedures 
approved by the Caldicott Guardians. In Scotland every person registered with a medical 
practitioner is assigned a Community Health Number224. This is a unique 10 digit 
identification number that is linked to information on address, postcode, medical 
practitioner registration status, deceased person and date of death. This information is held 
by the Tayside Health Board for the entire Tayside population. Tayside also uses this number 
as the patient identifier in all health care activities from primary to tertiary care thus 
allowing for the record-linkage of datasets.  
2.1.1 DARTS 
Diabetes Audit and Research in Tayside Scotland (DARTS) database includes information of 
all patients with diabetes in Tayside. Individuals with diabetes were identified from hospital 
records225. The database was validated against general practice records and was confirmed 
to be robust. The methodology used was shown to be more sensitive than general practice 
alone at identifying individuals with diabetes225. There are record linked data available for 
individuals within the DARTS cohort. 
2.1.2 Go-DARTS 
GoDARTS comprises 17,602 participants enrolled between December 1998 and May 2009 in 
which there are approximately equal numbers of participants without T2D (N=7773) and 
with T2D (N=9829). Participants with T2D were identified for enrolment through DARTS - a 
comprehensive and well validated region-wide clinical information system for diabetes that 
incorporates multiple clinical data sources225, 226. Age and sex matched diabetes-free 
participants were identified in populations within the region of Tayside from general 
practice records.  
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Relevant clinical data for all GoDARTS participants are drawn from electronic records of 
hospital admissions (Scottish Morbidity Register, SMR01), deaths (General Registry Office, 
GRO), biochemical tests and dispensed drug prescriptions, available for the Tayside region. 
Data are available from 1980 until present for the SMR hospital admissions data; from 1998 
for deaths from the GRO; from 1993 until present for prescriptions; and from 1980 until 
present for biochemical tests.  
The GoDARTS study was approved by the Tayside Committee for Medical Research Ethics 
and written, informed consent was obtained from each participant. A single sample of blood 
was collected for DNA extraction and genotyping, and the participant was assigned a unique 
anonymized system identifier. Baseline characteristics were recorded at time of recruitment 
for all participants226. 
2.1.3 CHI master index 
This is a demography database that contains one entry per study individual. This file 
includes information on the date of birth, ethnicity, sex and date of recruitment to the Go-
DARTS study. 
2.1.4 SMR01 
Scottish morbidity record 01 is a record of acute hospital admissions in Tayside and Fife, 
Scotland. The database consists of one line per patient admission that includes a date of 
admission, one principal diagnostic field and five additional diagnostic fields. This database 
also includes admissions for hospital procedures that include one principal procedure field 
and eight additional procedural fields. The hospital admissions are classified according to 
the International Classification of Diseases (ICD) 9th and 10th versions. Procedures are 
classified according to the Office of Population, Censuses and Surveys Classification of 
Surgical Operations and Procedures 3rd and 4th revisions.  
2.1.5 GRO death certification 
General Register Office (GRO) – Death certification database is a record of the date of death 
and cause of death. Deaths in Tayside have been electronically recorded since 1989 and the 
database includes a principal cause of death field and ten additional related causes of death 
fields. Cause of death is classified according to ICD9 and ICD10 codes. 
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2.1.6 Laboratory data 
The Tayside laboratory systems record all tests performed in surgeries, clinics and hospitals 
that have been sent to the Tayside laboratories for processing. Clinical laboratory data are 
available from 1992. The database contains biochemical, haematology, microbiology, 
virology and serology laboratory results and reports.  
2.1.7 Prescribing data 
HIC provides complete data for prescriptions dispensed in Tayside from 1993. Prescriptions 
dispensed between 1993-2004 were recorded as scanned paper prescriptions analysed with 
purpose written software. Since late 2004 all prescriptions were obtained in electronic 
format from the Practitioner Services Division (PSD). The PSD are responsible for the 
processing and pricing of all prescriptions in Scotland. The prescriptions recorded include all 
those dispensed in community pharmacies, dispensing doctors, and a small number of 
specialist appliance suppliers. Hospital prescriptions are included if they were dispensed in 
the community.  
Individual drug prescriptions are linked to an individual CHI number and are explicit on the 
name of the drug, date of prescription, amount dispensed as well as dosing instructions. 
Drugs are identified by name and individual drug codes linked to the British National 
Formulary (BNF).  
2.1.8 Vascular Laboratories Data 
2.1.8.1 Segmental Pressures Data 
The Segmental pressures data includes a subset of patients that have been referred to the 
vascular laboratories for a LEAD assessment. Measurements are taken to record the ankle 
brachial pressure indexes (ABI) on both the left and right side of the body, toe brachial 
pressure indexes (TBI) on both left and right size, exercise tests and records of claudication. 
2.1.9  Electronic stroke information system for Tayside 
The electronic stroke information system for Tayside (ESIST) has been designed as a 
research database for the study of stroke in Tayside. ESIST contains information on 
individuals who have been admitted to the stroke ward with a stroke from 2006. The 
database contains detailed information on the diagnosis that includes whether the stroke 
was a trans-ischaemic attack, an ischaemic stroke or a haemorrhagic stroke. The strokes 
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were then identified by subtype: Cardioembolism; large artery atherosclerosis; small vessel 
occlusion; stroke of other determined aetiology and stroke of undetermined aetiology. 
Information on blood pressure, smoking status, duration of hospital stay and discharge 
medication are available for each stroke event recorded in ESIST.  
2.2 Electronic medical records data manipulation 
The electronic medical records (EMR) are supplied as flat text files from which the relevant 
data are extracted and combined in forms suitable for statistical analyses. Phenotypes were 
derived from the EMR and all covariates were extracted from the EMR using the R statistics 
package227.  
2.3 Statistical analysis 
Statistical analyses were conducted in R227 using a variety of statistical packages available for 
the R statistic programs. The theory of the main regression analyses are given below. 
2.3.1 Multiple Regression  
Multiple linear regression is used to determine the relationship between a dependent 
variable and a number of predictor variables. One of the assumptions made is that there is a 
linear relationship between the dependent and independent variables so the following 
equation is used: 
Y=a+b1X1+b2X2+…+bnXn+e 
Where Y is the dependent variable, X is the predictor variable and b is the effect that the 
individual predictors have on determining the value of Y. Correlation between the 
dependent and independent variables can be demonstrated in a graph where a is the 
intercept and b is the slope of the line. The error term (e) represents a combined effect of 
the omitted variables. This is the variance in the model that cannot be explained by the 
independent variables included in the model228. 
While performing multiple regression the following assumptions are made: that the 
residuals in the model are normally distributed; error terms are constant and do not depend 
on the value of the independent variable and that independent variables are not correlated. 
Residuals are computed by subtracting the observed values of the dependent variable from 
those that are predicted by the model228 
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Linear regression is applied in cases where the independent variable is continuous and the b 
values can be interpreted as the expected change in y for one-unit change in the dependent 
variable if all other dependent variables are held constant. Logistic regression is applied in 
cases where the dependent variable is binary i.e. has two distinct values such as the 
occurrence of an event. The b values or regression coefficients describe the size of the 
contribution each step in the independent variable makes in predicting the identity of the 
dependent variable i.e. 1 or 0.  
2.3.2 Survival analysis using a Cox’s proportional hazards model  
Survival analysis or a Cox’s regression is often used in epidemiological studies to model the 
independent variables that determine the dependent variable which in this case is time to 
failure. In epidemiological studies an observation time is defined, usually time from patient 
recruitment until an outcome, death or end of the observation period. Each individual has a 
value for the observation time and a binary measure for outcome 1/0. To make up the 
Survivor function the survival time is broken up into intervals and for each time interval the 
proportion of individuals that have not failed and go on to enter a time period is measured. 
The number of cases that have had an outcome can be measured and the number of 
individuals that were censored for that interval can also be computed229.  
The Cox’s proportional hazard model can be applied to any distribution of the survivor 
function, the only assumptions that must be satisfied is that there are proportional hazards 
i.e. the estimation of the hazard function from independent variables does not depend on 
time and that there is a log-linear relationship between the independent variables and the 
underlying hazard function.  
h((t), (z1, z2, ..., zm)) = h0(t)*exp(b1*z1 + ... + bm*zm) 
Where the h(t) is the resultant hazard function given the values of the dependent variables 
for the cases in a time interval and h0(t) is the baseline hazard function when all the 
dependent variables are equal to zero229. 
Survival analysis is applied when survival time is of interest especially in terms of medical 
treatment. The method is tolerant of varying observation periods which is useful when 
patient recruitment has occurred at multiple time points so the observation periods are not 
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equal for all individuals in the study. Individuals who did not survive until the end of the 
study and have missing data for that time point wouldn’t be included in the study group for 
a multiple regression allowing for survival bias in multiple regression methods229.  
2.4 High Density Array Genotyping Data 
Samples, which were genotyped on the Genome-Wide Human SNP Array 6.0, were 
processed at Affymetrixs’ service laboratory for all samples passing Affymetrix's laboratory 
quality control; raw intensities were renormalized within collections using CelQuantileNorm. 
These normalized intensities were used to call genotypes with an updated version of the 
Chiamo software adapted for Affymetrix 6.0 SNP data. The sample processing for the 
CardioMetabochip was undertaken at Oxford University, Oxford and for the Immuno Chip 
processed at the Sanger Institute, Cambridge was identical to the above. The genotypes 
from the CardioMetabochip and the Immuno Chip were called using the Geno SNP 
algorithm.  
2.4.1 DNA preparation and genotyping 
The quality of the genomic DNA was validated using the Sequenom iPLEX assay designed to 
genotype four gender SNPs and 26 SNPs present on the Illumina Beadchips. DNA 
concentrations were quantified using a PicoGreen assay (Invitrogen) and an aliquot assayed 
by agarose gel electrophoresis. A DNA sample was considered to pass quality control if the 
DNA concentration was greater than or equal to 50 ng/μl, the DNA was not degraded, the 
gender assignment from the iPLEX assay matched that provided in the patient data manifest 
and genotypes were obtained for at least two thirds of the SNPs on the iPLEX. 
2.4.2 Sample Quality Control 
Genotype data quality control of the discovery samples was similar to other Wellcome trust 
case control consortium 2 (WTCCC2) studies published elsewhere99, 191, 230-232.  
For all individuals, we explicitly modelled the data as a mixture of 'normal' and 'outlier' 
individuals for each of ancestry, missing data and heterozygosity, and sex assignment. We 
fitted each model in a Bayesian framework and excluded individuals whose posterior 
probability of belonging to the outlier class was above 0.5145. This approach replaces the 
traditional concept of fixed exclusion thresholds for parameters such as call rate, 
heterozygosity and ancestry. 
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To assess relatedness among study individuals, we compared each individual with the 100 
individuals they were most closely related to (on the basis of genome-wide levels of allele 
sharing) and used a hidden Markov model (HMM) to decide, at each position in their 
genome, whether the two individuals shared 0, 1 or 2 chromosomes identical by descent 
(IBD). This allowed a more refined assessment of the relatedness between individuals than 
genome-wide sharing statistics (for example, parent-child relationships can be distinguished 
from those of siblings). Individuals were removed from the study iteratively to ensure there 
was no pair of individuals with IBD>= 5%. Within each pair of putatively related individuals, 
the individual with more missing genotypes was removed. 
2.4.3 Affymetrix 6.0 SNP genotyping array 
4000 diabetic cases were genotyped on the Affymetrix 6.0 SNP genotyping array that 
includes 1 000 000 SNPs. These individuals were specifically chosen for genotyping as they 
had all gone on to receive statins after recruitment to GoDARTS. 
2.4.4 Illumina Omni-express array 
 4000 diabetic cases were genotyped on the Illumina Omni-express array which consists of 
~700K SNPs selected from Hap Map 1-3 for SNPs with a MAF greater than 5%. The array was 
designed by selecting tag SNPs to serve as a proxy for a number of others SNPs across the 
genome. This approach allows for the broadest selection of maximally informative markers, 
resulting in genome-wide coverage of both common and rare variants.  
2.4.5 CardioMetabochip 
7,500 diabetic cases and controls were genotyped on the CardioMetabochip chip which 
consists of 196,725 SNPs. The loci on this custom array were chosen by Body Fat 
Percentage, CARDIoGRAM (coronary artery disease and myocardial infarction), DIAGRAM 
233, GIANT (anthropometric traits), Global Lipids Genetics (lipids), HaemGen (haematological 
measures), ICBP (blood pressure), MAGIC (glucose and insulin), and QT- IGC (QT interval) 
GWAS meta-analysis consortia. Loci were selected based on previous findings from GWAS, 
individual selections from consortia and earlier genetic studies234  
2.4.6 Immuno Chip 
The Immuno Chip is similar in design to the CardioMetabochip Chip. It was designed by 
consortia specifically to target loci associated with 12 immunologically related human 
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diseases. It is an Illumina Infinium HD genotyping array designed to integrate relevant 
1000Genomes data with disease-specific resequencing data and known immune-mediated 
disease loci that were identified by common variant GWAS. 
2.5 Manipulation of the genetic data 
High density SNP array data can be stored in a variety of formats. For the purposes of this 
thesis two file formats were used: the Chiamo47 and the PLINK binary PED235 formats. PLINK 
binary files were used when cleaning and analysing directly genotyped data. PLINK has a 
number of functions which were used to run the quality control checks for both sample and 
genotyping data described above. PLINK was used to prepare the input files for haplotype 
inference and subsequent genotype imputation.  
2.6 Genotype imputation 
Imputation takes place in two stages: the first is the estimation of haplotypes from the study 
population and the second is the imputation of genotypes by comparing study haplotypes to 
reference panel haplotypes. 
2.6.1 Haplotype inference 
There exist many methods for haplotype inference in unrelated populations236 that estimate 
haplotypes with varying accuracy. The segmented haplotype estimation and imputation tool 
(SHAPE-IT, http://www.shapeit.fr/)237 is the recommended method to estimate haplotypes 
for downstream imputation with IMPUTEv2238. The method is highly accurate and 
computational light when compared with other available methods239 and is particularly 
suited to populations that contain high linkage disequilibrium in their genomes such as 
Caucasians237. The inference of haplotypes is computed in a similar way to Phase v2240 
where all possible haplotypes are estimated from the available genotype set with an 
associated probability (Figure 2-1a). Since the number of haplotypes increases exponentially 
with the addition of more genotypes, there need to be methods to reduce the haplotype set 
to the most likely haplotype set.  
SHAPE-IT reduces the complexity of previous methods by collapsing the haplotype set into a 
graph structure and then performing hidden Markov model (HMM) calculations on the 
graph (Figure 2-1). So there is a set of all the possible haplotypes given the genotype set. 
The total haplotype set is then split into smaller segments that are disjoint (Hg) (Figure 2-
59 
 
1a). The nodes of each disjoint set are represented as a single marker that can have one of 
two alleles; the possible haplotypes in the disjoint sets are then estimated. This new set is 
compared to all the possible haplotypes given the genotype set then each edge is weighted 
by each haplotype in the total estimated set that traverse that edge (Figure 2-1a).  
 
Figure 2-1: Illustration of the SHAPE-IT model and the associated graphs in a simplified 
example. (a, b) In this example, H contains K = 8 haplotypes (rows in a) and the individual's 
genotype G contains four heterozygous SNPs (b), both defined over M = 8 markers 
(columns). In a, we illustrate how the graph Hg is built by splitting the haplotypes 
of H between markers 4 and 5, resulting in two segments that each contain J = 3 distinct 
haplotypes. The nodes of the graph are labelled either with allele 1 or allele 0. Each edge is 
weighted by the number of haplotypes in H that traverse it. A haplotype of H and its 
corresponding path in Hg is illustrated in magenta. In b, we illustrate how the graph Sg is 
built by making two segments of five and three SNP markers, each one containing two 
heterozygous markers in G (represented as state 1; state 0 and 2 are wild type and 
homozygous, respectively). Each segment has four possible haplotypes compatible with G. A 
pair of paths in Sg compatible with G is coloured blue and green239. 
This process is iterative where the haplotype set becomes progressively smaller based on 
the transition probabilities between segments and the weights at the edges of the graph. 
Segments are chosen based on the number of heterozygous genotypes in that segment.  
2.6.2 Imputation with IMPUTEv2 
IMPUTEv2 (http://mathgen.stats.ox.ac.uk/impute/impute_v2.html) uses the estimated 
haplotypes from SHAPE-IT to impute genotypes from the haplotype set238. Impute2 
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compares the study population haplotypes with up to two reference panels for the 
imputation of missing genotypes in the study population. Alleles are imputed into the study 
population by running a forward-backward algorithm to impute missing alleles with a 
certain probability238. The two sets of haplotypes are compared to each other and missing 
alleles are imputed into the study panel from the reference panel with certain probability. 
Certain SNPs will be found in haplotypes together so if one SNP is not present in the study 
panel but the haplotypes match we can impute an allele for that SNP with a certain 
probability given the alleles that are present in the reference panel and the alleles that are 
given in the study panel. So if there is good coverage of a haplotype on a particular chip and 
the haplotype is present in the reference panel the alleles will be imputed fairly accurately. 
If haplotypes are sparsely covered or SNPs are not in linkage disequilibrium with any other 
SNPs to form haplotypes then the alleles may be imputed with low confidence in their 
accuracy or may be missing all together. Given that we assume both sets of haplotypes are 
sampled from populations in Hardy-Weinberg equilibrium the allelic probabilities can be 
converted to genotypic probabilities238. 
2.7 Cluster computing 
The manipulation of these large genotype files and the imputation procedures are 
computationally intensive. Parallel computing on a high performance cluster (HPC) of 
computers was used to analyse and impute the genetic data. The HPC is managed by a Sun 
Grid Engine which is responsible for accepting jobs from users, scheduling and distributing 
jobs to cores within the HPC. SHAPE-IT supports threading of multiple cores so that they can 
be used as one processor to perform the pre-phasing steps chromosome by chromosome. 
Specific Perl programs were written to run the prephasing steps on the HPC using the multi-
threading capabilities of SHAPE-IT. Each chromosome was imputed by dividing the 
imputation intervals across 5Mb chunks of each chromosome. Each chunk was distributed 
to a separate core and specific Perl programs were written to run each of the imputation 
steps. The resulting files were combined into single chromosomes using bash scripting. 
Imputed files were also analysed chromosome by chromosome on the HPC. The analysis 
programs used for directly and imputed genotypes are described below. 
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2.8 Genetic associations 
Genotypes of directly typed SNPs are assigned using a threshold method at a probability of 
0.9. SNPs can be modelled in logistic and linear regressions on a log-additive scale. Similar to 
non-genetic covariates the effect of the SNP is modelled by steps from one genotype to 
another. SNPs are coded 0 for homozygotes of the non-effect allele, 1 for one copy of the 
effect allele in a heterozygote and 2 for a homozygote of the effect allele so the effect of 
each step translates to the effect of an additional copy of the effect allele on the outcome. 
Imputed SNPs are more complex to model as the three genotypes are estimated with some 
probability and the imputed data are assumed to be ‘missing’ in that they are not observed. 
Models of association for imputed genotypes need to take into account genotype 
uncertainty.  
SNPTESTv2 (https://mathgen.stats.ox.ac.uk/genetics_software/snptest/old/snptest.html) 
takes genotype uncertainty into account by using a missing data likelihood score test. Since 
SNPs may be imputed with varying certainty a threshold method may lead to a high 
proportion of missing data. It is possible to sum the probabilities of each genotype across 
individuals for a SNP and use all the available data in the association analysis. For a 
particular SNP data may be missing in some individuals and not in others so the data can be 
partitioned into observed and missing data. A score test can be used to estimate the 
likelihood of the observed data given the full set of data and taking into account the missing 
data241.  
2.9 Calculation genotypic scores 
The genotypes of the SNPs were coded as 0 - no effect alleles present; 1 - one effect allele 
present and 2 - two effect alleles present. Effect alleles were defined as those reported to 
raise levels of quantitative traits or risk of diabetes. Where the reported SNP was not typed 
or imputed a suitable proxy was identified. A genotype score for each trait was calculated 
for every participant based on the number of effect alleles the participant had for each SNP 
associated with a trait. Each SNP was weighted by the published per affect allele increase in 
quantitative trait or binary outcome (allele effect estimates): GS = SNP1 (0/1/2)*βEffect_allele + 
SNP2 (0/1/2)*βEffect_allele … + SNPij (0/1/2)*βEffect_allele. If a genotype was missing for an 
individual, a score value was imputed based on the probability of a homozygous effect allele 
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genotype for that individual multiplied by the effect allele weight: 2*MAFeffect_allele* 
βEffect_allele. 
2.9.1 Assessing the discriminatory power of genetic risk score to classify disease 
status 
If genetic risk scores are to be applied to predicting disease status we need methods to 
assess the discriminatory power of the genetic risk score to predict disease outcome. Since 
the outcome is binary we need methods that can specifically be applied to binary outcomes 
and the most commonly derived metrics are the R squared, concordance (C) statistic and 
more recently net reclassification improvement. 
The coefficient of determination or the R-squared value is a measure of the “goodness of 
fit” for a regression model and was developed for linear regression models. New methods 
have been developed to calculate the R-squared for logistic regression models. The value of 
R-squared ranges between 0 and 1 and the higher the value of R-squared the better the 
model is at predicting the outcome242. The C statistic is another measure of how well a 
model predicts the disease outcome.  
The C statistic for binary outcomes is the area under the receiver operating curve and takes 
on values between 0.5 and 1. The receiver operating curve is a graphical plot that illustrates 
the performance of a binary classifier; in this case it could be used to compare the predictive 
power of different logistic regression models to each other. The closer the c-statistic is to 1 
the larger the area under the ROC curve which indicates a higher discriminatory power for a 
given model243. The C statistic has been criticised for being too conservative for a 
meaningful improvement in prediction because increases can only be seen for variables that 
carry a very high relative risk for the disease outcome.  
The net reclassification improvement (NRI) is a new method to assess the improvement of 
model performance offered by a new variable 244. The method uses reclassification tables 
for constructed separately for diseased patients and those free of disease. Any upward 
movement in patients with disease is considered an improvement in classification while a 
downward movement is considered a worse reclassification. The opposite is true for 
individuals who do not suffer disease events. The improvement in classification can be 
quantified in patients who suffer events by adding the differences in the proportion of 
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individuals who move up minus those who move down. The inverse is applied to individuals 
who do not suffer disease events. The classification in each group can be compared by 
taking the difference in reclassification in the event and non-event groups. The larger the 
difference the more significant the improvement in disease prediction provided by the new 
variable244.  
2.10 Laboratory methods 
2.10.1  TaqMan Genotyping 
Direct typing of individual SNPs was performed using TaqMan allelic discrimination assays as 
supplied by Applied Biosystems (Carlsbad, CA) as “Assays on Demand”, or “Assays by 
Design”. All typing was performed in 384 well format using 10-20ng of DNA in 2ul reaction 
volumes using Universal TaqMan master mix (Applied Biosystems, Carlsbad, CA). Assays 
were plated using a DEERAC Equator GX microdispenser (Labcyte, Sunnyvale, CA), and 
thermal cycling was performed in a H2OBIT high throughput thermal cycler (KBiosystems, 
Basildon, Essex). End point fluorescence was measured and genotypes were called using an 
ABI 7900HT sequence detection system (Applied Biosystems, Carlsbad, CA).  
2.11 Meta-analysis 
In a meta-analysis summary statistics such as effect estimates and the variance of the effect 
estimates from individual studies are combined. This process allows us to estimate the 
effects of SNPs across any number of studies without the need to access individual level 
data. Summary statistics can be combined using either a fixed effects or random effects 
model191, 245-247. 
2.11.1  Fixed effects meta-analysis 
The fixed effects model assumes that the effect sizes are the same or fixed across studies. 
Effects are commonly combined using inverse-variance weighted effect size estimate and 
the weighted sum of z scores.  
 
Where Wi =1/(SE)2 and the SEmeta =  
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ZFE =  
A p value can be calculated from the z score assuming a two-sided test 
PFE= 2Ф(-|ZFE|) 
Where Ф is the cumulative density function of the standard normal distribution. 
191, 245, 246 
2.11.2  Random effects meta-analysis 
The random effects model assumes that the effect sizes are sampled from a probability 
distribution that has a variance 2 that can be estimated using various approaches246, 248 
such as the method of maximum likelihood and restricted maximum likelihood248. The 
estimated between study variance 2 hat is included in the calculation of the effect size 
estimate where 
 
 
And the z score can be calculated as follows: 
 
The p value can then be calculated as PRE= 2Ф(-|ZRE|) 
The current RE model assumes that there is heterogeneity under the null hypothesis 
however there should be no heterogeneity under the null hypothesis as all effect sizes are 
equal to zero. This assumption leads to overly conservative p values246. 
2.11.3  RE approach Han and Eskin 
The approach proposed by Han and Eskin partitions the estimation off the effects and the 
significance of the association into two parts. First the effect size and variance of the effect 
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size are estimated using the traditional random effects approach. To estimate the 
significance of the result a likelihood ratio test is applied to the effect estimate (ʮ)246. 
Where the likelihood of the effect estimate is maximised through a number of iterations and 
 is also estimated through a series of iterations. The calculation of the significance of the 
test statistic is complex as  is non-negative (there cannot be negative variance in an effect 
estimate) and follows a half normal distribution while the effect estimate (ʮ) is unrestricted 
and can be either positive or negative. This means that the test statistic follows a 1df and a 
2df chi square distribution simultaneously. The authors provide tables for corresponding p 
values under different conditions allowing for unequal sample sizes and small sample sizes. 
Therefore no heterogeneity is assumed under the null hypothesis but is taken into account 
when estimating the combined effect size and variance. This random effects method has 
been implemented in MetaSoft (http://genetics.cs.ucla.edu/meta/)246. 
2.11.4  Heterogeneity statistics I and Q 
Cochran’s Q statistic is computed by summing the variation of each study’s effect estimate 
from the overall effect estimate and weighting each study contribution by its inverse 
variance. The null hypothesis is that there is no heterogeneity in the effect sizes. The Q 
statistic follows a chi-square distribution with K-1 degrees of freedom where K is the 
number of studies included in the meta-analysis. The Q statistic has poorer power to detect 
true heterogeneity when the sample sizes are small. 
The I2 is another statistic used to estimate the between study heterogeneity and is related 
to the Q statistic. The I2 described the total variation across studies that is due to 
heterogeneity rather than chance.  
I2=  
Where Q is Cochran’s Q. I2 differs from Q as it not only indicates that there is heterogeneity 
present, it also indicates how much heterogeneity there is: 25% (I2 = 25), 50% (I2 =50), and 
75% (I2=75) would mean low, medium, and high heterogeneity, respectively.249, 250.  
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2.12 Testing for heterogeneity between estimates 
Interaction can be measured simply as the difference between two effect estimates. The 
two estimates have to be independently estimated and not obtained from the same 
individuals251. Effect estimates and their standard errors are required from both groups to 
calculate a z score that can be used to test for an interaction. The difference between the 
two effects can be calculated as follows251: 
 
Where E1 and E2 are effects estimated from two separate studies. The standard error of the 
difference is the square root of the sum of the variance of each effect estimate: 
SE(d)=  
Similar to the fixed effects method a z score can be calculated as: 
Z=  
Z can be compared to a standard normal distribution to get a p value. A significant p value 
indicates that d is sufficiently different to zero i.e. no difference in the effect estimates251. 
2.13 Tests for stratum specific effects 
GWAMA (http://www.well.ox.ac.uk/gwama/)252 has the option to analyse sex specific 
effects in a meta-analysis using a fixed-effects model. 
 
Where K denotes the sex of the ith GWAS and is equal to 1 if the study is male-specific and 0 
if the study is female specific. Where WMj =[Ki*1/(SE)2]
 -1 is the variance of male specific 
effect estimates and WFj =[(1-Ki)*1/(SE)2]-1
 is the variance of the of the effect estimate in 
females. We can then calculate chi-square statistics for each gender by: 
 and where each chi-square distribution with one 
degree of freedom. Cochran’s Q statistic can also be computed for each gender stratum by: 
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 for men and  for women.  
A sex differentiated test can then be performed by allowing for different effects in males 
and females given by    which has a chi-square distribution with two 
degrees of freedom. It is then possible to test for heterogeneity of effects between sex-
specific allelic effects by    where , the chi-square statistic assuming 
the same allelic effects in both sexes,  has a chi square distribution with 1 degree of 
freedom.  
The most powered analysis is achieved when there is no heterogeneity between the allelic 
effects in males and females for a causal variant. However, when there is heterogeneity in 
allelic effects the loss of power is not too large and is due to the necessary extra degree of 
freedom.  gives us the sex-differentiated estimate for association allowing for the 
heterogeneity in the allelic effects between sexes to estimate the overall association with 
the causal variant.  is a measure of the heterogeneity between estimates when 
compared to the overall meta-analysis estimate that does not take sex differentiation into 
account. This method can be applied to any stratified analysis for example to detect diabetic 
and non-diabetic specific effects on coronary artery disease. 
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Chapter 3: Using Electronic Medical Records to Investigate 
Cardiovascular Phenotype-Genotype Associations – A GoDARTS study 
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3.1 Introduction 
There is growing interest in the use of biobanks linked to medical electronic records (EMR) 
for genetic association studies due to the inherent versatility of the study design225, 253, 254. 
Individuals recruited to the Genetics of Diabetes and Audit Research in Tayside Scotland 
(GoDARTS) are linked to routinely recorded electronic medical records (EMR) and, a large 
proportion of the study, to high density genotyping data. Although GoDARTS was principally 
set up and has been used to study the genetics of type 2 diabetes (T2D)241, it has also been 
used to study pharmacogenetic interactions with metformin, commonly prescribed to treat 
diabetes, and statins, used to prevent and treat cardiovascular disease255-259, it is possible to 
define multiple phenotypes from the extended EMR and combine them with genetic data 
that are common to the entire GoDARTS study. This process is more efficient than recruiting 
multiple disease specific populations.  
Identification of individuals with cardiovascular disease from GoDARTS would provide a 
powerful tool to investigate the genetic determinants of cardiovascular disease. The 
identification process is not straightforward as EMR are kept throughout the lifetime of a 
patient and serve the primary purpose of providing information to health care professionals 
and are not for genetic association studies. Therefore algorithms to identify cardiovascular 
phenotypes in GoDARTS need to be optimised and well validated for applications in genetic 
studies.  
 Several genome wide association studies (GWAS) have identified loci associated with 
cardiovascular disease and with cardiovascular disease risk factors. The 9p21 region and the 
LPA gene have been established as important loci where 9p21 variants have been associated 
with CAD and IS38, 40, 48, 161 and LPA variants rs107455872 and rs3798220 have been 
associated with CAD, IS and LEAD50, 162. SNPs from GWAS studies of cardiovascular related 
traits have been combined into genetic scores (GS) for blood pressure loci, high-density 
lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) to assess the 
relationship between these traits and cardiovascular outcomes31, 260.  
The main aim of this chapter was to validate GoDARTS as a discovery cohort for genetic 
associations in cardiovascular disease. The strategy we followed was to develop algorithms 
to identify individuals with and without CAD, IS and LEAD from EMR and to verify the 
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algorithms for IS and LEAD using alternative EMR data. To show that these phenotypes 
could be used in genetic association studies we compared the association of known signals 
in the 9p21 and LPA regions within our study to published data and then we also compared 
the associations of GS, for known cardiovascular risk factors, to published associations and 
amongst the EMR derived phenotypes derived in GoDARTS.  
3.2 Materials and Methods 
3.2.1 Coronary artery disease definition 
CAD events were identified from the SMR01 and GRO death registry using International 
Classification of Diseases (ICD) 9 and ICD 10 codes. CAD events were defined as fatal and 
nonfatal records of myocardial infarction (ICD9 code 410 and ICD10 codes I21 and I22), and 
or, unstable angina (ICD9 code 411 and ICD10 code I20.0), and/or coronary 
revascularization. Coronary revascularization included percutaneous transluminal coronary 
angioplasty (PTCA) office of population, censuses and surveys classification of surgical 
operations and procedures (OPCS) 3 codes 881 and OPCS 4 codes K759, K491-K493, K498-
K499, K502, K504 and K508. Coronary artery bypass surgery (CABG) was identified using 
OPCS 3 codes 3043, 8814 and OPCS 4 codes K401-402, K411, K413, K433, K441-K442 and 
K449.  
3.2.2 Ischaemic stroke definition 
The phenotype definition for IS was developed and validated by Flynn et al., (2010)261. 
Briefly, IS were identified from SMR01 and GRO data using the following codes: ICD 9: 434.1, 
434.9, 435.9, 436.9 and ICD10: G450-4, G458, G459, I63.0-6, I63.8, I63.9, I64 and I69.3 and 
I69.4.  
3.2.3  Lower extremity arterial disease definition 
3.2.3.1 Vascular laboratory criteria 
LEAD cases were identified from the vascular laboratories data based on an ankle brachial 
index (ABI) of less than 0.9, and or an ABI greater than 1.3, and or no record of an ABI with a 
corresponding brachial pressure measure either on the left or the right body side, and or an 
ankle systolic pressure of greater than 255mmHg. Non atherosclerotic causes of LEAD were 
excluded if individuals had at least two records of the following codes in the Scottish 
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Morbidity Register 01 (SMR01): ICD9 747.22, 237.7, 443.1, 446.0, 446.4, 446.5, 446.6, 446.7, 
447.6, 710.1, 747.1, 747.64 and ICD10 I73.1, I77.6, M30.3, M31.1, M31.30, M31.4, M31.6, 
M34.9, Q25.1, Q25.2, Q25.3, Q27.32, Q85.00. Cases were also identified primarily based on 
the SMR01 data. 
3.2.3.2 Hospital admissions with a LEAD diagnosis  
LEAD cases were identified from the SMR01 data using codes pertaining to a diagnosis of 
LEAD: ICD9 440.2×, 440.3×, or 440.8×; ICD10 I73.1, I77.6, M30.3, M31.1, M31.30, M31.4, 
M31.6, M34.9, Q25.1, Q25.2, Q25.3, Q27.32, Q85.00. Additional cases were also identified 
from the SMR01 data using codes for procedures and corrective surgeries related to LEAD. 
3.2.3.3 Procedures and corrective surgery related to LEAD 
Procedures for lower extremity angiography with a concurrent record for a non-coronary 
vessel stent or a procedure code for lower extremity artery surgical and percutaneous 
vascular interventions were considered a positive indicator of LEAD. Lower extremity 
angiography: ICD9 88.48, 75710, 75711, 75712, 75716, 75717, 75718, 75630, 75631; OPCS4 
L63,L71,L72, U117 AND Z38 and a concurrent non-coronary vessel stent: ICD9 39.50, 39.90, 
37205, 37206, 37207, 37208, 37184, 37185, 37186 or ICD10 L76, L98. Procedure codes for 
lower extremity artery surgical and percutaneous vascular interventions: ICD9 : 38.18, 
39.50, 39.25, 39.29, 38.08, 38.38, 38.48, 39.49; 39.56, 39.57, 39.58, 39.90, 35302, 35303, 
35304, 35305, 35306, 35331, 35351, 35355, 35361, 35363, 35371, 35372, 35381, 35452, 
35454, 35456, 35459, 35470, 35472, 35473, 35474, 35481, 35482, 35483, 35485, 35491, 
35492, 35493, 35495, 35521, 35533, 35537, 35538, 35539, 35540, 35541, 35546, 35548, 
35549, 35551, 35556, 35558, 35563, 35565, 35566, 35571, 35582, 35583, 35585, 35587, 
35621, 35623, 35637, 35638, 35641, 35646, 35647, 35651, 35654, 35656, 35661, 35663, 
35665, 35666, 35671, 35226, 35256, 35286, 35700, 35721, 35741, 35876, 35879, 35881, 
35883, 35884, 37184, 37185, 37186, 37205, 37206, 37207, 37208; OPCS4 L51-, L52, L531, 
L532, L538, L539, L54, L59-, L60-, L62-, L66-, L68-, L70-, Z38-. Other reasons for the vascular 
surgery were excluded if the following codes were also present: ICD9 736.3×, 736.4×, 736.5, 
736.6, 736.7×, 736.8×, 736.9, 735.×, 754.3×, 754.4×, 754.5×, 754.6×, 754.7×, 755.02, 755.13, 
755.14, 755.3, 755.4, 755.6×, 755.8, 759.7, 759.89, 895.××, 896.××, 897.××, 820.××, 821.××, 
822.××, 823.××, 824.××, 825.××, 826.××, 827.××, 828.××, 829.××, 835.××, 836. ××, 837.××, 
838.××, 904.××, 928.××, 929.××, 959.6, 959.7, 996.4×, 996.66, 996.67, 996.77, 996.78; ICD10 
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M201, M202, M203, M204, M205, M206, M214, M216, M217, M219, M22-, M23-, M2406, 
M2416, M2426, M2436, M2446, M2456, M2466, M2476, M2476, M2486, M2496, M2506, 
M2516, M2526, M2536, M2546, M2556, M2566, M2576, M2586, M2596, M8406, M8416, 
M8426, M8436, M8446, M8456, M8466, M8476, M8486, M8496, Q682, Q683, Q684, Q685, 
Q65-, Q6-, Q692, Q702, Q703, Q704, Q72-, Q741, Q742, S72-, S730-, S75-, S77-, S78-, S797, 
S81-, S82-, S83-, S84-, S85-, S86-, S87-, S88-, S89-, S91-, S92-, S93-, S94-, S95-, S96-, S97-, 
S98-, T013, T016, T023, T025, T026, T033, T034, T043, T044, T047, T053, T054, T055, T056, 
T8416, T8426, T8436, T8446, T8456, T8466, T8476, T8486, T8496. Mid-thigh to mid-foot 
amputations were also considered positive indicators of LEAD. 
3.2.2.4 Mid-thigh to mid-foot amputations 
Amputations from thigh to mid foot that were not due to non-vascular causes such as 
accidents were used to identify LEAD cases. The following codes were used to extract 
records of amputation from the SMR01 data: ICD9 84.1×, 84.91, 27295, 27590, 27591, 
27592, 27598, 27880, 27781, 27782, 27888, 27889, 28800, 28805 and ICD10 X09, X10, X11. 
Further amputations were identified from amputation data available from the Scottish Care 
Information – Diabetes Collaboration (SCIDC) where variables in the data indicated 
amputation site and side. Non vascular amputations were excluded if there was also a 
record for : ICD9 736.3×, 736.4×, 736.5, 736.6, 736.7×, 736.8×, 736.9, 735.×, 754.3×, 754.4×, 
754.5×, 754.6×, 754.7×, 755.02, 755.13, 755.14, 755.3, 755.4, 755.6×, 755.8, 759.7, 759.89, 
895.××, 896.××, 897.××, 820.××, 821.××, 822.××, 823.××, 824.××, 825.××, 826.××, 827.××, 
828.××, 829.××, 835.××, 836. ××, 837.××, 838.××, 904.××, 928.××, 929.××, 959.6, 959.7, 
996.4×, 996.66, 996.67, 996.77, 996.78 and ICD10 M201, M202, M203, M204, M205, M206, 
M214, M216, M217, M219, M22-, M23-, M2406, M2416, M2426, M2436, M2446, M2456, 
M2466, M2476, M2476, M2486, M2496, M2506, M2516, M2526, M2536, M2546, M2556, 
M2566, M2576, M2586, M2596, M8406, M8416, M8426, M8436, M8446, M8456, M8466, 
M8476, M8486, M8496, Q682, Q683, Q684, Q685, Q65-, Q6-, Q692, Q702, Q703, Q704, 
Q72-, Q741, Q742, S72-, S730-, S75-, S77-, S78-, S797, S81-, S82-, S83-, S84-, S85-, S86-, S87-, 
S88-, S89-, S91-, S92-, S93-, S94-, S95-, S96-, S97-, S98-, T013, T016, T023, T025, T026, T033, 
T034, T043, T044, T047, T053, T054, T055, T056, T8416, T8426, T8436, T8446, T8456, T8466, 
T8476, T8486, T8496. 
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3.2.2.5 Dispensed medication for Claudication 
Claudication is a common symptom of LEAD therefore cases could be identified by 
prescription for medication used to treat claudication. These included Clisotazol, 
Pentoxifylline, Naftidrofuryl, Inositol nicotinate, Tymoxamine and their synonyms.  
The algorithm was aligned to the LEAD case definition developed at the Mayo Clinic 
eMERGE (electronic MEdical Records and GEnomics) centre262 but differed from that 
definition by including ICD 10, OPCS 3, OPCS4 and broader medication criteria.  
3.2.4 Cardiovascular disease controls  
Controls were identified from hospital admissions to be free of CAD, IS and LEAD. In addition 
to not meeting the case definition for CAD, IS and LEAD individuals with any lower extremity 
amputations regardless of site were excluded from the controls.  
3.3 Sensitivity and Specificity of Ischaemic stroke and LEAD case identification 
algorithms 
Sensitivity was calculated as the number of true positives divided by the sum of the number 
of true negatives and the number of true positives. Specificity was calculated as number of 
true negatives divided by the sum of the number of true negatives and the number of true 
positives.  
ESIST (described under heading 2.1.9) contained records of patients admitted to the stroke 
ward with any type of stroke and did not include records of non-stroke morbidities. A 
diagnosis of stroke subtype was made by stroke clinicians and recorded in ESIST, thus a 
‘true’ ischaemic stroke event was identified as a clinical diagnosis of ischaemic stroke and a 
‘negative’ diagnosis of ischaemic stroke was identified as a haemorrhagic stroke or stroke of 
unknown aetiology recorded from ESIST. Ischaemic strokes identified from SMR and GRO 
records were compared to corresponding records of confirmed diagnoses of stroke subtype 
recorded in ESIST and sensitivity and specificity were calculated.  
A clinical diagnosis of LEAD is based upon ABI readings where a normal range is considered 
an ABI between 0.9 and 1.2263 and anything outside of that range is considered abnormal. In 
this study a ‘true’ diagnosis of LEAD was defined as an ABI of less than 0.9 or greater than 
1.4 and a strict ‘negative’ diagnosis of LEAD was defined as an ABI between 1.1 and 1.2 
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based on ABI records in the vascular laboratories data. LEAD cases identified based on 
criteria that did not include the vascular laboratories data were compared to corresponding 
records in the vascular laboratories data. Specificity and sensitivity were calculated.  
3.4 Genotype information 
High density genotyping data were available for GoDARTS individuals : 4000 type 2 diabetic 
individuals were typed on the Affymetrix 6.0 SNP genotyping array and genotypes were 
imputed into this population from a reference panel of HapMap2 individuals and a panel of 
6000 British individuals typed on the Illumina Human 1M dual using IMPUTE2230, 264; 7178 
individuals were genotyped on the CardioMetabo Chip and 2500 individuals were 
genotyped on the Immuno Chip. A Full description of the genetic data and the imputation 
process are given under headings 2.4 and 2.6 respectively.  
Genotypes for rs10116277, rs2383207, rs1333040, rs1333049 and rs10757274 were 
extracted from the genetic data available for GoDARTS and the GS were calculated from the 
available genetic data. Rs10744872 and rs3798220 were typed using TaqMan allelic 
discrimination assays in the GoDARTS individuals. TaqMan allelic discrimination is described 
in full under heading 2.10.1. 
3.5 Statistical Methods 
3.5.1 Association of known SNPs with cardiovascular phenotypes 
Known variants in the 9p21 region (rs10116277, rs238207, rs1333040, rs1333049, 
rs10757274 and LPA region (rs10488572 and rs3798220) were associated with 
cardiovascular disease in binary logistic regressions while correcting for age, gender and T2D 
status using the stats package in R227.  
3.5.2 Meta-analysis of LPA SNPs in cardiovascular disease 
The association of rs10455872 and rs3798220 with cardiovascular phenotypes in GoDARTS 
and published effect estimates50, 162 were pooled by inverse-variance weighting245, weighted 
by the number of cases contributed by each study. 
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3.5.3 Association between Genetic Scores for cardiovascular risk factors and their 
corresponding traits 
SNPs identified from GWAS meta-analyses for CAD38, 47-49, 265, lipid traits54, blood pressure31, 
T2D266, type 1 diabetes (T1DM) 191 and fasting glucose267 were combined into Genetic Scores 
(GS). The SNPs used in each of the scores are reported in the appendices 1 to 6. 
3.5.4 Models used for individual traits and Genetic Scores 
To assess the effect of the GS on their corresponding traits logistic and linear regressions 
were conducted in R v2.14.1 using the stats package227 and were stratified by T2D status. 
The lipid trait GS for total cholesterol (TCHOL), LDL-C, HDL-C and triglycerides (TG) were 
associated with mean, statin-untreated lipid measures and were corrected for mean age 
and gender in a linear regression. To account for the effects of antihypertensive treatment 
on blood pressure measures 15mmHg was added to treated SBP measures and 10mmHg to 
treated DBP measures. Treated blood pressure measures were defined by a dispensed 
prescription for an antihypertensive medication up to 60 days prior to the blood pressure 
measure. The GS for DBP and SBP were associated with corrected blood pressure measures 
taken at study enrolment in a linear regression while correcting for age and gender. 
Similarly, the GS for fasting glucose (FGLU) was associated with fasting glucose while 
correcting for age, gender and body mass index (BMI). Fasting glucose measures were taken 
at study enrolment in non-diabetic individuals only as FGLU and were not available for the 
T2D subgroup.  
GS for binary traits CAD and T2D were tested for association with their respective traits in a 
logistic regression. The association between the GS for CAD and CAD was corrected for age 
and gender and stratified by T2D status. The GS for T2D was associated with T2D while 
correcting for age and gender. 
3.5.5 Association of genetic scores for known risk factors and corresponding traits 
with cardiovascular disease 
BMI, T2D, history of smoking, SBP, DBP, TCHOL, LDL-C, HDL-C, TG and glucose (GLU; fasting 
and non-fasting) were derived from EMR records as a record on the index date or nearest 
record. The index date for all models was defined as the time of event for cardiovascular 
disease cases and time of study enrolment for cardiovascular disease free controls. Possible 
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treatment confounding of blood pressure measurements and lipid levels was taken into 
account by correcting blood pressure measures for anti-hypertensive treatment as 
previously described and by identifying statin treated lipid measures by a dispensed 
prescription for a statin up to 60 days before the lipid measurement date. T2D was defined 
as ever T2D.  
Each GS (for SBP, DBP, T2D, T1DM, TCHOL, LDL-C, HDL-C, TG and FGLU) and corresponding 
risk factor were associated with a cardiovascular phenotype in a binary logistic regression 
using the stats package in R227 and were stratified by T2D status. All models were corrected 
for age and gender. Associations with lipid GS and serum lipid measures were corrected for 
statin treatment by including a binary variable for treated and untreated measures in the 
model. 
3.6 Results 
3.6.1 Description of cardiovascular phenotypes and phenotype confirmation in 
GoDARTS 
From the GoDARTS population of 17602 individuals: 2317 individuals with at least one CAD 
event, 701 individuals with at least one record of IS, 1881 individuals with at least one 
record of LEAD and 11,636 CVD controls were identified (Table 3-1). Pairwise t-tests were 
conducted in R v2.14.1227 comparing cardiovascular disease cases to cardiovascular disease 
free controls showed that the cases were different to the controls for cardiovascular disease 
risk factors investigated in this study (Table 3-1). 
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Table 3-1: Population characteristics of each cardiovascular phenotype and the cardiovascular disease free group 
Descriptive/Phenotype CAD  
mean (SD) or % 
Ischaemic 
stroke mean 
(SD) or % 
LEAD (SD) 
mean (SD) or 
% 
CVD controls 
mean (SD) or 
% 
N 2317 701 1881 11636 
Age  64.1 (11.5)*** 72.3 (11.2)*** 66.1 (11.2)*** 60.0 (12.6) 
Male % 68.1*** 57.1* 58.9** 49.7 
Type 2 diabetes % 80.9* 72.6*** 82.6*** 40.6 
BMI (kg/m2) 29.5 (5.1)*** 29.0 (5.1) 29.6 (5.5)* 29.0 (5.8) 
History of Smoking % 56.8* 63.6*** 59.4*** 53.9 
Systolic Blood pressure (mmHg) 151.4 (19.6)*** 141.9 (22.9)** 140.9 (20.9)** 137.9 (19.1) 
Diastolic blood pressure (mmHg) 85.5 (11.1)*** 76.6 (12.6)** 76.5 (11.4)*** 78.7 (10.3) 
Cholesterol (mmol/L) 5.5 (1.3)*** 5.7 (1.2)*** 5.2 (1.1)** 5.0 (1.1) 
Low-density lipoprotein (mmol/L) 3.2 (1.0)*** 3.2 (0.9)*** 3.2 (1.0)*** 3.2 (0.9) 
High-density lipoprotein(mmol/L) 1.2 (0.8)*** 1.3 (0.6)*** 1.3 (0.9)*** 1.4 (0.6) 
Triglycerides (mmol/L) 2.3 (1.6)*** 2.0 (1.5)** 2.2 (1.7)*** 1.9 (1.4) 
Glucose (mmol/L) 9.6 (5.2)*** 9.2 (4.8)*** 9.4 (5.1)*** 8.2 (4.4) 
* 1E-05=<p<=1E-02; **1E-10<= p<1E-05; ***p<1E-10 
C 
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3.6.2 Sensitivity and Specificity analysis 
The algorithm developed in this study showed high sensitivity and specificity to identify IS 
and LEAD cases from EMR data. The IS identification algorithm was 97.8% sensitive and 
100% specific when compared to confirmed clinical diagnoses of IS. Similarly the different 
criteria used to identify LEAD cases were 100% sensitive and had an average specificity of 
94.4% when compared to clinical diagnoses (Table 3-2). 
Table 3-2: Evaluation of the lower extremity arterial disease algorithm compared with ABI 
defined cases and controls. 
Criterion N  In data* Sensitivity Specificity 
Diagnosis LEAD 122 56% 100% 99.6% 
Amputations 197 60% 100% 97.7% 
Procedures 306 61% 100% 93.1% 
Prescriptions 561 40% 100% 87.1% 
* The data on segmental pressures only includes individuals that were referred to the 
vascular laboratories for a measurement. This indicates the percentage that was referred 
from each identification criterion. 
3.6.3 Association of known SNPs with cardiovascular phenotypes 
3.6.3.1 9p21 SNPs 
The association between 9p21 variants with CAD and IS were replicated in GoDARTS and 
were similar to published results. The associations with IS were not statistically significant 
but the effect allele and effect sizes were consistent with published effects. Even though 
these SNPs had not been previously associated with LEAD, the associations were similar to 
those observed for CAD (Table 3-3). 
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Table 3-3: Association of SNPs on chromosome 9 and 6 associated with cardiovascular disease with cardiovascular disease phenotypes in 
GoDARTS. 
         CAD  Ischaemic stroke  LEAD 
SNP Locus EA† EAF‡ N OR§ (95CI| |) P N OR (95CI) P N OR (95CI) P 
rs10116277 9p21 T 0.49 1375/7347 1.10 (1.01,1.20) 2.1e-02 398/6614 1.14 (0.98,1.32) 8.6e-02 1127/8407 1.15 (1.05,1.25) 3.0E-03 
rs2383207 9p21 G 0.52 1351/7285 1.10 (1.03,1.17) 6.0e-03 388/6565 1.11 (0.98,1.21) 8.6e-02 1109/8331 1.12 (1.05,1.19) 2.0e-03 
rs1333040 9p21 C 0.50 1585/8059 0.89 (0.82,0.96) 4.0e-03 481/7245 0.90 (0.79,1.04) NS 1263/9314 0.88 (0.81,0.96) 5.0e-03 
rs1333049 9p21 G 0.49 1567/7884 1.07 (0.99,1.15) NS 469/7087 1.11 (0.96,1.27) NS 1236/9149 1.03 (0.95,1.13) NS 
rs10757274 9p21 G 0.50 1620/8101 1.12 (1.04,1.21) 4.0e-03 488/7263 1.13 (0.99,1.29) 7.3e-02 1292/9387 1.13 (1.04,1.23) 3.0e-03 
rs10455872 LPA G 0.24 1711/10683 1.39 (1.21,2.58) 1.1E-06 519/9952 1.08 (0.84,1.39) NS 1351/12067 1.25 (1.08,1.45) 3.0E-03 
rs3798220 LPA G 0.02 1765/11343 1.18 (0.93,1.49) NS 537/10577 1.09 (0.70,1.72) NS 1413/12772 1.39 (1.09,1.79) 9.0E-03 
 
†Effect allele; ‡Effect allele frequency; §odds ratio;| |Confidence interval; All logistic models were correct for age, gender and diabetes status 
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3.6.3.2 LPA SNPs 
In this study we found that the minor allele of rs10455872 was associated with increased 
risk of CAD and LEAD, and not with IS and that the minor allele of rs3798220 was associated 
with LEAD but not with CAD or with IS (Table 3-3). 
3.6.4 Meta-analysis of rs10455872 and rs3798220 effects in cardiovascular 
phenotypes 
A fixed effect per minor allele of rs3798220 was 1.43 (1.26-1.61), p=5.32E-28 (Figure 3-1) 
and from the random effects model was 1.43 (1.18-1.72) on risk of CAD. The fixed effect 
estimate per minor allele for rs10455872 was 1.33 (1.06-1.29), p=1.06E-21 (Figure 3-1) and 
the random effects estimate was 1.33 (1.19-1.49). Significant heterogeneity was detected in 
the CAD phenotype so both fixed and random effects are reported.  
There was no association of rs107455872 p=0.67 or rs3798220 p=0.30 with IS in the meta-
analysis (Figure 3-1). Both LPA SNPs were associated with LEAD: rs107455872 had an 
OR=1.19 (1.08-1.31) per minor allele, p=4.0E-04 and rs3798220 had an OR=1.36 (1.16-1.63) 
per minor allele, p=9.0E-04 (Figure 3-1). No significant heterogeneity was detected in the 
meta-analysis of IS or LEAD allelic effects. 
 
 
Figure 3-1: Forest plots of the effect of LPA SNPs rs3798220 and rs10455872 on 
cardiovascular phenotypes combined across studies. 
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3.6.5 Association between GS for cardiovascular risk factors and their 
corresponding traits 
The GS scores showed a positive correlation and were all significantly associated with their 
corresponding traits - irrespective of diabetic status (Table 3-4) - and tests for interaction 
with T2D were not significant. 
Table 3-4: Association each genotype score with its corresponding trait in type 2 diabetics 
and non-diabetics in the GoDARTS study 
  Diabetic  Non-diabetic 
Trait* SNPs N Beta SE P N Beta SE P 
SBP 29 5583 0.28 0.142 4.47E-02 3902 0.76 0.152 6.050E-07 
DBP 29 5583 0.56 0.222 1.16E-02 3902 0.40 0.129 1.77E-03 
TCHOL 61 6119 0.88 0.053 1.28E-61 3535 0.98 0.057 4.62E-64 
LDL-C 48 4090 0.93 0.042 7.30E-102 2991 0.93 0.048 1.43E-77 
HDL-C 52 5838 0.70 0.080 1.65E-18 3489 0.90 0.059 1.66E-52 
TG 37 4549 0.74 0.062 2.69E-32 3069 0.40 0.040 9.32E-24 
FGLU 17     1886 0.86 0.133 1.29E-10 
   OR 95%CI   OR 95%CI  
CAD 45 8964 1.32 (1.17, 1.49) 1.10E-05 4881 1.34 (1.16-1.54) 5.91E-05 
T2D† 61 10207 1.16 (1.14, 1.19) 2.79E-86         
*All models were corrected for age and gender; untreated levels of the continuous traits 
were used for this analysis and the FGLU association was corrected for body mass index; 
†These scores were tested against a case control design of T2D cases compared to non-
diabetic controls where the score has been separated in deciles. 
3.6.6 Association of genetic scores for known risk factors and corresponding 
traits with cardiovascular disease 
3.6.6.1 Coronary artery disease 
The effects of the GS for SBP, DBP, T2D, LDL-C and FGLU on CAD were consistent with 
effects observed for measured traits where both GS and trait showed the same direction of 
effect and were significantly associated with CAD. Even though the GS for serum levels of TG 
and (directly measured) serum levels of TG per se were both significantly associated with 
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CAD they had opposing effects on CAD risk. While increasing serum levels of TG were 
associated with an increased risk of CAD the GS for increasing TG had a protective effect. 
The GS for total cholesterol (TCHOL) and HDL-C were not substantial modifiers of CAD risk 
despite the strong association of serum levels of TCHOL and HDL-C with CAD (Table 3-5). 
Table 3-5: Association of risk factors and genotype scores for risk factors associated with 
CAD, N cases = 1441, N controls=7523 
 Trait Genotype score 
Trait OR* 95%CI† P OR 95%CI P 
SBP‡,§ 1.02 (1.01,1.02) 2.94E-13 1.06 (1.02,1.10) 2.54E-03 
DBP 1.03 (1.02,1.04) 6.17E-14 1.10 (1.04,1.17) 7.27E-04 
T2D 5.67 (4.8,6.7) 1.01E-91 1.03 (1.01,1.05) 9.85E-03 
T1DM    1.00 (0.98,1.03)  NS 
TCHOL 1.37 (1.84,2.13) 3.93E-30 1.06 (0.84,1.34) NS 
LDL-C 1.32 (1.3,1.45) 1.44E-09 1.37 (1.14,1.65) 8.46E-04 
HDL-C 0.19 (0.16,0.22) 7.19E-106 1.03 (0.64,1.64) NS 
TG 1.14 (1.09,1.18) 4.34E-10 0.82 (0.72,0.94) 3.95E-03 
FGLU 1.04 (1.02,1.05) 3.08E-08 2.49 (1.31,4.71)  5.11E-03 
*Odds ratio; †Confidence interval; ‡ Systolic blood pressure (SBP), diastolic blood pressure 
(DBP), T2D (T2D), type 1 diabetes (T1DM), total cholesterol (TCHOL), LDL-C (LDL-C), HDL-C 
(HDL-C), triglycerides (TG), fasting glucose(FGLU); All models were corrected for age, gender 
and diabetes status except the association with T2D : SBP and DBP were corrected for 
hypertensive treatment; TCHOL, LDL-C, HDL-C and TG were corrected for statin treatment. 
3.6.6.2 Ischaemic stroke 
Direct measures for, TCHOL, LDL-C, HDL-C, TG and FGLU and clinically determined T2D and 
the GS for CAD, SBP and T2D were associated with increased risk of IS (Table 3-6). The GS for 
CAD, SBP and T2D showed the same direction of effect as their corresponding physical 
measures on IS risk. Although the associations were not statistically significant, the TG GS 
reduced the risk of IS while serum levels of TG increased the risk of stroke, similar to the 
associations with CAD (Table 3-5 and Table 3-6). 
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Table 3-6: Association of risk factors and genotype scores for risk factors associated with 
ischaemic stroke, N cases =426, N controls=6624 
 Trait genotype score 
 Trait OR* 95%CI† P OR 95%CI P 
CAD    1.05 (1.01,1.09) 1.48E-02 
SBP‡,§ 1.01 (1.00-1.01) NS 1.07 (1.10-1.14) 4.70E-02 
DBP 1.01 (1.00-1.02) NS 1.07 (0.97-1.18) NS 
T2D 7.54 (5.20-10.94) 1.90E-26 1.07 (1.03,1.11) 1.24E-03 
T1DM    1.00 (0.96,1.06) NS 
TCHOL 1.25 (1.14,1.37) 1.52E-06 0.91 (0.63,1.3) NS 
LDL-C 1.21 (1.05,1.41) 1.10E-02 1.01 (0.73,1.39) NS 
HDL-C 0.18 (0.12,0.27) 7.53E-18 1.25 (0.55,2.84) NS 
TG 1.11 (1.02,1.21) 1.50E-02 0.83 (0.65,1.04)  NS 
FGLU 1.04 (1.01,1.07) 4.00E-03 2.66 (0.76,9.26) NS 
*Odds ratio; †Confidence interval; ‡ Systolic blood pressure (SBP), diastolic blood pressure 
(DBP), T2D (T2D), type 1 diabetes (T1DM),total cholesterol (TCHOL), LDL-C (LDL-C), HDL-C 
(HDL-C), triglycerides (TG), fasting glucose(FGLU); All models were corrected for age, gender 
and diabetes status except the association with T2D : SBP and DBP were corrected for 
hypertensive treatment; TCHOL, LDL-C, HDL-C and TG were corrected for statin treatment. 
3.6.6.3 Lower extremity arterial disease  
An increase in the physical measurements of known LEAD risk factors TCHOL, LDL-C, FGLU 
and T2D status were associated with increased risk of LEAD; however, only the GS for FGLU 
and T2D were associated with increased risk of LEAD and had the same direction of effect as 
the measured trait. Similar to the relationship with CAD and IS, serum TG and the TG GS 
were significantly associated with LEAD but while increasing serum levels predicted 
increasing LEAD risk, a higher GS predicted reduced risk of LEAD. The associations of the 
CAD GS and T1DM GS were unique to the LEAD phenotype. No association was observed 
with the GS for CAD but the T1DM GS was significantly predictive of increased LEAD risk 
(Table 3-7). 
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Table 3-7: Association of risk factors and genotype scores for risk factors associated with 
lower extremity arterial disease, N cases =1195 , N controls=8650 
 Trait Genotype score 
 Trait OR* 95%CI† P OR 95%CI P 
CAD    1.07 (0.96, 1.18) NS 
SBP‡,§ 1.00 (1.00,1.00) NS 1.03  (0.99,1.06) NS 
DBP 0.98 (0.98,0.99) 6.96E-07 1.06 (1,1.12) 3.50E-02 
T2D 5.49 (4.55,6.62) 1.73E-70 1.05 (1.02,1.07) 3.93E-05 
T1DM    1.04 (1.01,1.07) 1.97E-03 
TCHOL 1.15 (1.09,1.21) 9.58E-08 0.85 (0.68,1.05) NS 
LDL-C 1.13 (1.04,1.24) 6.00E-03 0.87 (0.72,1.05) NS 
HDL-C 0.35 (0.29,0.42) 2.56E-26 1.58 (0.95,2.63) NS 
TG 1.07 (1.02,1.11) 2.00E-03 0.83 (0.72,0.95) 9.00E-03 
FGLU 1.03 (1.01,1.04) 1.76E-04 2.33 (1.18,4.59) 1.44E-02 
*Odds ratio; †Confidence interval; ‡ Systolic blood pressure (SBP), diastolic blood pressure 
(DBP), T2D (T2D), type 1 diabetes (T1DM), total cholesterol (TCHOL), LDL-C (LDL-C), HDL-C 
(HDL-C), triglycerides (TG), fasting glucose(FGLU); All models were corrected for age, gender 
and diabetes status except the association with T2D : SBP and DBP were corrected for 
hypertensive treatment; TCHOL, LDL-C, HDL-C and TG were corrected for statin treatment. 
3.7 Discussion 
We have presented algorithms to identify CAD, IS and LEAD cases from the GoDARTS study 
and validated the IS and LEAD phenotypes using the EMR approach. SNPs in the 9p21 and 
LPA region were associated with EMR derived cardiovascular phenotypes from GoDARTS 
and exhibited similar effect sizes and direction of effect when compared to published 
studies. We have shown that while direct measurements of known cardiovascular risk 
factors are positively associated with risk of cardiovascular disease that the GS for those risk 
factors do not always reflect that relationship. 
The 9p21 and LPA loci are reported in GWAS for cardiovascular disease38, 161, 268-275 and the 
9p21 SNPs examined in this study had similar effect sizes across CAD, stroke and LEAD and 
when compared to published results270, 272, 276. Although, the variants investigated in this 
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study had not been specifically reported for LEAD, variants linked to rs10757274 - 
rs1333049 and rs10757269 (R2>0.8, D’>0.92) - had been shown to increase the risk of LEAD 
and to lower ABI158, 268. The LPA SNPs were not associated with IS in this study but did show 
different allelic effects for LEAD and CAD.  
SNPs rs10455872 and rs3798220 map to the LPA gene and have been associated with 
lipoprotein (a) levels, an independent risk factor for CAD, IS and LEAD50, 277. Our meta-
analysis of the published effects of rs10455872 and rs3798220 confirmed the association of 
these SNPs with CAD and LEAD50, 162 but did not detect any relationship with ischaemic 
stroke based on estimates from GoDARTS and the HPS162. This may be due to a lack of 
power to detect effect as a meta-analysis showed a smaller effect of lipoprotein (a) levels on 
stroke when compared to CAD278. The varying effect sizes of LPA SNPs on individual 
cardiovascular disease types compared to the uniform effects observed for 9p21 SNPs 
indicates that the phenotypes derived from EMR are discrete enough to reveal differences 
in molecular patho-aetiological pathways. The associations with the GS further supports this 
premise as some previous associations with GS scores were replicated in this study but the 
associations with LEAD were novel and distinct from CAD and IS.  
A GS that combined the SNP effects of SBP and DBP into one score was shown to increase 
the risk of CAD and IS31 and we observed a similar relationship between separate GS for SBP 
and DBP with CAD and IS. We also confirmed previous findings that the GS for LDL-C 
increased the risk of CAD by the same magnitude as the serum levels of LDL-C and that 
there is no association between the GS for HDL-C and CAD, contrary to a marked protective 
effect of increasing serum HDL-C260. Despite the power to detect an association with GS for 
CAD and LDL-C, these GS were not associated with the LEAD while the GS for T1DM was 
distinctly associated with LEAD. These associations indicate that LEAD may have different 
genetic determinants to CAD and IS and different risk factors. Overall, the associations 
between different GS with CAD, IS and LEAD were usually consistent with the associations 
observed for physical measures but this was not true for triglycerides.  
The GS for TG showed a protective effect from cardiovascular disease while increased to 
serum levels of TG increased the risk. This is similar to studies related to T2D, a CAD risk 
factor, where TG raising alleles in GCKR have been associated with decreased T2D risk, 
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improved insulin sensitivity and plasma glucose concentrations267, 279-281. The inverse 
relationship may be explained in part by the mechanism modifying serum TG levels as 
observed for the I148M variant of PNPLA3. PNPLA3 has been proposed to increase 
circulating triglycerides by exporting TG particles from the liver into the blood stream and to 
protect against T2D and insulin resistance in a similar fashion to GCKR. Removing TG from 
the liver prevents lipotoxic liver damage, simultaneously reducing the risk of T2D and insulin 
resistance282. It may be that similar effects are operating in the vasculature and or cardiac 
tissue with respect to triglyceride efflux and lipotoxicity. 
Pleiotropic effects of TG associated SNPs may also explain the inverse relationship between 
the GS and CAD as only 6 of the SNPs were independent predictors of serum TG and 7 also 
predicted serum HDL-C and LDL-C levels. Teslovich et al. (2010) found that 13 of the TG 
associated SNPs included in the GS were also associated with CAD (p<0.05) and that the risk 
allele was not always the TG raising allele54. While the mechanisms that increase serum TG 
levels may reduce CAD risk the effect of the SNPs on other lipid traits may also modify other 
risk factors and the risk attributed to the TG GS. Presumably more prosaic reasons might 
include the fact that SNPs strongly related to TG levels may not be the same as variants that 
predispose to high TG in the context of a metabolic disturbance.  
Identifying related cardiovascular phenotypes from a single population allows for the 
comparison of SNP affects across these phenotypes and provides insights into how SNPs 
predict disease outcomes both generally and specifically. In the GoDARTS study, the similar 
effects of 9p21 SNPs on risk of cardiovascular disease indicate that the EMR identification 
algorithms are identifying individuals with generalised atherosclerotic vascular disease. The 
associations of the LPA SNPs with cardiovascular outcomes was more specific indicating that 
the algorithms are sensitive to different forms of vascular disease - a premise further 
supported by the specific associations of the CAD and T1D GS with cardiovascular outcomes. 
Validating EMR linked biobanks, like GoDARTS, for genetic studies is important for tracing 
the global clinical impact of disease related loci across correlated phenotypes within a single 
population. It improves our ability to assess the importance and impact of these loci on 
multiple disease outcomes, rather than in the isolation of a single phenotype.  
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Limitations of these analyses include the fact that cardiovascular cases were biased toward 
acute events that resulted in hospitalisation or death and include individuals with co-
morbidities such as T2D. Although individuals for this study were selected from the larger 
GoDARTS population and were enriched for T2D225, 226 and were biased toward acute end 
points it was still possible replicate published genetic associations. Despite a lack of power 
to detect significant associations with IS effect alleles and effect sizes were consistent with 
published findings161 and the identification algorithm is well validated. It is important to 
note that IS is made up of several stroke sub-types that have different disease pathways and 
this phenotype heterogeneity may have affected the power to detect significant 
associations. The ICD codes used to identify CAD from SMR01 have been well validated by 
the Heart-disease Evidence-based Audit & Research Tayside Scotland (HEARTS) study283. 
Furthermore, associations between established CAD loci and risk of CAD were well 
replicated in GoDARTS. 
This chapter demonstrates how well validated and characterised cardiovascular phenotypes 
can be derived from EMR data for genomics research and how these phenotypes can be 
used effectively to investigate the genetics of multiple facets of cardiovascular disease. 
Importantly this chapter suggests the existence of the shared and specific genetic 
architecture of LEAD and CAD. The ability to look across a wide range of both clinical and 
physiological phenotypes will provide insights into the pleotropic relationships between the 
both risk factors and disease, as well as across the different forms of vascular disease. The 
CAD algorithm derived in this study was used to contribute summary statistics to a large 
scale meta-analysis of CAD.  
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Chapter 4: Large-scale association analysis identifies new risk loci for 
coronary artery disease 
The CARDIoGRAMplusC4D Consortium 
This work has resulted in a publication in Nature Genetics, the pdf of which is included as 
appendix 7. A full list of authors and author contributions are given in appendix 7 
Natalie van Zuydam analysed the CardioMetabochip data for CAD and MI in the GoDARTS 
dataset, submitted summary statistics to the meta-analysis, analysed the GoDARTS data for 
the subgroup analyses including additional analyses for the manuscript, the gene score 
analysis for GoDARTS was provided for the analysis. Colin Palmer contributed to writing the 
manuscript  
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4.1 Introduction 
There are 31 loci that have been identified by large-scale genetic studies for CAD (Table 1-2) 
which explain about 10% of the total heritability38, 44, 48-52. The largest study to date included 
22,233 CAD cases and 64,762 CAD free controls of European descent from 14 genome-wide 
association studies48. In order to identify additional variants associated with CAD and to 
explain more of the heritability much larger sample sizes are required but genotyping on 
genome wide arrays is prohibitively expensive. In order to overcome the cost of genotyping 
larger sample sets the large consortia designed a custom Illumina array234.  
The CardioMetabochip consists of SNPs for replication and fine-mapped regions of interest 
contributed by the Body Fat Percentage, CARDIoGRAM (coronary artery disease and 
myocardial infarction), DIAGRAM 233, GIANT (anthropometric traits), Global Lipids Genetics 
(lipids), HaemGen (haematological measures), ICBP (blood pressure), MAGIC (glucose and 
insulin), and QT-IGC (QT interval) GWAS meta-analysis consortia. Loci were selected based 
on previous findings from GWAS, individual selections from consortia and earlier genetic 
studies234. For the genetics of CAD the purpose of the array was to provide a focused SNP 
set for replication and to investigate independent effects in fine-mapped regions. The cost 
of genotyping individuals on the CardioMetabochip is considerable less than genome wide 
SNP arrays allowing for a large sample size to be genotyped for a set of SNPs and loci likely 
to be associated with CAD. 
SNPs identified as risk loci for CAD from large genetic studies should increase our power to 
predict future disease based on genetics. Clinically, CAD risk is assessed by combining known 
risk factors into a score. The Framingham risk score combines clinically measured systolic 
blood pressure, low density lipoprotein cholesterol (LDL-C), high-density lipoprotein 
cholesterol (HDL-C) and includes age, sex, diabetes and smoking status into a weighted 
score284. Each risk category is assigned a different weight which is added up and compared 
to a curve to predict the risk of CAD over 10 years as a percentage284. A desirable clinical 
outcome of large scale meta-analyses for CAD would be to combine the loci into a genetic 
risk score to provide improved prediction of CAD above what is already provided by 
traditional risk factors.  
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The main aim of this study was to replicate an LD pruned SNP set of 6222 SNPs which 
reached nominal significance p<0.01 by Schunkert et al. (2011) in an independent sample of 
190,000 genotyped on the CardioMetabochip (CM). The other SNP content on the CM was 
also investigated for novel loci that may be associated with CAD. External to the meta-
analysis we combined the loci identified at an FDR threshold of less than 5% for association 
with CAD into a CAD gene score. The predictive ability of the CAD genetic risk score was 
compared to conventional risk factors in an independent group of individuals from 
GoDARTS. 
4.2 Materials and methods 
4.2.1 Analyses prepared from GoDARTS 
4.2.1.1 Meta-analysis population and genotyping data 
Coronary artery disease cases and controls were identified according to the definition under 
heading 3.2.1. Individuals typed on the CardioMetabochip were included in all analyses 
submitted for the meta-analysis (Figure 4-1). A full description of the CardioMetabochip 
genotyping data is given under heading 2.4.5.  
 
 
 
GoDARTS 
Individuals typed on the 
CardioMetabochip 
Individuals typed on the 
Affymetrix 6.0 SNP array 
CARDIoGRAM+C4D meta-
analysis 
False discovery rate score 
analysis 
Figure 4-1: A sub-population of GoDARTS was used to estimate summary statistics which 
were included in the meta-analysis and a separate sub-population was used to calculate 
an CAD risk score.  
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4.2.1.2 Statistical methods 
Logistic regression analyses were performed in PLINK using prescribed models: all CAD cases 
with all controls, adjusted for sex and age; male CAD cases with male controls, adjusted for 
age; female CAD cases with female controls, adjusted for age; early-onset CAD cases with 
early age of onset (≤50 years) with all CAD controls, adjusted for sex; late-onset CAD cases 
(>50 years) with all controls, adjusted for sex; and all myocardial infarction cases with all 
controls, adjusted for age and sex. Age was defined as the recruitment age for controls and 
the event age for cases. 
4.2.2 Large scale replication and meta-analysis 
A full description of the meta-analysis methods are given in Appendix 7 under online 
methods. 
4.2.3 CAD genetic risk score 
4.2.3.1 Score population 
Individuals that conformed to the CAD case and control definition but were not included in 
the large-meta-analysis were identified in GoDARTS (heading 3.2.1). These individuals were 
genotyped on the Affymetrix 6.0 array. A full description of these data can be found under 
heading 2.4.3.  
4.2.3.2 SNPs included in the CAD genetic risk score and score calculation 
SNPs associated with CAD in the meta-analysis at an FDR of 5% and known CAD SNPs were 
used to calculate a genotype score. The genotyping data was taken from the Affymetrix 6.0 
SNP genotyping array (2.4.3) which had been imputed to HapMap2 and the Wellcome Trust 
Common Control set typed on the Illumina Human 1M dual using Impute2238( 
http://mathgen.stats.ox.ac.uk/impute/impute_v2.html). Where the index SNP was not 
available a proxy with R2>=0.8 was used.  
4.2.3.2 Derivation of cardiovascular risk predictors from electronic medical 
records 
All cardiovascular risk factors were calculated at the index date which was the time of the 
CAD event for cases and date of study enrolment for controls. Systolic blood pressure was 
calculated as a mean of all blood pressure measures before the index date; HDL-C and LDL-C 
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were also mean values taken before the index date. Smoking status was coded as ever or 
never with respect to the index date. Age was calculated at the index date.  
Cardiovascular risk factors were extracted from multiple EMR sources. Age and sex were 
extracted from data on demography for individuals in the cohort. Low density lipoprotein 
cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) were extracted from 
biochemistry records linked to the cohort (heading 2.1.7). Records of smoking status and 
regular blood pressure measures are available for the cohort and relevant data was 
extracted from these sources. Prescribing data was used to identify individuals who were 
dispensed lipid-lowering and or antihypertensive medication (heading 2.1.8). 
4.2.3.3 Genotype score calculation 
Genotype scores were calculated for individuals who had not been included in the meta-
analysis (Figure 4-1) using the method described under heading 2.9. Risk alleles were 
weighted using the stage 2 allelic effects estimated in the meta-analysis.  
4.2.3.4 Statistical methods 
All statistical analyses were conducted using the R statistics software227. First the association 
of the CAD genetic risk score with CAD was established in GoDARTS using a logistic 
regression analysis corrected for age and sex. Pseudo R square and c statistics were 
estimated from logistic regression analyses for individual predictors using the lrm function 
from the rms package. The net reclassification improvement was calculated for all models 
compared to age and sex and then for all the risk factors compared to all the risk factors and 
the CAD genetic risk score. These analyses were conducted using PredictABEL. A series of 
logistic regression models were run to assess the gain in disease prediction inherent in each 
disease predictor. The basic model included age and sex as predictors and compared the 
predictive capability of HDL-C, LDL-C, systolic blood pressure, smoking status to the CAD 
genetic risk score. 
4.3 Results 
4.3.1 Meta-analysis population from GoDARTS 
A total of 619 CAD cases and 2146 CAD free controls were included in the estimation of 
summary statistics which were submitted to the meta-analysis. The numbers of individuals 
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included in each of the sub-analyses are given in supplementary Table 1a285. 118,658 SNPs 
were submitted for each analysis and the main analysis had a lambda of 1.03 given in 
supplementary table 3a285.  
4.3.2 Large scale replication and meta-analysis 
A full description of the results is given in Appendix 7. Briefly, the meta-analysis included 
63,746 CAD cases and 130,681 CAD free controls. 15 new loci (Appendix 7: table 2) were 
identified at genome wide significance and 153 loci were associated with CAD at an FDR of 
5%. Rs16986953 was genome wide significant in the young CAD and male subgroups and 
had a significant interaction with age (p=0.033). These loci explain a quarter of the total 
heritability of CAD attributed to additive genetic variance. Network analysis of the SNPs that 
passed the FDR threshold showed and enrichment for lipid metabolism signals and to a 
lesser extent with blood pressure loci and obesity traits.  
4.3.3 Score population and characteristics 
737 CAD cases and 1771 CAD free controls were included in this CAD genetic risk score 
analysis. The controls were older than the cases, included more smokers, more statin and 
antihypertensive treated individuals and had higher HDL-C than the cases (Table 4-1). The 
cases had higher LDL-C, higher blood pressure and a higher proportion of males (Table 4-1). 
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Table 4-1: Population characteristics of the coronary artery disease cases and controls used 
in this study 
Trait Cases Controls 
Number 737 1771 
Age 63.1 (11.2) 65.3 (10.4) 
Male % 65 50 
Type 2 diabetic % 100 100 
History of smoking % 60 72 
Low density lipoprotein cholesterol (mmol/L)(SD) 2.3 (0.9) 2.1 (0.8) 
High density lipoprotein cholesterol (mmol/L)(SD) 1.2 (0.4) 1.4 (0.4) 
Statin treated % 29 63 
Systolic blood pressure (mmHg) (SD) 147.3 (18.1) 142.8 (11.9) 
Antihypertensive treatment 29 41 
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4.3.4 The genetic risk score for coronary artery disease and its association with 
coronary artery disease 
153 SNPs identified at an FDR <5% in the meta-analysis were included in the score 
(Appendix 8): 152 of the SNPs were the actual index SNP reported and rs1034565 was 
represented by a proxy rs7285377 (R2=D’=1). The CAD genetic risk score ranged from 7.29 
to 10.59 for individuals included in the study. The CAD genetic risk score was divided into 
equal quartiles where each quartile increase in score was associated with a 12% increase in 
the risk of CAD, the odds ratio was 1.12 (1.04-1.21) and the p value=3.8E-03. When the 
score quartiles were associated categorically with CAD there was a non-linear increase in 
CAD risk for increasing score quartiles (Figure 4-2) 
 
Figure 4-2: A forest plot of the odds ratio of coronary artery disease by quartile of the false 
discovery rate score. 
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4.3.5 Evaluation of the CAD genetic risk score as a predictor of coronary artery 
disease 
The pseudo R square, C statistics and net reclassification improvements (NRI) were 
estimated in a population that was independent of the population used in the meta-
analysis. The pseudo R square gives an indication of the ability of a predictor to predict a 
future outcome and the C statistic is a measure of the area under the receiver operating 
curve explained by the predictor, and is another measure of how well a predictor classifies 
individuals as either a case or a control. The net reclassification improvement is also a 
measure to compare the discriminatory power of two models and is more sensitive than the 
C statistics in detecting improvements in discriminatory power.  
In this study the greatest predictor of CAD outcome was HDL-C which had an R-square 
=0.244, a C statistic of 0.766 and an NRI of 0.83 [0.75 - 0.92] that was a significantly better 
predictor (p<7.8E-03) when compared to just age and sex alone indicating that it is a good 
predictor of CAD outcome. The second highest predictor was LDL-C with an R-square value 
of 0.159, a C statistic of 0.710 and an NRI 0.69 [0.61 - 0.78] that was a significantly better 
predictor (p<7.8E-03) when compared to just age and sex alone. Both these predictors 
improved the risk prediction above accounting for age and sex. SBP and history of smoking 
were also good predictors but were not as predictive as the lipid traits (Table 4-2).  
When compared to the other risk factors the CAD genetic risk score was not a good 
predictor on its own and offered very little additional predictive value above the traditional 
risk factors which are included in the Framingham equation284 (Table 4-2). When the model 
that included all the risk factors was compared to the model that included all of the risk 
factors and the CAD genetic risk score the NRI was 0.12 [0.03 - 0.20]and was nominally 
insignificant p=7.8E-03  
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Table 4-2: R square and c statistics for individual predictors of coronary artery disease in 737 
CAD cases and 1771 CAD free controls 
Model R square C statistic NRI [95% CI] 
Age and Sex 0.033 0.599 - 
Age, sex and history of smoking 0.058 0.626 0.53 [0.44 - 0.61] 
Age, sex, systolic blood pressure and 
antihypertensive treatment 
0.051 0.618 0.44 [0.35 - 0.52] 
Age, sex, high density lipoprotein 
cholesterol and statin treatment 
0.244 0.766 0.83 [0.75 - 0.92] 
Age, sex, low density lipoprotein 
cholesterol and statin treatment 
0.159 0.710 0.69 [0.61 - 0.78] 
Age, sex and all risk factors 0.218 0.753 0.80 [ 0.71 - 0.88] 
Age, sex and CAD genetic risk score 0.041 0.606 0.12 [0.03 - 0.20]* 
Age, sex, all risk factors and the CAD 
genetic risk score 
0.224 0.756 0.82 [0.73 - 0.90] 
*Nominally insignificant after multiple testing p=7.8E-03 
4.4 Discussion 
The largest meta-analysis for CAD revealed 15 new loci and enrichment for loci in lipid 
pathways. Rs16986953 was also found to interact with age in the subgroup analyses. 
Bringing the total number of confirmed CAD associated loci to 46. 153 loci associated with 
CAD at an FDR of 5% explain 10.6% of the narrow sense heritability. The predictive power of 
the FDR loci for CAD was not assessed in the meta-analysis paper but we investigated this 
aspect in a group of GoDARTS individuals that were independent of the meta-analysis 
population.  
In this chapter we found that a gene score made up of 153 independent loci for CAD was 
not as strong a predictor of CAD outcome as serum measures of LDL-C and HDL-C. When the 
score was included with other predictors it did not notably increase the prediction of CAD 
above the information provided by conventional risk factors which was in agreement with 
results that have not been published for the Atherosclerosis Risk in Communities (ARIC) 
study. This would indicate that we are still unable to use the current set of loci to predict 
CAD over and above traditional risk factors. 
The CAD genetic risk score does not include variants with a minor allele frequency (MAF) of 
less than 2% and excludes SNPs like rs3798220 and rs10455872 from the LPA locus which 
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have a large effect on CAD risk50. It may be that other predictors of CAD are variants that 
have a MAF of less than 1% and haven’t been detected by conventional GWAS and meta-
analysis methods. Large-scale analyses of genotyping data imputed to 1000G are currently 
being undertaken in order to identify rare variants that influence the risk of CAD. These 
efforts may explain a proportion of the missing heritability for CAD and increase our power 
to use genetics to predict CAD. Constructing a risk score for CAD may not be as 
straightforward as a weighted score based on the variants influence on CAD.  
Many of the loci detected at the FDR threshold are linked to the lipid metabolism pathway. 
In this study we found that LDL-C and HDL-C are the strongest predictors of CAD but the risk 
score did not improve the predictive power beyond these measured risk factors. We know 
that lipid raising alleles do not always confer increased CAD risk and many have pleiotropic 
effects on multiple lipid subgroups54(Chapter 3). It may be more useful to use a more 
comprehensive score which combines known loci for CAD with loci for known risk factors 
like nicotine dependence and hyperlipidaemia. There are many pitfalls in this approach and 
large Mendelian randomisation studies would have to be undertaken to identify the best 
genetic instruments to include in a CAD genetic risk score. Working from this basis the 
genetic loci included in the score and the architecture of the score would have to be refined 
in large prospective studies.  
A weakness of these analyses is that the sample size used to investigate the effects of the 
CAD genetic risk score and known risk factors was small, although our findings agree with 
those obtained by ARIC. Given that the risk factors included in this study are strong 
predictors and the genotype score is a well powered instrument when compared to 
individual genotypes we were still powered to detect an effect. The individuals included in 
the analysis were all diabetic and the allelic effects were estimated from a mixture of 
diabetic and non-diabetic individuals. The strengths of our analyses are that we used a 
completely independent sample from the population used to estimate the allelic effects of 
SNPs on CAD risk. The individuals in GoDARTS are well characterised and the values given 
for each of the risk factors were estimated from multiple measurements lending strength to 
the statistical models used in this chapter.  
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30% of the heritability of CAD remains unexplained and further studies are required to 
identify variants that contribute to the missing heritability. Despite the 3-4 fold increased 
risk of CAD in individuals with T2D, large-scale association studies have not identified an 
overlap in loci that predict T2D and also predict CAD. Some of the missing heritability may 
be found in these loci. To follow on from the large meta-analysis we will conduct a meta-
analysis of CAD in T2D to identify novel loci associated with CAD in T2D individuals and to 
assess the role of known loci in determining CAD in T2D populations. 
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Chapter 5: A meta-analysis of Coronary Artery disease in 18,158 
patients with type 2 diabetes 
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this study that was submitted to the CARDIoGRAM+C4D steering and executive committees 
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5.1 Introduction 
 In the previous chapter we presented the results from a large-scale meta-analysis of 
coronary artery disease (CAD) in mixed diabetic and non-diabetic populations. This work 
identified 46 loci that were associated with increased risk of CAD38, 48, 285. The estimated 
variance explained by 153 loci which passed a false discovery rate threshold explained 
10.6% of the additive variance which is just a quarter of the heritability estimated from twin 
and family studies31 and is not much larger than the component explained by the previously 
established loci48. We know that the main pathways that have been implicated in the 
pathology of CAD are inflammation and lipid metabolism pathways (Chapter 4). However, 
diabetes increases the risk of CAD 3-4 fold30 and is the most common macrovascular 
complication of diabetes. Despite evidence of an epidemiological association between CAD 
and T2D the largest meta-analyses for CAD and T2D, which included GoDARTS, found no 
overlapping risk loci at genome wide significance266, 285.  
Heritability estimates for subclinical markers of cardiovascular disease in T2D populations 
are estimated between 30-50%, indicating that there is a large heritable component286. 
Based on the epidemiological relationship and the heritability component it is interesting 
that so far no overlap in risk loci has been observed for these two diseases in conventional 
meta-analyses. This may be due to the lack of analyses specifically designed to identify an 
overlap between CAD and T2D in large genetic studies.  
In this chapter we aimed to identify loci associated with CAD specifically in T2D populations. 
We aimed to identify novel loci for CAD in T2D populations by combining summary statistics 
from the European Network for Genetic and Genomic Epidemiology (ENGAGE), Surrogate 
markers for micro- and macro-vascular hard endpoints for innovative diabetes tools 
(SUMMIT) and CARDIoGRAM+C4D in a meta-analysis. We also examined the role of known 
CAD and T2D loci in the same cohorts.  
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5.2 Materials and Methods 
5.2.1 Study Design Summary 
We combined summary statistics estimated from patients with type 2 diabetes, from 14 
genome wide association studies (GWAS) that included 5142 CAD cases and 6828 CAD free 
controls with 8 CardioMetabochip (CM) studies that included 1813 cases and 4375 controls, 
in a meta-analysis.  
5.2.2 Phenotype 
5.2.2.1 Type 2 diabetes 
Type 2 diabetic individuals were identified by individual studies according to a clinical 
diagnosis of T2D based on either the world health organisation (WHO) or American diabetes 
association (ADA) guidelines. If the type of diabetes was unknown we assumed type 2.  
5.2.2.2 Coronary artery disease cases and controls 
Individuals with coronary artery disease were identified by individual studies based on a 
number of criteria given in Table 5-1. Controls were identified to be free of CAD by 
individual studies. Since the diagnosis of T2D can vary with respect to the diagnosis of CAD 
in the clinical setting, CAD cases with a diagnosis of T2D up to 5 years after the event were 
accepted as T2D CAD cases and the same criteria applied to CAD free controls who were 
classified as T2D if they had a date of diagnosis up to 5 years after the date of study 
enrolment. 
5.2.3 Genotypes and imputation 
Operational details of the 14 GWAS studies are given in Table 5-3 and Table 5-4, and the 8 
CM studies are given in table 5-5. The GWAS studies were typed on the Affymetrix 6.0, 
Illumina Human Omni1-Quad and the Illumina Omni Express SNP arrays (Table 5-3). To 
obtain an increased marker set that was comparable across all GWAS platforms individual 
studies imputed their GWAS data to the HapMap2 CEU reference panel. Individual studies 
applied quality control pre-imputation and the details of that QC are given in Table 5-3. 
Either MACH or IMPUTE2 were used to impute missing genotypes yielding a maximum of 
2,619,962 SNPs (Table 5-4).  
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5.2.4 Statistical methods 
5.2.4.1 Individual studies 
The details of the analyses performed and the software used by individual studies are given 
in Table 5-4. Briefly analysis software that took genotype uncertainty into account were 
used to analyse imputed data. Imputed SNPs were tested for their association with CAD 
using a log-additive model frequentist tests adjusted for age (onset of the first event for 
cases or time of recruitment for controls), gender and centre specific covariates to account 
for population structure was applied to imputed SNPs. Directly typed SNPs were modelled 
log-additively in a logistic regression that was corrected for age, gender and centre specific 
covariates to account for population structure.  
5.2.4.2 Data cleaning steps applied before conducting the meta-analysis 
Quality control of the data was performed centrally. SNPs with a MAF lower than 1% or 
those with less than 10 minor allele homozygotes calculated as (2 x (Number of cases) x 
MAF)) were removed from individual studies. Specific quality control criteria were applied to 
directly typed and imputed SNPs separately. Directly typed SNPs with a MAF greater than 
5% were removed if the p value for the exact test for Hardy-Weinberg equilibrium (HWE) 
was less than 5.7E-07 and for SNPs with a MAF less than 1% with a less than 1E-04. Imputed 
SNPs were removed if they had an R2 value less than 0.3 if imputed with MACH and an R2 
value less than 0.4 if imputed using IMPUTE2. If imputed SNPs were analysed using SNPTEST 
then imputed SNPs were removed if the proper info value was less than 0.4. Pairwise allele 
frequency plots were drawn for each study for imputed and directly typed data separately 
to check for allele frequency outliers and strand differences amongst the summary meta-
data submitted for analysis.  
5.2.4.3 Statistical model checking 
The summary statistics for individual studies were checked by drawing plots, for directly 
typed and imputed SNPs separately, of the beta distribution by MAF category (0-0.01, 0.01-
0.05, 0.05-0.2, and 0.2-0.5). A deviation of the mean beta values from zero and scattered 
outliers were an indication of problems with the models used or low quality SNPs. To check 
for population stratification quantile-quantile plots were drawn from the p values submitted 
by each study and lambda was calculated.  
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5.2.4.4 Fixed effects meta-analysis 
The primary analysis comprised of two stages: a meta-analysis of the GWAS and a combined 
analysis of the GWAS cohorts and the CM cohorts. Our default meta-analysis used a fixed-
effect model with inverse variance weighting and a calculation of two homogeneity 
statistics: Cochran's Q and I2 using GWAMA (http://www.well.ox.ac.uk/gwama/)252. A Full 
description of these methods and statistics are given under heading 2.11. Individual studies 
were corrected for genomic inflation using GWAMA and the overall meta-analysis was 
corrected for genomic inflation by adjusting the standard error of the estimates by the 
inflation factor (SE*sqrt(λ)) and recalculating the p values. When there was no indication for 
heterogeneity for a SNP based on a Cochran’s Q p value greater than 0.01 the fixed effect 
model was maintained.  
5.2.4.5 Random effects meta-analysis 
When heterogeneity was present (Cochran’s Q p value <0.01) the study with the most 
extreme result was excluded and the meta-analysis was repeated. If heterogeneity was still 
apparent, we adopted and reported a random-effects model246 for that SNP excluding the 
outliers. The random effects model was applied using MetaSoft 
(http://genetics.cs.ucla.edu/meta/)246. A full description of the random effects model is 
given under heading 2.11.3.  
5.2.4.6 Comparison of effects estimated form the meta-analysis with known 
coronary artery disease loci and Type 2 diabetes loci 
The allelic effects estimated from this study were compared with published effects for 46 
CAD and 65 T2D loci. The effect estimates for the CAD loci were taken from the largest 
meta-analysis to date, and is described in chapter 4285. The T2D loci were taken from the 
largest meta-analysis of type 2 diabetes287. Within study effect estimates were plotted 
against published estimates using the plot function in R227.  
Power calculations were performed using the PS – Power and sample size calculator 
(http://biostat.mc.vanderbilt.edu/PowerSampleSize)288 to identify loci that we should be 
able to detect given the size of the study and a nominal significance level of 0.05. The within 
study estimates were compared with published estimates for loci which we had the power 
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to detect and for those that reached nominal significance of p<0.05 by testing for 
heterogeneity. The heterogeneity calculation is given under heading 2.12. 
5.2.4.7 Testing for independent effects in the 9p21 region 
CAD and T2D share a locus 9p21, rs1333049 is the lead SNP for CAD and rs944801 
(represented by rs7030641, R^2=0.966, D’=1) and rs10811661 are independent signals for 
CAD in the 9p21 region and the SNPs are not in strong linkage disequilibrium. To determine 
if the signals are independently predictive of CAD in T2D, we investigated their relationship 
with CAD in a sub-population of GoDARTS that had been genotyped on the 
CardioMetabochip. All analyses were conducted in R227 using the glm function from the stats 
package. Binary logistic regression analyses were corrected for age, sex, and for diabetes 
status where necessary. 
 First the SNPs were associated with CAD in a mixed population and T2D to determine if the 
SNPs were predictive of CAD and T2D in GoDARTS. The SNPs were then tested for 
interaction with diabetes status with CAD as an outcome. The second analysis restricted the 
association of the SNPs with CAD to just individuals with T2D to ascertain their affect and 
association with CAD in a T2D background. Finally all the SNPs were included in the same 
CAD model in T2D individuals to identify any changes in the effect estimates of the SNPs by 
including the other in the model.  
5.3 Results 
5.3.1 Study population 
The case phenotype definitions largely overlapped to include at least one of the following 
criteria: myocardial infarction, unstable angina or corrective procedures (Table 5-1). Cases 
were identified either by angiography or from hospital admission and death records (Table 
5-1). All controls were identified as CAD free individuals and excluded the case definition 
criteria (Table 5-1).  
Age in cases ranged from 41-66 years in cases and 40-72 years in controls; the current 
smoking status of in cases ranged from 15-85% and controls between 15 and 88% and the 
BMI in cases ranged from 28 to 34 kg/m2 in cases and controls 28-33 kg/m2 (Table 5-2). 
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Table 5-1: Population characteristics for all cohorts in the CAD meta-analysis 
Study Full name Reference Ethnicity 
Region of 
Recruitment 
Phenotype Case Control  
Cleveland 
Clinic 
GeneBank 
Study 
Cleveland Clinic 
GeneBank Study 
(21475195 289) European Cleveland, OH CAD 
Subjects undergoing 
elective diagnostic 
cardiac 
catheterization 
procedure 
Controls free of 
CAD at baseline 
Corogene COROGENE study 290 European Finland MI 
Hospital admission 
codes and death 
records for: MI only 
Controls free of 
CAD 
DGI 
Data not yet 
submitted      
 
CATHGEN 
Duke Cardiac 
CATHeterization 
GENetics 
(CATHGEN) study 
www.cathgen.duhs.d
uke.edu 
Caucasian USA CAD 
at least one of these 
criteria: significant 
CAD on cath, ever MI 
(history, current or 
subsequent), hx PCI, 
hx CABG 
no CAD on cath, no 
hx of cabg or PCI, 
no ever MI 
EGCUT 
Estonian Genome 
Center, 
University of Tartu 
291
 European Estonia CAD 
Hospital admission 
codes 
Controls free of 
CAD 
Go-DARTS 
The Genetics of 
Diabetes Audit and 
Research in Tayside 
Scotland 
225
 European Scotland CAD 
Hospital admission 
codes and death 
records for: 
MI/Unstable 
Angina/Corrective 
procedures (PTCA & 
Controls free of 
CAD 
107 
 
Study Full name Reference Ethnicity 
Region of 
Recruitment 
Phenotype Case Control  
CABG) 
KORAF3 
Lübeck Registry of 
Structural Heart 
Disease /KORA 
(Kooperative 
Gesundheitsforsch
ung 
48 
292 
European German CAD 
Consecutive patients 
referred for 
coronary 
angiography, 
classified as 
CAD/MI cases based 
on the coronary 
angiogram; CAD < 65 
y in males, CAD 
< 70 y in females 
Controls free of 
CAD 
LURIC 
Ludwigshafen Risk 
and Cardiovascular 
Health Study 
42
 European Germany CAD Angiography 
Controls free of 
CAD 
PennCath 
Data not yet 
submitted      
 
MedStar 
Data not yet 
submitted      
 
MIGen 
Data not yet 
submitted      
 
RS 
Data not yet 
submitted      
 
SDR 
Scannia Diabetes 
Register 
      
       
Controls free of 
CAD 
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Study Full name Reference Ethnicity 
Region of 
Recruitment 
Phenotype Case Control  
EGCUT 
Estonian Genome 
Center, University 
of Tartu 
291
 European Estonia CAD 
Hospital admission 
codes 
Controls free of 
CAD 
IMPROVE 
 
293
 European 
Finland, 
Sweden, 
Netherland, 
France, Italy 
CAD 
 
 
SCARFSHEEP 
 
294
 European Sweden MI/CAD 
First confirmed 
myocardial 
infarction 
No history, 
symptoms or signs 
of cardiovascular 
disease 
AMC-PAS 
Premature 
Atherosclerosis 
Study 
 
European Netherlands CAD 
MI, surgical or 
percutaneous 
revascularisation, 
coronary angiograph 
with ≥70% stenosis 
in a major epicardial 
artery 
 
PMB Pfizer-MGH-Broad 
 
European 
Finland, 
Sweden 
CAD/MI 
 
Controls free of 
CAD 
MORGAM 
Monica Risk 
Genetics Archiving 
and Monograph 
295
 European Finland CAD 
Hospital admission 
codes and death 
records for: 
MI/Unstable 
Angina/Corrective 
procedures (PTCA & 
CABG) 
 
THISEAS The Hellenic Study 296 European Greece CAD/MI First-ever mi before <30% stenosis 
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Study Full name Reference Ethnicity 
Region of 
Recruitment 
Phenotype Case Control  
of Interactions 
between 
Snps and Eating in 
Atherosclerosis 
Susceptibility 
age of 70 yrs.; first 
CAD (>50% stenosis 
in one of the three 
main coronary 
vessels assessed by 
coronary artery 
angiography - no 
history of ACS) 
assessed by 
coronary artery 
angiography or 
negative stress 
test; age 
matched without 
MI/CAD 
history 
DILGOM 
Dietary, life style, 
and genetic 
determinants of 
obesity and 
metabolic 
syndrome 
297
 European Finland CAD 
All CAD: Incident 
definite or possible 
MI or coronary 
death, or unstable 
angina 
during follow-up, 
Coronary 
revascularization 
during follow-up, 
Documented MI at 
baseline, or an 
unclassifiable 
coronary death 
during 
Follow-up. MI: 
Definite myocardial 
Infarction. 
Non-cases from 
the same 
population-based 
longitudinal 
cohort study 
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Table 5-2: Population characteristics for all studies included in the meta-analysis of coronary 
artery disease in type 2 diabetic individuals 
Study 
Mean age (SD) years 
cases/controls 
N Diabetic CAD/MI 
cases/controls 
% current smoker 
CAD/MI 
cases/controls 
BMI (kg/m2) 
CAD/MI 
cases/controls 
CCF 
61.54 (11.06)/ 
72.79 (6.42) 
510/30 84.7%/15.3% 
31.02 (6.38)/ 
29.46 (5.67) 
Corogene 
66.3423 (11.68)/ 
55.58 (12.19) 
257/117 38.1%/24% 
 
DGI 67.26/62.11 365/524 39.7%/35.7% 
28.25 (4.05)/ 
28.54(4.55) 
CATHGEN 
63.51 (11.27)/ 
58.47 (11.79) 
397/132 58.1%/41.3% 
32.13 (7.13)/ 
35.21 (9.68) 
EGCUT 
65.03(12.76)/ 
49.84(19.67) 
 
171/214 
14.42%/30.5% 
31.18(5.94)/ 
31.04(6.04) 
GoDARTS 
62.75 (10.97)/ 
65.43(10.07) 
877/2187 74.8%/61.2% 
30.72 (5.45)/ 
31.1 (5.74) 
KORA F3 
67.57 (6.53)/ 
66.44 (7.60) 
51/136 23.53%/11.03% 
30.96 (5.18) 
/31.08 (4.51) 
LURIC 
59.36 (10.56) / 
60.13 (11.53) 
934/283 70.2%/51.1% 
28.06 (4.01)/ 
28.75 (4.64) 
PennCath 
Data not yet 
submitted    
MedStar 
Data not yet 
submitted    
MIGen 
Data not yet 
submitted    
RS 
70.5 (7.60)/ 
68.80 (8.30) 
 
188/380 24.5%/25.9% 
27.00(3.50)/ 
27.80 (4.00) 
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Study 
Mean age (SD) years 
cases/controls 
N Diabetic CAD/MI 
cases/controls 
% current smoker 
CAD/MI 
cases/controls 
BMI (kg/m2) 
CAD/MI 
cases/controls 
SDR 
Data not yet 
submitted    
EGCUT 
59.64(10.53)/55.7 
(10.9) 
223/517 20.6%/25.4% 
33.65(5.30)/ 
33.33(5.36) 
IMPROVE 
65.73 (5.98)/ 
64.15 (5.38) 
47/907 19.4%/14.6% 
30.15 (5.11)/ 
29.19 (4.63) 
SCARFSHEEP 
57.62 (7.33)/ 
58.50 (7.20) 
237/104 40.7% /27.1% 
28.34 (4.44)/ 
27.95 (4.43) 
AMC-PAS 
41.34(5.76)/ 
40.11(5.99) 
62/6 73.6%/88.5% 
29.66(4.89)/ 
30.28(4.38) 
PMB 
    
MORGAM 
59.3 (8.65)/ 
55.73 (10.52) 
195/281 28.13%/27.38% -- 
THISEAS 
    
DILGOM 
63.79 (7.68)/ 
51.82 (13.50) 
39/267 18.65%/17.4% -- 
     
5.3.2 Imputation quality control and analysis methods for individual studies 
Each cohort was genotyped separately on a number of different platforms. In order to make 
the GWAS studies more comparable genotypes were imputed from HapMap2. Pre-
imputation quality control and imputation to HapMap2 were conducted by individual 
studies. The pre-imputation quality control criteria and the number of directly typed SNPs 
included by each study are given in Table 5-3, generally different thresholds for missingness 
by individual and by genotype were applied. Hardy-Weinberg equilibrium p value thresholds 
were also imposed. Table 5-4 includes the details of the imputation software and the 
reference panel used to impute genotypes, generally either MACH or IMPUTE2 were used to 
impute genotypes from HapMap2. Directly typed and imputed genotypes were analysed 
separately by individual cohorts and the analysis software used to generate the summary 
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statistics as well as the number of directly typed and imputed SNPs submitted are given in 
Table 5-4.  
The CardioMetabochip is a much smaller array which contains very different content to the 
genome wide arrays. This array contained content from a number of different genome wide 
array platforms so they were not imputed. The software used to analyse the 
CardioMetabochip data by individual cohorts as well as the model run and the number of 
SNPs that were submitted with summary data are given in table 5-5.  
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 Table 5-3: Genotyping platforms and pre-imputation QC for genome wide studies 
Study 
Genotyping 
Centre 
Genotyping 
Array 
Calling 
algorithm 
Pre-Imputation 
 QC Exclusion  
Criteria 
Sample 
 call rate 
SNP  
call rate 
HWE 
CCF 
University 
of 
 Ottawa 
Affymetrix 
 6.0 
Birdseed 
Filtered samples for IBS, 
heterozygosity, sex 
consistency and standardized 
IBS eigenvector outliers 
97% 95% 1.00E-04 
Corogene Sanger 
Illumina 
 610K 
Illuminus 
failed gender check, 
 Low genotype 
frequency(<95%),  
excess heterozygosity, 
 non-European,  
excess relatedness, 
 low MAF, 
 
>97% 95% 1.00E-06 
DGI 
Broad 
Institute 
Affymetrix 500K 
 
Birdseed 
MAF>0.01; Multiple hits;; Sex 
check; Cryptic relationships 
 
 
>95% >95% 1.00E-06 
CATHGEN Duke 
Illumina 
HumanOmni1-
Quad_v1_0_C 
GenomeStudio 
Genotyping 
module 
MAF < 1% 99% 99% None 
EGCUT 
Estonian 
Biocenter, 
Genotyping 
Core Facility 
OmniExpress GenomeStudio 
Sex mismatch; cryptic 
relatedness 
95% 95%, MAF 0.01 1.00E-06 
Go-DARTS Sanger Affymetrix 6.0 CHIAMO 
 
99% 
99% if MAF<0.05  
& 0.95 if 
1.00E-06 
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Study 
Genotyping 
Centre 
Genotyping 
Array 
Calling 
algorithm 
Pre-Imputation 
 QC Exclusion  
Criteria 
Sample 
 call rate 
SNP  
call rate 
HWE 
MAF>0.05 
KORAF3 
 
Affymetrix 500K 
  
Call rate 95%; Sex check; 
Cryptic relationships 
 
95% 95% 1.00E-06 
LURIC 
LURIC Study 
non-profit 
LLC 
Affymetrix 6.0 Birdseed v2 
 
99% 98% 1.00E-04 
PennCath 
Data not 
yet 
submitted 
      
MedStar 
Data not 
yet 
submitted 
      
MIGen 
Data not 
yet 
submitted 
      
RS 
 
Illumina 550K 
 
Sex check; IBS check; 
Heterozygosity check; Ethnic 
outliers 
 
97.5% 90% 1.00E-06 
SDR 
Data not 
yet 
submitted 
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Table 5-4: Imputation procedures and reference panels for genome wide cohorts 
Study  
Imputation 
 Software 
Reference 
 Panel 
Analysis 
 software 
Analysis 
 Model 
Total SNPs included  
in analysis diabetic only 
 [genotyped/imputed] 
CCF  MACH 1.0.16 Hap map R22 PLINK Logistic regression 2543887 
Corogene  MACH1.16 
Hap Map 2 
 release 22 CEU 
ProbABEL Logistic regression 
2543887 
[521288/2022599] 
DGI  MACH HapMap2 PLINK/ProbABEL Logistic regression 
 
CATHGEN  Impute2 
HapMap2/ 
Illumina Duo 
SNPTEST Logistic regression 800488/2647475 
EGCUT  Impute2 HapMap2 SNPTEST2 Logistic regression 615575/2523018 
Go-DARTS  Impute2 
HapMap2/ 
Illumina Duo 
SNPTEST Logistic regression 2500000 
KORAF3  Impute2 Hap Map 2 SNPTEST Logistic regression 
 
LURIC  MACH HapMap2 
QUICKTEST 
 /PLINK 
Logistic regression 2543887 
PennCath  
Data not yet 
submitted     
MedStar  
Data not yet 
submitted     
MIGen  
Data not yet 
submitted     
RS  MACH HapMap2 ProbABEL Logistic regression 
 
SDR  
Data not yet 
submitted     
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 Table 5-5: Genotyping information and analysis model applied for the CardioMetabochip studies 
Study 
Genotyping 
centre 
Genotyping array 
Calling 
algorithm 
Analysis 
software 
Analysis 
model 
Total SNPs 
included in analysis 
diabetic only  
EGCUT 
Estonian 
Biocenter, 
Genotyping Core 
Facility 
Illumina 
CardioMetabochip 
GeneCall PLINK/SNPTEST2 
Logistic 
regression 
129838 
IMPROVE Uppsala, Sweden 
Illumina 
CardioMetabochip 
GeneCall PLINK 
Logistic 
regression 
185704 
SCARFSHEEP Uppsala, Sweden 
Illumina 
CardioMetabochip 
GeneCall PLINK 
Logistic 
regression 
185704 
AMC-PAS SANGER 
cardiochip IBC 
Array 
Beadstudio PLINK 
Logistic 
regression 
48105 
PMB Broad institute 
Illumina 
CardioMetabochip 
Birdseed PLINK 
Logistic  
Regression 
121812 
THISEAS Sanger 
Illumina 
CardioMetabochip 
GenoSNP PLINK 
Logistic 
regression 
120383 
MORGAM Sanger Illumina GenCall PLINK Logistic 196610 
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Study 
Genotyping 
centre 
Genotyping array 
Calling 
algorithm 
Analysis 
software 
Analysis 
model 
Total SNPs 
included in analysis 
diabetic only  
CardioMetabochip regression 
DILGOM Helsinki 
Illumina 
CardioMetabochip 
Illuminus PLINK 
Logistic 
regression 
183812 
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5.3.3 Data cleaning and statistical model checking 
Three different types of plots were drawn to check the integrity and the accuracy of the 
summary statistics submitted by individual cohorts. Pairwise allele frequency plots were 
drawn for genotyped and imputed data (Figure 5-1A), which should produce a diagonal line 
through 0:0 and 1:1. Deviations from that line may indicate either allele frequency 
differences or stand inconsistencies as can be seen in Figure 5-1A. Effect coefficients plotted 
by minor allele frequency category indicate whether there are any inconsistencies by minor 
allele frequency or a general problem with the statistical model. We would expect to see a 
normal distribution of the beta coefficients around a mean of 0. Deviations from that mean 
line as seen in Figure 5-1B indicates that there are some summary statistics for SNPs with a 
minor allele frequency less than 5% which are not normally distributed. Effect estimates like 
this need to be examined carefully to identify the source of the bias. Similarly quantile to 
quantile plots are used to determine if there is any deviation in the p values from the 
expected values. We expect some deviation in the tail of the plot if there are variants that 
are associated with CAD but a systematic inflation or a deflation as see for PennCath in 
Figure 5-1D reflected in a lambda of 0.94 needs to be scrutinised. In this case it is due to a 
depowered analysis that contains too few CAD cases but inflation can also be indicative of 
population structure.  
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C D 
 
Figure 5-1: Data cleaning and model checking plots are drawn from summary statistics prior 
to meta-analysis. A – A pairwise allele frequency plot. B- A box plot of beta coefficients 
(ln(OR)) by minor allele frequency category; C and D - Two quantile- quantile plots from p 
values submitted by Corogene and PennCath  
5.3.4 Post meta-analysis QC 
Based on the data checking plots drawn for each cohort quality control criteria were applied 
to summary statistics from each cohort. All strand issues were rectified to ensure that the 
combined summary statistics were combined correctly by effect allele. The number of 
genotyped and imputed SNPs included in the meta-analysis for the GWAS studies and CM 
studies are given in Table 5-6. Briefly 8414213 imputed and genotyped SNPs were included 
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in the combined meta-analysis. After applying quality control criteria 2295146 SNPs were 
analysed using the fixed effects method and 17904 were analysed using random effects. 
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Table 5-6: Description of the number of SNPs that were included in the meta-analysis and the genomic inflation factors of each cohort. 
Cohort Platform # SNPs # directly typed SNPs post QC # imputed SNPs post QC Lambda 
directly typed 
Lambda 
imputed 
 CCF GWAS 2451062 - 2357360 - 1.02 
Corogene GWAS 2543888 513724 1816006 1.00 1.00 
DGI GWAS 2398087 383527 1937384 1.00 1.01 
DUKE GWAS 3447964 724138 1895824 1.00 0.99 
EGCUT GWAS 2523020 574838 1716794 1.02 1.01 
Go-DARTS GWAS 2632475 711373 1885991 1.01 1.01 
Go-DARTS-
SUMMIT 
GWAS 2332500 578594 1552188 1.00 1.01 
KORA F3 GWAS 2635496 275465 1543479 1.06 1.06 
LURIC GWAS 2543888 607266 1762568 0.99 1.00 
MedStar GWAS 5399009 655592 4743417 0.95 1.01 
MIGen GWAS 727228 686824 - 0.99 - 
PennCath GWAS 5242195 626345 4615850 0.97 0.98 
RS GWAS 3105354 506650 1811761 0.98 0.98 
SDR GWAS 2356360 613049 1714553 0.99 0.99 
GWAS total    8414213 2295146 1.02  
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Cohort Platform # SNPs # directly typed SNPs post QC # imputed SNPs post QC Lambda 
directly typed 
Lambda 
imputed 
EGCUT Cardio 
Metabochip 
129839 112901  1.07  
IMPROVE Cardio 
Metabochip 
184733 57890  0.96 - 
PAS IBC 39799 23585  1.20 - 
PMB Cardio 
Metabochip 
130735 120218  1.01 - 
SCARF/SHEEP Cardio 
Metabochip 
184734 83127  1.06 - 
MORGAM Cardio 
Metabochip 
196610 102843  1.02 - 
THISEAS Cardio 
Metabochip 
196725 102322  1.04 - 
DILGOM Cardio 
Metabochip 
183812 55900  0.96 - 
CardioMetabochip total 196725 149871  1.01  
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5.3.5 Fixed effects meta-analysis 
The quantile-quantile plot for the overall fixed effects meta-analysis shows a deviation of 
the p values from in the tail of the plot (Figure 5-2). The fixed effects meta-analysis detected 
signals in the ADAMTS7/MORF4L1/CHRNB4 at genome wide significance (Figure 5-2, Figure 
5-3 and Table 5-7). There are two distinct signals in this region marked by rs7173743 and 
rs4380028 (Table 5-8 and Figure 5-5). The top SNP rs11072811 is in linkage disequilibrium 
with rs7173743 that has been reported at genome wide significance for CAD43. A forest plot 
of individual study estimates for rs11072811 is given in Figure 5-4. Rs11634042 in linkage 
with rs4380028, which has also been reported at genome wide significance for CAD, was 
detected at 5.73E-08 (Table 5-7 and Figure 5-5). Other SNPs which did not achieve genome 
wide significance but were detected at a threshold less than 1E-05 were found in or close to 
LY75, the 9p21 region, CHRNB4, MSRA, CXCL12, FGFR3, PON2, ACVR2A, TNFRSF21, CD2AP, 
SPRY1, KCNE4, ACSL3, MTCH2, CELF1, STIM1 and APOB (Table 5-7).  
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Figure 5-2: A – Quantile-quantile plot of p values from a meta-analysis of 14 genome wide 
association studies for coronary artery disease in type 2 diabetic populations. B- QQ plot of 
p values from a meta-analysis of 14 genome wide association studies and 8 
CardioMetabochip studies for coronary artery disease in type 2 diabetic populations 
B 
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Figure 5-3: A Manhattan plot of from a meta-analysis of 14 genome wide association studies and 8 CardioMetabochip studies for coronary 
artery disease in type 2 diabetic populations. Green dots indicate suggestive signals.  
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Figure 5-4: Forest plots of the top hit for ADAMTS7 rs11072811 that reached genome significance for risk of coronary artery 
disease in type 2 diabetic individuals and of rs17228212 in SMAD3 which has been previously associated with CAD but does 
not replicate in T2D individuals despite power to detect an association. 
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Figure 5-5: Locus zoom plots of ADAMTS7 and CDKNBAS base on the p values obtained in a 
meta-analysis of coronary artery disease in type 2 diabetic individuals 
rs11634042 
 
rs944801 
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Table 5-7: Top hits from the combined meta-analysis of CAD in T2D pruned for LD at p<1E-
05 
CHR BP SNP EAF** EA* ORϮ SE¥ P i2 Gene 
15 79132330 rs11072811 0.47 A 0.83 0.022 3.89E-11 0.00 MORF4L1/ 
ADAMTS7 
15 76892405 rs11634042 0.42 T 0.85 0.024 5.73E-08 0.18 MORF4L1/ 
ADAMTS7 
2 160729820 rs10497206 0.05 G 0.64 0.054 1.26E-06 0.56 LY75-CD302/ 
PLA2R1 
9 22124504 rs1333047 0.53 A 0.88 0.023 1.44E-06 0.38 CDKN2B-AS1/ 
UBA52P6/ 
DMRTA1 
15 78945040 rs8023822 0.23 C 1.17 0.037 1.86E-06 0.00 CHRNB4/ 
CHRNA3/ 
CHRNA5 
8 10123974 rs13250969 0.44 C 1.18 0.040 3.86E-06 0.00 MSRA/ 
LINC00599/ 
MIR124-1/ 
PRSS51/PRSS55 
17 10917434 rs5002484 0.35 T 1.18 0.040 4.97E-06 0.35 RPL15P21/ 
SHISA6 
10 44691241 rs1623851 0.20 G 0.85 0.029 8.04E-06 0.00 LINC00619/ 
CXCL12 
4 1762287 rs732754 0.19 A 1.23 0.055 8.49E-06 0.00 TACC3/FGFR3 
7 95072081 rs43043 0.17 T 1.22 0.052 9.77E-06 0.00 PON2/PON3/ 
ASB4 
2 148472953 rs12053348 0.11 T 0.78 0.041 1.04E-05 0.00 RNA5SP106/ 
ACVR2A 
6 47362214 rs6458567 0.39 T 0.84 0.032 1.04E-05 0.00 TNFRSF21/ 
CD2AP 
4 125266797 rs672858 0.49 G 0.89 0.024 1.25E-05 0.00 SPRY1/ 
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CHR BP SNP EAF** EA* ORϮ SE¥ P i2 Gene 
TECRP2 
2 223936738 rs1440072 0.05 C 1.39 0.098 1.38E-05 0.00 KCNE4/ACSL3/ 
ATG12P2/ 
HIGD1AP4 
11 47699398 rs7930612 0.15 A 0.85 0.031 1.58E-05 0.42 AGBL2/MTCH2/ 
FNBP4 
11 47496827 rs7102372 0.14 T 0.84 0.032 1.75E-05 0.33 CELF1/RAPSN/ 
NDUFS3/ 
PTPMT1/ 
KBTBD4/ 
RNU5E-10P 
5 38412674 rs16903965 0.11 T 1.26 0.065 1.76E-05 0.00 EGFLAM 
11 4111900 rs3794050 0.12 A 0.79 0.041 1.83E-05 0.00 STIM1/ 
RPS29P20/ 
RRM1 
5 130463135 rs6874948 0.24 C 1.18 0.043 2.07E-05 0.00 ARL2BPP4/ 
HINT1/LYRM7 
2 21112689 rs12710745 0.41 G 0.88 0.025 2.14E-05 0.00 C2orf43/APOB 
22 30865337 rs9620997 0.20 A 1.19 0.047 2.34E-05 0.00 SEC14L3/ 
MTFP1/ 
SDC4P 
*Effect allele; **Effect allele frequency; ϮOdds ratio; ¥Standard error 
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Table 5-8: Linkage disequilibrium relationships between known hits rs7173743 and rs4380028 and SNPs that reached genome wide 
significance in the coronary artery disease in type 2 diabetic populations meta-analysis estimated from HapMap2. 
SNPs 
 rs7173743 rs4380028 rs11072811 rs7168915 rs4539564 rs8032771 rs8035039 rs11072810 
 R2/D’ R2/D’ R2/D’ R2/D’ R2/D’ R2/D’ R2/D’ R2/D’ 
rs7173743 Known   0.62/0.91 0.78/0.96 0.93/0.97 0.76/0.96 0.76/0.96 0.73/0.96 0.78/0.96 
rs4380028 Known     0.51/0.90 0.67/0.96 0.55,0.95 0.55/0.95 0.55/0.95 0.51/0.90 
rs11072811 Meta       0.78/0.96 0.97/1.00 0.97/1.00 0.97/1.00 1.00/1.00 
rs7168915 Meta         0.82/1.00 0.97/1.00 0.82/1.00 0.78/0.96 
rs4539564 Meta           1.00/1.00 1.00/1.00 0.97/1.00 
rs8032771 Meta             1.00/1.00 0.97/1.00 
rs8035039 Meta               0.97/1.00 
rs11072810 Meta                 
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5.3.6 Random effects model 
The random effects model was applied to 17904 SNPs where significant heterogeneity was 
detected in the effect estimates. After removing extreme outliers from MedStar and 
PennCath there was no deviation in the mean lambda estimate and the lambda for 
heterogeneity of 10.19 was used to correct the random effects model. The final analysis did 
not reveal any signals at genome wide significance (Table 5-9); however the top hit was 
rs2891168, a proxy for rs4977574 and rs1333049 in the 9p21 region that has been reported 
at genome wide significance for CAD (Figure 5-6). The same risk allele was reported for 
rs2891168 that has been reported for rs4977574 and rs1333049. Based on estimates from 
this study we found the random effects model (RE2) proposed by Han and Eskin to be more 
powered to detect an association than the traditional RE model (Table 5-9). 
 
Figure 5-6: A Forest plot of the top hit from the Han and Eskin random effects model. 
Rs2891168 in the 9p21 region has heterogeneous allelic effects amongst the cohorts 
included in the meta-analysis 
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Table 5-9: Random effects models all SNPs with a p value of less than 1E-03 for the random effects model proposed by Han and Eskin from the 
combined analysis 
Gene SNP Studies EA* EAF** PFEϮ ORFE SEFE PRE¥ ORRE SERE PRE2Ф I
2 PQ 
CDK2NBAS rs2891168 19 G 0.47 4.89E-04 1.09 0.0267 3.36E-02 1.08 0.0402 8.05E-04 41.38 3.11E-02 
ASTN2 rs2210769 10 T 0.12 6.75E-04 1.23 0.0615 1.05E-01 1.21 0.1177 8.34E-04 66.90 1.30E-03 
ARL2BPP6 rs7716149 10 G 0.82 6.64E-04 1.13 0.0404 5.81E-03 1.17 0.0669 9.47E-04 53.28 2.31E-02 
ARL2BPP6 rs11748167 10 G 0.80 6.87E-04 1.13 0.0404 5.90E-03 1.17 0.0669 9.79E-04 53.24 2.32E-02 
*Effect allele; **Effect allele frequency; ϮFE ~ fixed effects p value (P), odds ratio (OR) and standard error (SE); ¥RE ~ random effects p value (P), 
odds ratio (OR) and standard error (SE); ФHan and Eskin Random effects model p value 
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5.3.7 Comparison of effects estimated form the meta-analysis with known 
coronary artery disease loci and Type 2 diabetes loci 
5.3.7.1 Coronary artery disease 
We detected an association at p less than 0.05 for 23 of the CAD loci (Table 5-10). The risk 
allele from the current meta-analysis was consistent with the published risk allele for 22 of 
the 23 significant signals (Figure 5-7A). The power calculations identified three loci that we 
had the power to detect for the published effects: SMAD3 (rs17228212), VEGFA (rs6905288) 
and ABO (rs514659). Rs17228212 in SMAD3 had an inverse effect on CAD risk when 
compared to the published estimate at a p value of 3.99E-02 (Table 5-10 and Figure 5-7). We 
detected no association with ABO and VEGFA in this study. 
The 23 significant loci, VEGFA and ABO were tested for heterogeneity in allelic effects 
observed in this meta-analysis compared to the estimates obtained in chapter 4. Rs7173743 
in ADAMTS7 had heterogeneous allelic effects when compared to published estimates 
(p=5.60E-03) and had a greater effect on CAD in T2D (Table 5-10). The well-known CAD 
signal rs1333049 in CDK2NBAS was also significantly heterogeneous (p=4.15E-04) and had a 
smaller allelic effect on CAD in T2D. Rs17228212, in SMAD3, also had highly heterogeneous 
allelic effects (p=1.00E-06) where the published risk allele has a nominally protective effect 
on CAD in T2D (Table 5-10). Rs6905288 in VEGFA also displayed heterogeneous allelic 
effects and was found not to be associated with CAD in T2D by this study and while we 
found no heterogeneity in the effect estimates for ABO we also do not detect an 
association. Rs7865618, in CDKN2BA and rs4380028 in ADAMTS17, also showed 
heterogeneity in effect estimates that was nominally significant. 
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Table 5-10: Association of previously reported coronary artery disease loci with coronary artery disease in this meta-analysis 
SNP Gene EA* EAF** ORϮ published OR study P N studies N samples Pheterogeneity 
rs7173743 ADAMTS7 T 0.57 1.07 1.15 3.62E-09 19 16564 5.60E-03 
rs4380028 ADAMTS7 C 0.62 1.07 1.13 1.49E-06 19 16593 5.00E-02 
rs1333049 9p21 C 0.47 1.23 1.11 2.14E-05 21 16968 4.15E-04 
rs1746048 CXCL12 C 0.86 1.09 1.15 4.27E-05 18 15803  
rs501120 CXCL12 A 0.86 1.07 1.14 1.84E-04 18 15541  
rs515135 APOB G 0.82 1.08 1.12 2.65E-04 17 15480  
rs1122608 LDLR G 0.75 1.10 1.10 4.81E-04 20 16907  
rs1561198 VAMP5-VAMP8- GGCX A 0.46 1.05 1.10 7.17E-04 20 16912  
rs7865618 9p21 A 0.57 1.18 1.09 9.25E-04 20 16910 1.20E-02 
rs1412444 LIPA T 0.33 1.09 1.12 1.85E-03 11 9785  
rs602633 SORT1 C 0.78 1.12 1.10 2.04E-03 19 16413  
rs6725887 WDR12 C 0.12 1.12 1.13 2.95E-03 18 15801  
rs646776 CELSR2 T 0.77 1.14 1.09 3.15E-03 19 16425  
rs2023938 HDAC9 G 0.10 1.07 1.14 3.16E-03 16 15282  
rs9982601 KCNE2 T 0.13 1.13 1.12 4.12E-03 17 15479  
rs9369640 PHACTR1 A 0.63 1.09 1.07 8.53E-03 20 16906  
rs12526453 PHACTR1 A 0.67 1.09 1.06 2.08E-02 20 16912  
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SNP Gene EA* EAF** ORϮ published OR study P N studies N samples Pheterogeneity 
rs17465637 MIA3 C 0.72 1.14 1.07 2.99E-02 17 14277  
rs11556924 Z3HC1 C 0.62 1.09 1.06 3.60E-02 21 16976  
rs12190287 TCF21 C 0.60 1.07 1.06 3.78E-02 20 16907  
rs4845625 IL6R T 0.44 1.04 1.06 3.83E-02 20 16655  
rs17228212 SMAD3 C 0.27 1.21 0.94 3.99E-02 21 16979 1.00E-06 
rs2895811 HHIPL1 C 0.43 1.06 1.06 4.88E-02 19 16592  
rs2246833 LIPA T 0.34 1.06 1.05 7.08E-02 20 16913  
rs2505083 KIAA1462 C 0.43 1.06 1.05 8.67E-02 20 16909  
rs264 LPL T 0.14 1.05 0.93 9.79E-02 17 15207  
rs7651039 BTG C 0.51 1.06 0.96 1.15E-01 19 16535  
rs4252120 PLG T 0.72 1.06 1.05 1.21E-01 20 16893  
rs17514846 FURIN-FES A 0.45 1.05 1.04 1.26E-01 17 15137  
rs579459 ABO C 0.21 1.10 1.05 1.35E-01 19 16593  
rs17464857 MIA3 T 0.86 1.05 1.06 1.42E-01 17 15605  
rs964184 ZNF259, APOA5, APOA4, APOC3, APOA1 G 0.13 1.13 1.07 1.54E-01 13 10859  
rs10933436 INPP5 A 0.44 1.06 1.04 1.56E-01 17 15516  
rs12205331 ANKS1A C 0.77 1.04 1.05 1.64E-01 15 14851  
rs17609940 ANKS1A G 0.77 1.07 1.05 1.70E-01 13 10863  
rs2954029 TRIB1 A 0.53 1.04 1.03 1.95E-01 20 16656  
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SNP Gene EA* EAF** ORϮ published OR study P N studies N samples Pheterogeneity 
rs3184504 SH2B3 T 0.48 1.07 1.04 1.96E-01 17 15659  
rs2075650 APOE-APOC1 G 0.15 1.11 1.06 2.00E-01 13 13095  
rs6905288 VEGFA T 0.56 1.23 1.03 2.14E-01 19 16570 1.00E-03 
rs4773144 COL4A1, COL4A2 G 0.42 1.07 1.03 2.38E-01 21 16955  
rs688034 SEZ6L T 0.34 1.11 0.96 2.82E-01 14 10929  
rs974819 PDGFD A 0.27 1.07 1.03 2.82E-01 17 15962  
rs2252641 ZEB2-AC074093.1 G 0.43 1.04 1.03 3.32E-01 20 16915  
rs9319428 FLT1 G 0.32 1.05 1.03 3.35E-01 19 16523  
rs9818870 MRAS T 0.15 1.07 1.03 3.82E-01 18 15802  
rs4937126 ST3GAL4 G 0.70 1.06 0.97 3.87E-01 11 9781  
rs7692387 GUCY1A3 G 0.80 1.06 1.03 4.01E-01 17 13548  
rs11206510 PCSK9 T 0.83 1.08 1.03 4.18E-01 20 16098  
rs273909 SLC22A4-SLC22A5 C 0.13 1.09 1.03 4.22E-01 18 15469  
rs15563 UBE2Z, GIP, ATP5G1, SNF8 C 0.52 1.04 1.02 4.66E-01 18 15688  
rs12936587 RASD1, SMCR3, PEMT G 0.56 1.04 1.02 4.73E-01 17 15963  
rs6544713 ABCG5-ABCG8 T 0.31 1.06 1.02 4.86E-01 15 14886  
rs514659 ABO C 0.36 1.21 1.02 5.22E-01 19 16592  
rs204832 LPA G 0.72 1.06 1.03 5.33E-01 12 10545  
rs1878406 EDNRA T 0.13 1.06 1.03 5.37E-01 16 13314  
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SNP Gene EA* EAF** ORϮ published OR study P N studies N samples Pheterogeneity 
rs3739998 KIAA1462 C 0.44 1.15 1.02 5.63E-01 13 10859  
rs10947789 KCNK5 T 0.75 1.06 0.98 5.72E-01 19 16593  
rs365302 FNDC1 C 0.23 1.11 1.02 6.28E-01 13 10868  
rs12413409 CYP17A1, CNNM2, NT5C2 G 0.91 1.12 1.02 6.32E-01 17 15465  
rs9326246 ZNF259, APOA5, APOA4, APOC3, APOA1 C 0.07 1.09 1.02 6.51E-01 15 14955  
rs6922269 MTHFD1L A 0.26 1.23 1.01 6.68E-01 18 15984  
rs16893526 FAM46A –IBTK G 0.92 1.13 0.98 6.70E-01 16 15146  
rs12539895 7q22 A 0.21 1.08 0.99 6.85E-01 18 16361  
rs17114036 PPAP2B A 0.91 1.11 1.02 7.03E-01 15 14952  
rs2259816 HNF1A T 0.36 1.08 1.01 7.10E-01 20 16908  
rs2943634 KIAA1486 C 0.68 1.21 1.01 7.68E-01 21 16971  
rs7808424 ASZ1 G 0.10 1.10 1.01 9.13E-01 12 10664  
rs1231206 SMG6 A 0.34 1.07 1.00 9.31E-01 12 10545  
*Effect allele; **Effect allele frequency; ϮOdds ratio 
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Figure 5-7: A - Comparison of odds ratios from coronary artery disease in type 2 diabetic individuals with published odds ratios estimated from 
mixed non-diabetic and diabetic populations. B - Comparison of the published odds ratios for known type 2 diabetes genes with OR for CAD if 
the SNP was associated with CAD at p<0.05 
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 5.3.7.2 Type 2 diabetes 
Of the 65 T2D loci tested 9 SNPs were also associated with CAD at a threshold of 0.05 (Table 
5-11). Six of these SNPs in the 9p21 region, TTP53INP2, TP53INP1, PEPD, CDKAL3 and 
CDKAL1 shared the same risk allele with CAD and T2D (Table 5-11 and Figure 5-7B). The 
odds ratio for CAD and T2D was identical for rs944801 in the 9p21 region but the SNP was 
not in linkage with other SNPs reported for CAD in the 9p21 region (Table 5-12 and Figure 5-
5). However the previously established T2D SNP in the 9p21 region, rs10811661, was not 
associated with CAD in this study (OR=1.03 for the C allele, p=0.38). The published risk allele 
is the major T allele and the OR is 1.20 for T2D298. We also found that the risk allele for CAD 
and T2D were inverted for SNPs in ZFAND6, THADA and UBE2E3 (Table 5-11 and Figure 5-
7B).  
Table 5-11: Comparison of allelic odds ratios obtained from the meta-analysis of coronary 
artery disease in type 2 diabetes individuals, presented here, compared to odds ratios from 
the DIAGRAM type 2 diabetes meta-analyses for diabetes associated loci 
RSID EA* EAF** CAD ORϮ CAD P  T2D OR¥  T2D P Gene 
rs944801 C 0.56 1.08 3.87E-03 1.08 2.42E-09 9p21 
rs896854 T 0.51 1.07 1.37E-02 1.05 2.13E-05 TP53INP2 
rs7845219 T 0.52 1.06 1.71E-02 1.06 4.57E-06 TP53INP1 
rs7612463 C 0.89 0.86 1.86E-02 1.10 9.79E-04 UBE2E3 
rs8182584 T 0.38 1.07 2.29E-02 1.04 2.20E-03 PEPD 
rs9368222 A 0.30 1.07 2.57E-02 1.17 7.04E-34 CDKAL3 
rs7756992 G 0.30 1.07 2.83E-02 1.17 6.95E-35 CDKAL1 
rs11634397 G 0.66 0.94 3.00E-02 1.05 1.35E-04 ZFAND6 
rs11899863 C 0.92 0.89 3.97E-02 1.15 9.48E-11 THADA 
*Effect allele; **Effect allele frequency; ϮCoronary artery disease odds ratio; ¥Type 2 
diabetes odds ratio 
5.3.8 Testing for independent effects in the 9p21 region 
The lead SNP for CAD rs133304938 is not in linkage with the two T2D signals rs944801 and 
rs10811661266 in the 9p21 region. Rs944801 and rs10811661 are also independent signals 
for T2D (Table 5-12). While rs944801 was reported in the meta-analysis of CAD in T2D 
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individuals the SNP was not available for a subset of GoDARTS individuals typed on the 
CardioMetabochip so rs7030641 (rs944801, R^2=0.966, D’=1) a proxy for rs944801 was used 
to represent this SNP. 
First we replicated the known associations of rs1333049 with CAD and rs7030641 
(rs944801) and rs10811661 with T2D in GoDARTS (Table 5-13). Rs1333049 minor allele (G) 
was associated with an increased risk of CAD (odds ratio=1.15) irrespective of T2D status as 
has been previously published. The major T allele of rs7030641 (odds ratio=1.11) and the 
major T allele of rs10811661 (OR=1.17) were associated with increased risk of T2D, 
consistent with the published associations.  
We then investigated whether the SNPs interacted with T2D status to affect the risk of CAD. 
We found a nominally insignificant interaction for rs7030641 (rs944801) T allele with 
diabetic status, where the odds ratio of the interaction was 1.24 for diabetes status and the 
p value for interaction was 8.19E-02 in GoDARTS. Rs1333049 and rs10811661 did not 
interact with diabetes status and CAD in GoDARTS. The association of the SNPs was tested 
just in the T2D subgroup and we found that rs1333049 and rs7030641 (rs944801) were both 
associated with CAD in T2D. We observed that the allelic effect of rs7030641 (rs944801) on 
CAD was greater in the T2D population of GoDARTS compared to the allelic effect estimated 
from a GoDARTS population that included diabetics and non-diabetics – 1.17 vs. 1.11. This 
difference in effects is supported by the nominally insignificant result we observed for an 
interaction for this SNP with T2D status in GoDARTS. We were unable to compare the allelic 
effects observed for rs7030641 with CAD in GoDARTS to the allelic effects observed in the 
CARDIoGRAM+C4D meta-analysis as they were not available. Consistent with published 
findings rs10811661 was not associated with CAD in the general or T2D populations from 
GoDARTS (Table 5-13).  
When all three SNPs were included in the logistic regression model none of them were 
associated with CAD (p>0.05) and the OR of rs1333049 was reduced from 1.16 for CAD in 
T2D to 1.08 in the three SNP model (Table 5-13) in T2D individuals. These results indicate 
that rs1333049 is associated with CAD irrespective of T2D status and confirms previous 
findings that rs10811661 is not associated with CAD irrespective of T2D status. Rs944801 
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has been identified as a novel locus for CAD in T2D and interacts with T2D status to confer a 
higher risk of CAD in T2D individuals (Figure 5-8).  
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Table 5-12: The 9p21 region is a locus for coronary artery disease (CAD) and type 2 diabetes (T2D). This table shows the linkage disequilibrium 
relationships amongst the reported signals for CAD and T2D. 
Disease  SNP 
rs7044859 rs1333049 rs3217992 rs944801 rs10811661 
  R
2/D’ R2/D’ R2/D’ R2/D’ R2/D’ 
Coronary artery disease rs7044859   0.145/0.395 0.593/0.905 0.577/0.985 0.001/0.038 
Coronary artery disease rs1333049     0.301/0.667 0.256/0.639 0.009/0.179 
Coronary artery disease rs3217992       0.395/0.966 0.004/0.133 
Type 2 diabetes rs944801         0.01/0.142 
Type 2 diabetes rs10811661           
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Table 5-13: The association of coronary artery disease signal rs1333049 and type 2 diabetes signals rs10811661 and rs944801 in the 9p21 
region with CAD in T2D individuals in the GoDARTS population. 
SNP Model EA* EAF** Diabetes Coronary artery disease Interaction with diabetes 
    ORϮ 95%CI¥ P OR 95%CI P OR 95%CI P 
rs1333049 All G 0.48 1.05 (0.97-1.13) 1.78E-01 1.15 (1.02-1.29) 2.11E-02 1.07 (0.83-1.38) 5.44E-01 
rs944801Ф All T 0.57 1.09 (1.01-1.18) 1.49E-02 1.11 (0.98-1.24) 8.82E-02 1.24 (0.96-1.60) 8.19E-02 
rs10811661 All T 0.85 1.17 (1.06-1.29) 9.32E-04 0.90 (0.77-1.05) 1.81E-01 0.84 (0.54-1.09) 3.29E-01 
rs1333049 T2D G 0.47    1.16 (1.01-1.33) 4.22E-02    
rs944801Ф T2D T 0.59    1.17 (1.02-1.34) 4.07E-02    
rs10811661 T2D T 0.85    0.86 (0.70-1.04) 1.30E-01    
rs1333049 T2D 3 SNPs G 0.47    1.08 (0.90-1.29) 3.52E-01    
rs944801Ф T2D 3 SNPs T 0.59    1.14 (0.95-1.36) 1.32E-01    
rs10811661 T2D 3 SNPs T 0.85    0.85 (0.70-1.04) 1.18E-01    
*Effect allele; **Effect allele frequency; ϮOdds ratio; ¥95% confidence intervals; ФRepresented by rs7030641 (R^2=0.966, D’=1) in GoDARTS 
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Figure 5-8: Rs1333049 is an established SNP for coronary artery disease (CAD) and is not 
associated with type 2 diabetes (T2D) and has a significantly lower effect in T2D populations. 
Rs10811661 is an established SNP for type 2 diabetes and is not associated with CAD however a 
signal marked by rs944801 is associated with both CAD and T2D and has a stronger effect on 
CAD in T2D individuals 
5.4 Discussion 
Here we report the largest genetic study to date to identify common variants that contribute to 
CAD in T2D individuals. We combined genetic data from 6995 CAD cases and 11203 controls 
and identified two independent signals in ADAMTS7 that are associated with CAD in T2D at 
genome wide significance. Other suggestive signals were detected in LY75, the 9p21 region, 
CHRNB4, MSRA, CXCL12, FGFR3, PON2/3, ACVR2A, TNFRSF21, CD2AP, SPRY1, KCNE4, ACSL3, 
MTCH2, CELF1, STIM1 and APOB. A comparison of within study allelic effects with published 
effects for known CAD loci revealed unexpected deviations. The allelic effects of variants in 
ADAMTS7 were inflated compared to published estimates while allelic effects in the 9p21 
region were deflated and the allelic effects for SMAD3 were inverted. Despite the power to 
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detect an association with VEGFA and ABO these loci were not associated with CAD in T2D in 
this study. No overlap between diabetes loci and CAD risk loci has been reported by large 
genetic studies but in this study we found an overlap in signal in the 9p21 region. 
5.4.1 Top hits and novel signals detected by the fixed effects model  
ADAMTS7 is a member of the metalloproteinase family of a disintegrin and metalloproteinase 
with thrombospondin motifs. Studies in rats have shown that overexpression of this gene 
increases migration and invasion of the endothelium by vascular SMCs and increases the 
thickness of injured arteries299. Two independent signals represented by rs7173743 and 
rs4380028 had been published for ADAMTS7 for CAD in diabetic and we detect proxies for 
these SNPs at genome wide significance in this study43, 48. 
We detected suggestive novel signals in CXCL12, SPRY1 and FGFR3 that have also been 
implicated in plaque formation and structure. Signals in CXCL12 have been reported from large 
genetic studies of CAD38, 48. Studies in rabbits have revealed that LDL-C induces the expression 
of CXCL12 in endothelial cells that increases monocyte adhesion to atherosclerotic plaque 
extremities61. The expression of FGFR3 expression is restricted to within atherosclerotic 
plaques300 where it acts as a receptor for FGF-1 and FGF-2, pleiotropic growth factors that 
affect cell types involved in restenosis and atherosclerosis301. SPRY1 is involved in the negative 
regulation of angiogenesis that occurs in the final stages of atherosclerosis302. Other suggestive 
signals affect atherosclerotic risk factors such as central obesity and oxidative stress. 
Two separate signals in MSRA have been associated with central obesity and with rheumatoid 
arthritis247, 303, while the signal detected in this study is not linked to either of the reported 
signals, the gene has been implicated for central obesity a risk factor for CAD and T2D247. 
MTCH2 is another gene that is associated with BMI304, 305 which is also in the top set of genes 
detected in this meta-analysis. Increased serum levels of PON2/3 have been positively 
correlated with pro-inflammatory markers in CAD patients306. Within the liver and vasculature, 
paraoxonases such as PON3 protect the body from atherosclerosis through their antioxidant 
activity on HDL-C and from premature apoptosis307-310. CHRNB4/CHRNA3/CHRNA5 have all been 
associated with nicotine dependence and increased smoking194, 195, a well-established risk 
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factor for cardiovascular disease. APOB and ACSL3 are involved with lipid metabolism311, 312. 
Other signals were observed in genes that control cellular processes and have a direct effect on 
the heart. 
ACVR2A, TNFRSF21, CD2AP are involved in cell proliferation, differentiation and apoptosis. 
CD2AP is specifically involved in actin remodelling and membrane trafficking, and contains a 
signal for Alzheimer’s disease313. KCNE4 has a role in the regulation of heart rate314 while CELF1 
and STIM1 have been associated with Myotonic dystrophy315 and cardiac hypertrophy316. These 
signals may have an effect on CAD through their action on cells in the atherosclerotic plaques or 
directly on the heart muscle itself increasing the risk of a CAD event. A new random effects 
model which has been proposed by Han and Eskin has been tested for the first time on 
summary statistics from a large population.  
5.4.2 Evaluation of the Han and Eskin random effects model 
Based on the findings from this study the random effects model proposed by Han and Eskin, 
2012 has increased power to detect significant signals when compared to the traditional 
random effects model. The new random effects model does not assume heterogeneity under 
the null hypothesis and partitions heterogeneity into heterogeneity of allelic effects from 
heterogeneity due to other factors like population stratification. These features and the 
performance of the new random effects model in this meta-analysis would indicate that it is 
more powered to detect an effect than traditional random effects models.  
5.4.3 Known CAD signals in the context of CAD in T2D populations 
We detected 23 of the known CAD SNPs at nominal significance (p<0.05) with allelic effects 
consistent with published allelic estimates for 17 SNPs and heterogeneous allelic effects for 5 
loci. Power calculations also identified SNPs in VEGFA and ABO which we had the power to 
detect but we did not observe a significant association with CAD in this analysis. Significant 
(p<0.05) heterogeneity in allelic effects was detected between published estimates and effects 
estimated in this study for the genome wide significant signals in ADAMTS7, for two signals in 
the 9p21 region and for a signal in SMAD3. 
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The CAD signal in SMAD3 has the opposite risk allele compared to published data and the allelic 
effect is nominally significant (p<0.05)48. SMAD3 is directly involved in atherosclerotic processes 
as it is directly phosphorylated by TGF-β, which allows it to bind SMAD4 and travel to the 
nucleus where the complex regulates the expression of target genes317. In atherosclerotic 
regions TGF-β acts specifically on smooth muscle cells in fibrous plaques and macrophages in 
streaks/fatty lesions318 but SMAD signalling can also be activated through the RAGE and 
MAPK/38 pathways to produce vascular sclerosis319. The inverted allelic effects for the reported 
SNP could be due to a number of different factors.  
Thiazolidinedione (TZD) drugs are routinely prescribed to improve insulin sensitivity in T2D 
individuals. TZDs exert their effects by activating peroxisome proliferator-activated receptors, in 
particular PPAR ƴ, to alter the expression of genes related to glucose and lipid metabolism320. 
While some TZDs like rosiglitazone and repaglinide have been removed from the market 
because trials have shown an increased risk of cardiovascular disease, pioglitazone has been 
shown to reduce the risk of all cause death, myocardial infarction, stroke321 and reduces the 
size of atherosclerotic plaques322. Pioglitazone inhibits the expression of TGF-β in the kidneys323, 
324 and protects diabetic individuals against nephropathy323, 324. It may be that the suppression 
of TGF-β negates the effect of the risk allele of SMAD3 in the T2D population but further 
investigations will have to be carried out to verify this hypothesis. 
The effect of the risk alleles for both signals in ADAMTS7 on CAD is much larger in T2D 
individuals but is still directionally consistent with the published estimates but the reason for 
this is not apparent. We also detected heterogeneous allelic effects for VEGFA and in the 9p21 
region. The lack of association of SNPs VEGFA with CAD in T2D may be due to an interaction 
with the general obesity observed in T2D populations as this locus has also been associated 
with waist-hip ratio. However, the heterogeneity observed in the 9p21 region is not easily 
explained. Results from this study have indicated that there is complex genetic architecture 
across the 9p21 region with respect to its association with CAD and T2D.  
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5.4.4 Rs944801 is determinant of both T2D and CAD 
The literature to date indicates that signals in the 9p21 region, rs10811661 for T2D and 
rs1333049 for CAD, do not overlap325. We confirmed that rs1333049 was associated with CAD 
in this study but was not associated with diabetes and did not interact with diabetes status. We 
also found that rs10811661 was not associated with CAD and did not interact with T2D status. 
We did find an overlap in both T2D and CAD phenotypes for the new T2D signal rs944801 in the 
9p21 region which has been associated with CAD and T2D, and increases the risk of CAD in T2D 
individuals in GoDARTS. These findings indicate that rs1333049 is purely a CAD signal; that 
rs10811661 is purely a T2D locus and rs944801 is both a CAD and T2D locus. 
5.4.5 Concluding remarks 
 One of the weaknesses of the current study is the inability to detect loci that have 
heterogeneous allelic effects between diabetics and non-diabetics. The published analyses 
include populations that are not independent of the populations included in this meta- analysis 
therefore it is not possible to test for SNPs for an interaction with T2D status. Therefore we 
have requested identical non-diabetic analyses from participating cohorts so that we may 
formally test for loci that interact with T2D status. Another weakness of the study is that we 
only have estimates for the full population for SNPs that overlap between the GWAS data and 
the CardioMetabochip so we are not powered to detect SNPs from the GWAS data with small 
effect sizes. We plan to add additional data from cohorts that have GWAS data to refine some 
of the suggestive signals.  
We have conducted the first and largest meta-analysis of CAD in T2D populations. We have 
detected associations of two previously published signals in ADAMTS7 at genome wide 
significance with CAD in T2D. Several suggestive signals have also been identified in biologically 
relevant genes such as PON2/3, MSRA, FGFR3 and LY75 that warrant further investigation. We 
have shown that rs944801 in the 9p21 region is associated with CAD in T2D and overlaps the 
T2D and CAD phenotypes. We have shown that VEGFA and ABO are not associated with CAD in 
T2D despite the power to detect a signal and that SMAD3 has a protective effect against CAD in 
T2D. Loci with heterogeneous allelic effects will be identified through a formal diabetes 
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stratified analysis. As part of the SUMMIT programme these data will also be combined with 
proteomic and metabolomics biomarker data that is being generated for some overlapping 
samples. These data will form part of a combined analysis to identify new biomarkers for CAD in 
T2D populations.  
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Chapter 6: Single nucleotide polymorphisms directly influencing 25-
hydroxyvitamin D levels have the expected effect on coronary artery 
disease events – a Mendelian randomization study in Go-DARTS 
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6.1 Introduction 
Low vitamin D levels are common326-329 and an extensive body of observational data supports 
an association between low 25-hydroxy vitamin D (25OHD) levels and higher risk of 
cardiovascular events including patients referred for coronary angiography, patients with type 2 
diabetes and in the general population326, 330, 331. Establishing a causal relationship between 
vitamin D status and cardiovascular disease is difficult. Age, obesity, pre-existing comorbid 
illness, poor diet and sedentary lifestyle leading to lower sun exposure and lower oral intake of 
vitamin D are all potential confounders of any association. These confounders are difficult to 
fully control for in observational studies, and while large randomized controlled trials of vitamin 
D supplementation specifically for treating cardiovascular disease are underway the results 
have not been reported.  
Mendelian randomization is a method where measured variation, such as single nucleotide 
polymorphisms (SNP), in genes directly influencing a modifiable exposure, are used to examine 
the causal relationship between a modifiable exposure and a disease332. This method provides 
an opportunity to overcome some of the challenges of confounding encountered in 
observational studies333 and has proved valuable in determining the relationship between 
cardiovascular disease and other associated factors such as the interleukin-6168, C-reactive 
protein334, and triglycerides335. 
Recent data show that single nucleotide polymorphisms located within or near 4 genes related 
to vitamin D metabolism: rs2282679 in vitamin D binding protein ; rs12785878 in 7-
dehydrocholesterol reductase (DHCR7); rs10741657 in cytochrome P450 2R1 (CYP2R1) and 
rs6013897 in CYP24A1 are associated with differences in 25OHD levels2, 6. If the relationship 
between 25OHD levels and CAD is causal then we would expect 25OHD decreasing alleles to 
increase the risk of coronary artery disease to the same extent as their influence on decreasing 
circulating 25OHD332.  
Genotyping information from these 4 genes was combined with phenotypic and long-term 
outcome data from a large, well-characterized group of patients. This information was analysed 
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using a Mendelian randomization study design to investigate the causal relationship between 
25OHD levels and coronary artery disease events.  
6.2 Methods 
6.2.1 25-hydroxyvitamin D levels 
Serum 25OHD levels were measured using tandem mass spectroscopy at a single centre (Dept. 
of Clinical Chemistry, Glasgow Royal Infirmary, and Glasgow, Scotland) and were available for 
approximately 5% of patients in this study. Where more than one measure was available for an 
individual a mean value was used. As 25OHD tests had been requested by clinicians for specific 
clinical indications rather than being a random sample we compared demographic data for this 
subgroup with the main study.  
It is well established that 25OHD levels are greatly influenced by season so a seasonal 
adjustment was made to all 25OHD levels using the mean difference obtained from paired t-
tests227 in a subgroup of 14 participants who had 25OHD measures for all four seasons. The 
seasons were defined according to the Wang et al., 2010 criteria as spring (April-June), summer 
(July-September), autumn (October-December), and winter (January-March) - which was used 
as a reference for the seasonal adjustment6. A linear regression was performed where the 
effect of age, sex, body mass index and season of measurement were determined on a single, 
seasonally corrected 25OHD measure for each of the participants that had 25OHD 
measurements. The null hypothesis was tested that there would be no significant impact of 
season of measurement on seasonally adjusted levels. 
6.2.2 Coronary artery disease definition 
Coronary artery disease cases and controls were defined using the criteria described in chapter 
3.  
6.2.3 Genotyping 
Rs2282679 (ABI assay ID: C__26407519_10), rs6013897 (ABI assay ID: C__29958084_10), 
rs10741657 (ABI assay ID: C___2958430_101) and rs12785878 (ABI assay ID: C__32063037_10) 
were genotyped in the Go-DARTS study using TaqMan-based allelic discrimination336 described . 
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An exact Hardy-Weinberg equilibrium test was performed on the genotyping data and duplicate 
samples were used to test for concordance.  
6.2.4 Effect of 25OHD on coronary artery disease 
It was only possible to determine the effect of 25OHD on CAD status in 5% of the total 
population who had 25OHD levels and conformed to the case/control definition. CAD cases 
were defined as above and controls were defined as participants with no known cardiovascular 
disease (including stroke, CAD and lower extremity arterial disease). A Logistic regression using 
a case control analysis was required in this context as available 25OHD levels were obtained as 
clinically indicated and may therefore have been obtained retrospectively or prospectively with 
respect to study enrolment. Age, sex, history of smoking, hypertension and body mass index 
were included as covariates. The effect of square root transformed 25OHD levels on CAD status 
was determined and this value was used to calculate the expected effect of the genotype score 
on CAD status. To show that decreasing 25OHD levels were associated with CAD status, mean, 
seasonally corrected 25OHD levels were associated with CAD as categorical values of high to 
low 25OHD levels: high (> 40nmol/L) 25OHD, medium (>22nmol/L and <= 40 nmol/L) and low 
(<=22 nmol/L).  
6.2.5 Association of effect alleles from established vitamin D reducing loci in the Go-
DARTS study 
The per allele reduction in square root transformed 25OHD measures were determined in this 
study and compared to the published data for the four SNPs known to be associated with 
reducing 25OHD levels. To calculate effect estimates compatible with published effect 
estimates the SNPs were associated with square root transformed seasonally corrected 25OHD 
using an additive model in a multivariate linear regression227 while correcting for age, sex and 
body mass index. The effects of rs2282679 and rs10741657 on square root transformed 25OHD 
levels were compared to those observed by Ahn et al., 20102. The effects of these SNPs on 
untransformed 25OHD measures using the same model but the 25OHD measures were not 
transformed. 
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6.2.6 Comparison of 25OHD reduction by genotype from the GoDARTS study with 
published data 
The mean 25OHD measures for individuals that were homozygous for the 25OHD reducing 
alleles were compared to the mean 25OHD measures for individuals carrying no 25OHD 
reducing alleles (0 vs. 2) for each of the four SNPs investigated here. A percentage difference 
between the two groups was calculated and this was compared to the percentage change 
observed for these two groups by Wang et al., 2008 and Ahn et al, 20102, 6.  
6.2.7 Genotype score calculation 
Genotype scores were calculated for each participant in the study. The genotypes of the four 
SNPs were coded as 0 - no effect alleles present; 1 - one effect allele present and 2 - two effect 
alleles present. Effect alleles were defined as those alleles reported to decrease 25OHD by 
Wang et al., (2010) and Ahn et al., 20102, 6 and were also confirmed in the present study. A 
genotype score (GS) was calculated using the methodology described under heading 2.9.  
6.2.7.1 Genotype score 1 
Allele effect estimates derived from large meta-analyses were preferred to those obtained from 
a single study as these are more likely to have greater precision as estimates of the actual allelic 
effect sizes. Meta-analysis effect sizes were calculated for 25OHD measures on the square root 
scale so the effect estimates for each additional effect allele on the square root of mean, 
seasonally corrected 25OHD was estimated using a linear regression while correcting for mean 
age, sex and body mass index. The allele effect estimates for rs2282679 and rs10741657 (a 
known proxy for rs2060793, r2=1) on square root transformed 25OHD levels were published2. 
Although rs6013897 and rs12785878 had been reported to decrease 25OHD levels the meta-
analysis allele effect estimates were not published6. Therefore a primary genotype score “GS1” 
was calculated by weighting rs2289679 and rs10741657 by the published allelic effect estimates 
combined with allelic effect estimates from this study for rs6013897 and rs12785878.  
6.2.7.2 Genotype score 2 
 A secondary genotype score “GS2” was calculated by weighting each effect allele by the size of 
its effect on mean, seasonally corrected 25OHD levels. This score was completely based on 
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within study estimates and was used to determine the effect of per nmol/L reductions in 
25OHD on the increased risk of incident CAD within this study. 
Tertiles of GS1 and GS2 were determined for the entire study and were not sub analysis 
specific. Tertiles of GS1 were associated with 25OHD levels in a linear regression while 
correcting for average age, sex and body mass index. This analysis was repeated for GS2. GS1 
and GS2 were tested for association with incident CAD in a survival analysis. 
6.2.8 Effect of genotype score on the risk of CAD 
Cox’s regression analyses were performed to compare event rates for CAD across tertiles of 
GS1337. Participants with no prior stroke or CAD events were followed up from enrolment (date 
of genotyping) until first ever CAD event, death or end of the observation period. To 
demonstrate that the results were not biased by the allelic effect estimates used to calculate 
the genotype scores, analyses were repeated using GS2. 
Analyses were performed a) unadjusted, b) adjusted for age, sex, body mass index and history 
of smoking, which are known to affect 25OHD levels (model 1), c) further adjusted for 
covariates recorded at baseline: a diagnosis of hypertension (based on a recorded blood 
pressure reading >160/90 mmHg or a prescription of antihypertensive medication), a diagnosis 
of diabetes mellitus and total cholesterol level (model 2). A final adjustment was made (model 
3 – fully adjusted model) by including a prescription for statin medication at baseline. Statins 
were specifically included as a covariate as some statins have been reported to increase vitamin 
D levels338, 339 while other studies have shown that vitamin D insufficiency may decrease the 
lipid lowering effect of some statins340.  
Individual SNPs were also tested for association with incident CAD in a Cox’s regression with 
adjustment for age and sex to assess the contribution of individual SNPs to CAD risk. All 
analyses were performed using the R statistical package version 2.12.0227.  
6.2.9 Observed vs. expected effects of the GS1 on CAD 
In order to determine if the observed effect of GS1 on risk of CAD was consistent with what 
would be expected based on the effect of GS1 on 25OHD levels we used a method proposed by 
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Freathy et al. (2008)341. Under the assumption that GS1 affects the risk of incident CAD through 
its influence on 25OHD levels, it is possible to determine an expected value for the effect of the 
genotype score on the risk of CAD as c=a x b, where c is the expected effect of the genotype 
score on CAD risk; a the observed effect of the genotype score on square root transformed 
25OHD levels and b the observed effect of square root transformed 25OHD on CAD (Figure 1-7). 
Heterogeneity between the observed and expected effects of GS1 was calculated using the 
equations described under heading 2.12. The null hypothesis was that there was no difference 
between the observed and expected effect sizes of GS1 on risk of CAD. If there was no 
statistically significant difference between the observed and the expected effect (p=>0.05) then 
there was a failure to reject the null hypothesis but in cases where p<0.05 then the null 
hypothesis was rejected and the observed effect was not consistent with that expected. In this 
case the effect of GS1 would have mediated the risk of CAD through factors external to its 
effect on decreasing circulating 25OHD levels. 
6.2.10  Power calculation 
The power to detect an effect of 250HD and GS1 on CAD were calculated using the method 
described by Demidenko, 2007 342.  
6.3 Results 
6.3.1 Study population 
11,332 participants from Go-DARTS who had complete baseline data and had a genotype call 
rate of at least 75% were included in the study population and baseline characteristics are given 
in Table 6-1. For the incident CAD analysis a further 878 participants with previous CAD events 
were excluded leaving 10,454 participants in the incident CAD analysis. 25OHD levels were 
available for 599 participants and characteristics for this sub-population are given in Table 6-1. 
This sub-population was slightly older than the wider study population; was enriched for female 
individuals, and individuals with diabetes (all t-test p-value <0.05), however they were not 
dissimilar from the wider study population for BMI and history of smoking (t-test p-value>0.05) 
(Table 6-1). The median 25OHD level in this subpopulation was 43 nmol/L (IQR 23 to 58).  
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 Table 6-1: Study population characteristics and genotype frequencies 
Characteristic 25OHD Overall GS1 tertile 1 GS1 tertile 2 GS1 tertile 3 
Male (%) 238 (40) 6023 (53) 2001 (53) 1874 (53) 1909 (54) 
Mean age at genotyping (SD) 68.7 (12) 63.4 (13) 63.2 (13) 63.5 (12) 63.7 (12) 
Diabetes mellitus (%) 351 (59) 5661 52 1849 (49) 1780 52 1790 52 
Body mass index (SD) 28.2 168 29.3 168 29.3 168 29.4 168 29.3 168 
History of smoking (%) 341 (57) 6653 (59) 2205 (59) 2054 (58) 2124 (60) 
rs2282679 (G) 0 280 (51) 5595 (49)    
1 225 (41) 4737 (42)    
2 39 (8) 1000 (9)    
rs6013897 (T) 0 359 (68) 7438 (66)    
1 151 (29) 3474 (31)    
2 18 (3) 420 (4)    
rs10741657 (G) 0 80 (17) 1837 (16)    
1 249 (51) 5463 (48)    
2 158 (32) 4032 (36)    
rs12785878 (G) 0 371(68) 7563 (67)    
1 163(30) 3351 (30)    
2 12 (2) 418 (4)    
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6.3.2 Seasonal correction of 25-hydroxy vitamin D measures 
For single 25-hydroxy vitamin D measures per participant (N=599) that were not adjusted 
for season of measurement the season of measurement showed a reduction of -0.09nmol/L 
(Standard Deviation=0.02) of circulating 25OHD for every season change from Spring to 
Winter p=9.8E-05. The linear regression was corrected for age, sex and body mass index. 
The paired t-tests of intra-individual variation showed that there was a substantial 
difference when comparing the mean 25OHD measure for winter with spring, summer and 
autumn individually (N=14). The mean difference between winter and spring was -
3.37nmol/L, winter and summer was -9.12nmol/L, and winter and autumn was -
0.00017nmol/L. Study-wide measurements of 25OHD were adjusted by subtracting the 
mean difference from the measured 25OHD according to the season the test was requested 
in, while winter measurements were unadjusted. Using the same single 25OHD measures as 
before the season was associated with the seasonally corrected 25OHD measure while 
correcting for age, sex and body mass index. The season of measurement was no longer 
associated with the seasonally corrected 25OHD measures p=0.54 and the seasonal effect 
was greatly reduced -0.01nmol/L (Standard Deviation=0.02) per season change from spring 
to winter. 
6.3.3 Genotyping 
Rs2282679 (MAF=0.26, PHWE =0.992, percentage genotyped = 99.5%, concordance=0.99), 
rs6013897 (MAF=0.19, PHWE=0.4, percentage genotyped = 97%, concordance=1), 
rs10741657 (MAF=0.40, PHWE =0.37, percentage genotyped=90%, concordance=1), 
rs12785878 (MAF=0.18, PHWE =0.66, percentage genotyped = 99.7%, concordance=1) were 
successfully genotyped in the Go-DARTS study.  
6.3.4 Effect of 25OHD on coronary artery disease 
Square root transformed 25OHD levels were associated with a reduced risk of CAD, 
OR=0.80, 95% CI (0.66, 0.99), p=0.034 (Table 6-2). This corresponded to a beta coefficient 
effect of -0.21, SE=0.10, p=0.039. This showed that as the square root transformed value 
increased so the risk of CAD decreased. When decreasing 25OHD levels were associated 
with CAD as categorical variable ranging from high to low, the category representing 25OHD 
levels in the range of 22nmol/L to 40nmol/L associated with increased risk of CAD OR=1.81, 
95% CI (0.76 to 4.3), p=0.18 and the lowest category representing 25OHD measures of less 
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than 22nmol/L associated with an increased risk of CAD OR=3.94, 95%CI (1.62 to 9.55), 
p=2.45E-03 (Table 6-2). 
Table 6-2: Association of square root transformed 25OHD measures and categorical 
measures of 25OHD grouped into high, medium and low 25OHD levels with coronary artery 
disease. 
Model Covariate OR 95%CI P value 
1 Square root transformed 25OHD 0.80 (0.66-0.99) 0.034 
2 High 25-OHD (>40) 1 - Ref 
 Medium 25-OHD (>22 and <= 40) 1.81 (0.76,4.3) 0.180 
 Low 25-OH D (<22 nmol/L) 3.94 (1.62,9.55) 0.002 
 
Model 1: Association of square root transformed 25OHD levels with outcome. The model is 
corrected for age, sex, hypertension, smoking history and body mass index. 
Model 2: Categories of 25OHD levels medium and low are compared to the highest tertile. 
The model was corrected for age, sex, smoking history, hypertension and BMI. 
6.3.5 Effects of 25OHD reducing alleles on square root transformed 25OHD 
levels 
The effect of the 25OHD reducing allele of rs2282679 on square root transformed corrected 
25OHD levels was -0.46 (SE=0.15), p = 1.6E-03 (Table 6-3). Compared to the meta-analysis 
estimate of -0.36 (SE=0.05), p=1.1E-222 both estimates have overlapping confidence 
intervals. The effect of the 25OHD reducing allele of rs10741657 on square root 
transformed 25OHD levels was -0.10 (SE=0.13), p=4.6E-01. Compared to the published 
effect of -0.25 (SE=0.05), p=2.9E-172 these two estimates show overlapping confidence 
intervals. Rs6013897 showed a per minor allele effect of -0.21 (0.16), p=1.8E-01, on square 
root transformed 25OHD (Table 6-3). The minor allele of rs12785878 showed a per allele 
reduction in square root transformed 25OHD of -0.17 (SE=0.17), p=3.0E-01 (Table 6-3). 
Comparable values for these two SNPs were not presented in the literature. 
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Table 6-3: Association of SNPs previously associated with vitamin D insufficiency with square root transformed 25 hydroxyvitamin D levels in a 
subgroup of the main study (N=599) 
SNP ID Effect allele AF* Effect 95% CI† P value Gene 
rs2282679 C 0.278 -0.46 (-0.75,-0.18) 1.6E-03 GC‡ 
rs6013897 T 0.176 -0.21 (-0.54,0.10) 18E-01 near CYP24A1§ 
rs10741657 G 0.569 -0.10 (-0.36,0.17) 4.7E-01 near CYP2R1|| 
rs12785878 G 0.170 -0.17 (-0.51,0.16) 3.0E-01 DHCR7# 
Genotype score   -0.98 (-1.54,-0.43) 5.2E-04  
Genotype Score   Effect on 25OHD 
(nmol/L) 
95%CI P value  
GS1    -16.08 (-25.30,-6.87) 6.5E-04  
 
*Allele frequency; †Confidence interval; ‡Vitamin D binding protein; §1,25-dihydroxyvitamin D (3) 24-hydroxylase; || Vitamin D 25-hydroxylase; 
#7-dehydrocholesterol reductase 
161 
 
 
6.3.6 Effects of 25OHD reducing alleles on untransformed 25OHD levels 
The minor allele of rs2282679 showed a per allele reduction in 25OHD of -6.44nmol/L, 
95%CI (-10.32,-2.57), p=1.6E-03 per minor allele in the Go-DARTS study (Table 6-4). The 
major allele of rs10741657 showed a per allele reduction in 25OHD of -0.94nmol/L, 95%CI (-
4.49, 2.60), p=6.1E-01 (Table 6-4). The minor allele of rs12785878 showed a per allele 
reduction of -2.01nmol/L, 95%CI (-6.49, 2.47), p=3.8E-01 (Table 4). The minor allele of 
rs6013897 showed a per allele reduction in 25OHD of -2.4 nmol/L, 95%CI (-6.68, 1.88), 
p=2.7E-01 (Table 6-4). 
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Table 6-4: Association of 25OHD lowering SNPs with mean seasonally corrected 25OHD measures in the Go-DARTS study 
SNP ID Effect allele AF* Effect on  
25OHD nmol/L 
95% CI† P value Gene 
rs2282679 C 0.278 -6.44 (-10.32,-2.57) 1.6E-03 GC‡ 
rs6013897 T 0.176 -2.40 (-6.68,1.88) 2.7E-01 near CYP24A1§ 
rs10741657 G 0.569 -0.94 (-4.49,2.60) 6.1E-01 near CYP2R1|| 
rs12785878 G 0.170 -2.01 (-6.49,2.47) 3.8E-01 DHCR7# 
GS2   -1.00 (-1.54, -0.47) 2.7E-04  
 
*Allele frequency; †Confidence interval; ‡Vitamin D binding protein; §1,25-dihydroxyvitamin D (3) 24-hydroxylase; || Vitamin D 25-hydroxylase; 
#7-dehydrocholesterol reductase 
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6.3.7 Comparison of difference in mean 25OHD levels between genotype groups 
in GoDARTS compared to published data 
The mean 25OHD measure for rs2282679 in individuals who had no 25OHD reducing alleles 
(Group 0) was 42.7nmol/L (SD=26.7nmol/L) and in the group that were homozygous for the 
25OHD reducing alleles (Group 2) was 31.5nmol/L (SD=21.9nmol/L), this corresponded to a 
26% reduction in mean 25OHD between the two groups. This estimate was within the 
percentage range of mean 25OHD reduction observed in other studies: Framingham Heart 
Study (FHS) of 22%, 15% reduction seen in the 1958 British Birth Cohort (1958 BC)6 and the 
range of reduction observed by Ahn et al,(2010) of between -6.64 to -34.4%2.  
For rs10741657 the mean 25OHD levels for group 0 was 41.1nmol/L (23.3nmol/L) and for 
group 2 was 39.4nmol/L (25.96nmol/L) corresponding to a percentage reduction of 4%. The 
percentage difference observed in this study was within the range of percentage reduction 
observed in other studies: in the FHS the percentage reduction observed was 8%, the 1958 
BC 7% and a range of reduction observed by Ahn et al, 2010 of between 1.5% and 14.4%. 
For rs12785878 the mean 25OHD measure was 40.2nmol/L (SD=25.3nmol/L) for group 1 
and 35.9nmol/L (SD=22.2nmol/L) for group 2, this corresponded to a percentage reduction 
of 11%. Rs12785878 was only reported as associated with 25OHD reduction by Wang et al, 
(2008) and the mean percentage change observed in the FHS was 10% and in the 1958 BC 
was 7%. Although the estimate did not fall in that range it was not dissimilar to the 
percentage difference observed in the FHS. No published effects on mean 25OHD by 
genotype were available for rs6013897.  
 6.3.8 25OHD Genotype scores calculated from internal and external data. 
6.3.8.1 Genotype score 1 
GS1 was computed, from the individual allele effects on square root transformed, seasonally 
corrected 25OHD given in Table 6-3, by combining effect estimates for rs6013879 (Effect= -
0.21, SE=0.16) and rs12785878 (Effect=-0.17, SE=0.17) from our study with published effect 
estimates for rs2282679 (Effect = -0.36, SE=0.05) and rs10741657 (Effect = -0.25, SE=0.05)2 .  
GS1 had a range of 0 to 1.81; tertiles were <=0.50, >0.50 to 0.78 and >0.78. When the 599 
participants in whom 25OHD levels were measured were assigned to predefined tertile 
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categories based on GS1, the mean 25OHD level for the first tertile was 43.3 nmol/L 
(SD=26.3), 38.4 nmol/L (SD=24.9) for the second tertile and 34.8 nmol/L (SD=22.6)for the 
third tertile (Table 3). GS1 associated with decreased 25OHD, effect= -16.08nmol\L, SE=4.69, 
per step increase in of GS1 and p=6.5E-04 (Table 6-3). 
6.3.8.2 Genotype score 2 
GS2 was calculated by using within studies estimates for a per allele reduction in mean 
25OHD measures given in Table 6-4. GS2 was also associated with a 1nmol/L, 95% CI (-1.54,-
0.47), reduction in 25OHD levels per step of the genotype score, p=2.7E-04, results are given 
in Table 6-4. The range of GS2 was 0 to 22.64; tertiles were <=3.34, >3.34 and <=8.32, and 
>8.32. The mean 25OHD level for tertile 1 was 44.7nmol/L (SD=27.1nmol/L), for tertile 2 was 
40.5nmol/L (SD=25.4nmol/L) and for tertile 3 was 34.0nmol/L (SD=22.8nmol/L). 
6.3.9 Association of 25OHD gene scores with incident coronary artery disease 
events 
During a mean follow up of 4.5 years, a total of 254 incident CAD events occurred in 10,454 
participants included in the study population.  
6.3.9.1 Association of GS1 with risk of Incident CAD 
GS1 was associated with an increased risk of CAD in an unadjusted model, HR=1.50 (1.07 to 
2.11), p=0.020 and this finding remained significant after adjustment for multiple factors 
known to influence 25OHD levels and cardiovascular risk, including statin treatment (model 
3), HR=1.49 (1.61 to 2.10), p=0.022 (Table 6-5). This association was most marked in the 
third tertile of GS1 (representing the lowest 25OHD), that showed an association with 
increased risk of CAD when compared to the reference tertile in an unadjusted model, 
HR=1.41 (1.07 to 1.86), p=0.014 and this finding remained significant after adjustment for 
multiple factors known to influence 25OHD levels and cardiovascular risk, including statin 
treatment (model 3): HR=1.39 (1.06 to 1.84) and p=0.019 (Table 6-5). 
6.3.10 Power Calculations 
We had 19% power to detect an effect of 25OHD levels on CAD outcomes at p<0.05, given 
the sample size and the effect detected in this study. We had 7% power to detect an 
association between GS1 and CAD outcomes in the survival analysis at p<0.05. 
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Table 6-5: Association between coronary artery disease events (No. cases =254 and no. 
controls=10,200) and tertiles of GS1 associated with square root transformed 25-
hydroxyvitamin D levels  
Continuous 25OHD score HR 95%CI  P value# 
Unadjusted 1.50 (1.07 -2.11)#  0.020 
Adjusted model 3 1.49 (1.06 -2.10) #  0.022 
Phenotype/model Tertile 1 
HR* 
Tertile 2 HR  
(95% CI) 
Tertile 3 HR  
(95% CI) 
P value# 
Unadjusted 1 1.27 (0.96- 1.70) 1.41 (1.07- 1.86)# 0.014 
Adjusted model 1‡ 1 1.23 (0.93- 1.65) 1.36 (1.03- 1.80) # 0.028 
Adjusted model 2§ 1 1.25 (0.93- 1.66) 1.39 (1.05- 1.83)# 0.021 
Adjusted model 3|| 1 1.25 (0.94- 1.67) 1.39 (1.06 - 1.84)# 0.019 
 
*Hazard ratio; †Coronary artery disease; ‡Model 1: Adjusted for age, sex, smoking history 
and body mass index; §Model 2: As model 1, plus adjusted for history of hypertension, 
diabetes mellitus and cholesterol level; ||Model 3: As per model 2, plus adjusted for statin 
use at enrolment into study; #p<0.05 
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6.3.9.2 Association of GS2 with incident CAD 
GS2, which was the score weighted by per effect allele nmol/L reduction in 25OHD 
estimated from this study, was associated with increased risk of CAD HR=1.03, 95% CI (1.00-
1.06), p=0.036 and this association remained significant after adjusting for multiple factors 
known to influence 25OHD levels and cardiovascular risk, including statin treatment (model 
3): HR=1.03 (1.00 to 1.05), p=0.044 (Table 6-6). This corresponds to a 3% increase in risk per 
1nmol/L reduction in 25OHD levels for individuals in this study. The association was most 
marked in the third tertile that represented the greatest reduction in 25OHD levels by 
genotype in an unadjusted model HR=1.44, 95%CI (1.05 to 1.97), p=0.025 and in a fully 
adjusted model for multiple factors known to influence 25OHD levels and cardiovascular 
risk, including statin treatment (model 3): HR =1.41, 95%CI (1.02 to 1.93), p=0.037 (Table 6-
6).  
GS2 had a range of 0 to 0.64 and was associated with decreased 25OHD, effect=-0.12nmol/L 
(-0.20,-0.05) per tertile increase in GS2, p=9.2E-04. Both the 2nd and 3rd tertiles of GS2 were 
associated with increased risk of CAD in an unadjusted model, 2nd tertile: HR=1.53 (1.14 to 
2.07), p=5.3E-03 and the 3rd tertile: HR=1.50 (1.09 to 2.07), p=0.01. This association 
remained significant after adjustment for multiple factors known to influence 25OHD levels 
and cardiovascular risk, including statin treatment (model 3): 2nd tertile: HR=1.48 (1.09 to 
2.00), p=0.01 and the 3rd tertile: HR=1.47 (1.07 to 2.03), p=0.02. 
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Table 6-6: Association between coronary artery disease events (No. cases =254 and no. 
controls=10,200) and tertiles of GS2 associated with 25-hydroxyvitamin D levels 
Predictor/model HR* 95%CI  P value# 
GS1 continuous     
Unadjusted 1.03 (1.00-1.06)#  0.036 
Adjusted model 3|| 1.03 (1.00-1.05) #  0.044 
GS 1 tertiles Tertile 1 HR Tertile 2 HR  
(95% CI) 
Tertile 3 HR  
(95% CI) 
 
Unadjusted 1 1.28 (0.92-1.77) 1.44 (1.05-1.97)# 0.025 
Adjusted model 1‡ 1 1.25 (0.90-1.72) 1.37 (1.00-1.99)  0.050 
Adjusted model 2§ 1 1.25 (0.90-1.73) 1.40 (1.01-1.92)# 0.040 
Adjusted model 3 1 1.25 (0.90-1.73) 1.41 (1.02-1.93)# 0.037 
 
*Hazard ratio; †Coronary artery disease; ‡Model 1: Adjusted for age, sex, smoking history 
and body mass index; §Model 2: As model 1, plus adjusted for history of hypertension, 
diabetes mellitus and cholesterol level; ||Model 3: As per model 2, plus adjusted for statin 
use at enrolment into study; #p<0.05 
6.3.9.3 Effects of individual SNPs on CAD outcome 
To assess the direction of effect of individual SNPs compared to the effects of GS1 and GS2 
on outcome, Cox’s regression analyses were performed using an additive model for 
individual SNPs (Table 6-7). The direction of effect on CAD was consistent for the 25OHD 
decreasing alleles across all four SNPs although no individual SNP was significant on its own.  
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Table 6-7: Association between individual genotype variants and risk of cardiovascular 
events 
Phenotype/SNP* HR (95% CI) † P‡ 
Coronary artery disease events   
Rs2282679 1.06 ( 0.89-15) 0.537 
Rs6013897 1.20 (0.99-1.47) 0.069 
Rs10741657 1.18 (0.99-1.39) 0.064 
Rs12785878 1.08 (0.91-1.27) 0.625 
 
*Single nucleotide polymorphism; †Hazard ratio and confidence interval; ‡Adjusted for age 
and sex the effect allele in all cases is the allele associated with lower 25OHD levels 
6.3.10 The observed effect of GS1 on risk of incident CAD was consistent 
with the effect expected based on the genotypic effects on 25OHD 
levels  
In this study we have shown that GS1 decreases square root transformed, seasonally 
adjusted 25OHD levels by 0.98 (0.25) per step of GS1 (Table 6-3) which is the value for a. 
The results of the logistic regression demonstrated that square root transformed 25OHD 
were associated with decreased risk of CAD, OR=0.80 (0.66-0.99) and p=0.034 (Table 6-2) 
corresponding to the value for b, a beta estimate of -0.21 (0.10), p=0.039 (Table 8).Thus, c = 
a x b=-0.98 x -0.21=0.21, SE=0.18 (Table 8). This represented a hazard ratio of 1.23 (0.86, 
1.75) for the expected effect of GS1 on risk of CAD while the observed estimate was a 
hazard ratio of 1.49 (1.06 to 2.10) (Table 6-5). Z was calculated as: Z=0.40-
0.21/sqrt[0.172+0.182)], where 0.40=log(1.49) was the observed effect estimate for GS1 on 
risk of incident CAD , 0.21 was the expected effect estimate and 0.17 and 0.18 were the 
corresponding standard errors of these estimates (Table 6-8). The z-score corresponded to a 
p value of 0.42 indicating that there was no major difference between the expected and the 
observed effects of GS1 on CAD risk. 
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Table 6-8: The observed association between coronary artery disease and the genotype 
score for decreasing 25 hydroxyvitamin D levels is not significantly different from that 
expected based on the association of the score with 25OHD levels and the association 
between 25OHD levels and CAD 
Covariate Outcome Observed effect 
(SE) 
Expected effect 
(SE) 
P value  
25OHD levels* CAD -0.21 (0.10) - - 
Genotype score 25OHD levels* -0.98 (0.25) - - 
Genotype score CAD 0.40 (0.17) 0.21(0.18) 0.42 
 
*These represent square root transformed 25OHD levels 
6.4 Discussion 
Mendelian randomization is the random assortment of genes that occurs as a result of 
meiosis. Since this process is random, genes found to modify an exposure may be associated 
with a disease if the exposure is causally related to the disease and this association is not 
susceptible to reverse causation or confounding332. Our results show that a composite 
genotype score, based on SNP alleles previously associated with lower 25OHD levels, 
predicted higher rates of future coronary artery disease events and the association was 
consistent with the effects of low 25OHD increasing the risk of CAD. 
The association of the genotype score with incident CAD was not driven by a single locus 
and was not abrogated by adjustment for traditional risk factors. The observed effect of the 
genotype score on the risk of incident CAD was not different to the expected effect, which 
was predicted based on the effect of the genotype score on square root transformed 
vitamin D levels and the effect of square root transformed vitamin D levels on the risk of 
CAD.  
It is important to note that the genotype score used in this study comprised of four SNPs 
localized within or near genes that have well established and specific roles in Vitamin D 
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homeostasis (comprising three key 25OHD metabolic enzymes and a major vitamin D 
binding globulin) and the increase in risk of CAD attributed to the genotype score was 
consistent with the increase in the risk of CAD attributed to reduced vitamin D levels. Both 
of these features strengthen the case that the observed results were due to vitamin D 
mediated effects. The 25OHD decreasing alleles for the four loci were associated with an 
increased risk of incident CAD and were in accordance with the overall result for the 
genotype score, suggesting that the results were not driven by a single locus. The effect of 
the genotype score on the risk of incident CAD was only marginally attenuated with 
adjustment for a range of factors known to be associated with lower 25OHD levels and with 
cardiovascular risk. The evidence presented here strongly argues for a direct role of 25OHD 
on influencing cardiovascular risk. 
Prospective observational studies have demonstrated a relationship between lower 25OHD 
levels and incident cardiovascular events326, 330, 331, in a community-dwelling population with 
no previous history of cardiovascular events, in patients with diabetes mellitus, and in a 
large group of patients referred for coronary angiography. In this study we have replicated 
the association of lower 25OHD levels with increased risk of coronary artery disease. 
However, vitamin D supplementation trials have found conflicting evidence for the 
association of vitamin D supplementation with cardiovascular disease event reduction. 
Previously reported intervention studies have not been designed specifically to test the 
effect of vitamin D supplementation on cardiovascular event rates. One meta-analysis of 
trials conducted for other indications (mostly falls and osteoporosis) showed a 7% reduction 
in all-cause mortality with vitamin D supplementation197; it was not possible in this meta-
analysis to dissect out causes of death. A more recent meta-analysis failed to confirm a 
reduction in all-cause mortality in patients receiving vitamin D supplementation in 
randomized controlled trials; this analysis also found no reduction in stroke or myocardial 
infarction with supplementation343. One large study of vitamin D supplementation reported 
data for cardiovascular deaths344 and found that those receiving vitamin D had an age-
adjusted relative risk of death compared to the placebo group of 0.84 (95% CI 0.65 to 1.10, 
p=0.2). Inadequate dose of vitamin D and co-administration of calcium may increase the risk 
of myocardial infarction345, and the fact that existing trials were not designed to detect 
cardiovascular endpoints, may explain the lack of a convincing signal of efficacy in 
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intervention studies to date. In our study we showed that a 1nmol/L reduction in vitamin D 
corresponded to a 3% increase of incident CAD. This is larger than an estimate of an 
increase of 5% in cardiovascular disease and all cause death per 10nmol/L reduction in 
25OHD346. It is possible that exposure to lower levels of vitamin D has a cumulative effect on 
vascular health over many decades; the fact that participants in our study had differential 
exposure to vitamin D from birth, courtesy of their genetic makeup and geographic location, 
may explain the stronger effect seen in contrast to relatively short-term intervention trials. 
Remarkably the association of the genotype score with incident CAD was not affected by 
correcting for traditional risk factors.  
Little change to the strength of the associations was found after adjusting for history of 
hypertension, total cholesterol levels or statin treatment, suggesting that any effect of the 
composite genotype score and hence 25OHD may be mediated via alternative mechanisms. 
Vitamin D has anti-inflammatory properties347, can improve endothelial function 
independently of its effect on blood pressure348, and has a role in modifying the process of 
vascular calcification349. It is therefore possible that these mechanisms contribute to our 
findings.  
Strengths of our study include the use of a well-characterized population with defined 
endpoints, enriched for people with diabetes mellitus, with a long duration of follow-up. We 
also used the published effect estimates for rs2282679 and rs10741657 that were based on 
a large meta-analysis2 indicating that the association of the genotype score is not due to Go-
DARTS study specific effect estimates. However, using a genotype score solely based on 
within study effect estimates of per allele nmol/L reduction in 25OHD was still associated 
with increased CAD risk. We also found that the association between the genotype score, 
that included published effects, for 25OHD decreasing alleles and CAD outcomes that was 
observed in this study did not differ from the association that was expected indicating that 
the association of the score with increased risk of CAD is consistent with the effects of the 
SNP alleles on lowering 25OHD levels. 
Weaknesses of our study are that the number of participants with 25OHD measures and 
CAD events in the Go-DARTS study place limits on the statistical significance of our findings; 
larger studies involving combinations of existing studies will be necessary to confirm our 
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findings. In addition we were underpowered to detect an association between 25OHD and 
CAD, and an association between GS1 and CAD outcomes in the survival analysis. Despite 
the lack of power we do detect associations but these will need to be confirmed in larger 
studies. We were unable to use 25OHD levels from a random sample of the Go-DARTS 
population, and thus selection bias for these values is still possible, however when the mean 
25OHD measures were calculated by genotype and the percentage difference between 
those carrying two vitamin D reducing alleles and non-carrier individuals the percentage 
reduction observed in this study was in the range of published reductions. The association 
between the genotype score and incident CAD requires replication in a much larger study, 
the evidence presented here is the result of a hypothesis driven experiment based on an 
equivocal association between 25OHD and CAD, we have indirectly confirmed the 
association of the genotype score with incident CAD by comparing the observed association 
with the association expected and found no difference. We lacked sufficient statistical 
power to demonstrate effects on cardiovascular event rates at the level of individual SNPs, 
but this was ameliorated by the greater power of the genotype score. The Go-DARTS 
population was overwhelmingly Caucasian in ancestry, which limits the generalizability of 
both the genotypic and phenotypic findings. We have chosen to focus on macrovascular 
outcomes in this study, as the observational evidence is strongest for the association of 
25OHD levels and these outcomes. A similar examination of the relationship between 
25OHD genotype and microvascular outcomes in patients with diabetes mellitus would be a 
target for future research. 
Whilst Mendelian randomization experiments cannot substitute for randomized controlled 
trials, our results lend weight to a causal, albeit complex, relationship between vitamin D 
levels and cardiovascular disease. As such, these results strengthen the case for conducting 
large randomized controlled trials of vitamin D intervention. 
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Chapter 7: A meta-analysis of SNP effects on lower extremity arterial 
disease in patients with and without diabetes mellitus, and in 
smokers and non-smokers 
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7.1 Introduction 
The most common method of diagnosing lower extremity arterial disease (LEAD) is an 
abnormal ankle brachial index (ABI) measurement of less than 0.9 or greater than 1.3. The 
heritability of ABI has been estimated from family studies to be between 21 and 30%158. To 
date two large-scale genetic studies have been conducted to identify the genetic 
determinants of LEAD that have reported rs10757278 in the 9p21 region160 and rs1051730 
in CHRNA3159. Signals in the 9p21 region have been associated with many different 
atherosclerotic diseases38, 161, 273 but it remains unclear exactly what role the gene plays in 
atherogenesis. CHRNA3 is an established locus for nicotine dependence and signals in the 
locus have been associated with increased smoking frequency159. Other variants in AGT, 
CSMD1, ITGB3, IL6, ENPP1, OSBPL10, NOS3, MTHFR, VSP13D and MMP3 have been reported 
at nominal significance in candidate gene studies169, 170, 176, 179, 350 but the genetic 
determinants of LEAD remain largely unidentified. 
Smoking status is the largest predictor of LEAD that increases the occurrence of LEAD up to 
10 fold351. Compared to other cardiovascular diseases smoking is more common in 
individuals with LEAD, where individuals with LEAD smoke higher quantities of cigarettes352. 
Indeed one of the genome wide association hits for LEAD is within a nicotine receptor locus 
CHRNA3/CHRNA5. Rs1051730 is associated with increased smoking quantity and has also 
been associated with lung cancer and LEAD through its effect on nicotine addiction159. 
However, individuals who have never smoked are still at risk of LEAD.  
Diabetes mellitus increases the risk of LEAD up to three fold353, 354 and is the second largest 
predictor of LEAD along with previous cardiovascular disease353. The prevalence of LEAD in 
diabetics has been estimated at above 20% compared to a much lower prevalence in non-
diabetics of 12.5%355, 356. Prevalence and risk of LEAD are greatly increased with increasing 
glycated haemoglobin (HbA1c)156, 357, 358. The increase in risk of LEAD in diabetics can be 
attributed to the common risk factors for cardiovascular disease such as smoking, elevated 
blood pressure and dyslipidaemia355. Diabetics also have a higher level of vascular 
inflammation which puts them at higher risk of atherosclerotic disease156. 
In this study we had two main aims: to identify risk variants for LEAD and to identify variants 
with heterogeneous allelic effects for LEAD in smokers and LEAD in non-smokers. We 
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combined meta-analysis results from 4 cohorts to identify common variants associated with 
LEAD. We compared the findings from GWAS and candidate gene studies with the results of 
the meta-analysis to confirm or disprove previous findings. Finally we conducted an 
interaction analysis in three of the cohorts, which had smoking status available, to identify 
loci that had different allelic effects in smokers vs. non-smokers. 
7.2 Materials and Methods 
7.2.1 Study Design Summary 
We combined summary statistics from 4 genome wide association studies imputed to 
HapMap2 in a meta-analysis. We stratified analyses in 3 cohorts by smoking status and 
tested loci for an interaction with smoking status. 
7.2.2 Phenotype 
7.2.2.1 Lower extremity arterial disease cases and controls 
Individuals with LEAD were identified by individual studies based on a number of criteria 
given in (Table 7-1). Briefly, the main diagnosis was based on an ABI of less than 0.9 or 
greater than 1.4, thigh through to mid-foot amputations and corrective procedures related 
to LEAD. Controls were identified to be free of LEAD by individual studies.  
7.2.2.2 Genotypes and imputation 
Operational details of the 4 GWAS studies are given in Table 7-1. The GWAS studies were 
typed on the Affymetrix 6.0, Illumina Human Omni1-Quad and the Illumina Omni Express 
SNP arrays (Table 7-1). To obtain an increased marker set that was comparable across all 
GWAS platforms individual studies imputed their GWAS data to the HapMap2 CEU 
reference panel. Individual studies applied quality control pre-imputation and the details of 
that QC are given in Table 7-1. Either MACH or IMPUTE2 were used to impute missing 
genotypes yielding a maximum of 2,619,962 SNPs (Table 7-1).  
7.2.2 Statistical methods 
7.2.2.1 Individual studies 
The details of the analyses performed and the software used by individual studies are given 
in Table 7-1. Briefly analysis software that took genotype uncertainty into account was used 
to analyse imputed data. Imputed SNPs were tested for their association with LEAD using a 
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log-additive model frequentist tests adjusted for age (onset of the first event for cases or 
time of recruitment for controls), gender, diabetes status and centre specific covariates to 
account for population structure was applied to imputed SNPs. Directly typed SNPs were 
modelled log-additively in a logistic regression that was corrected for age, gender, diabetes 
status and centre specific covariates to account for population structure. The analysis was 
also stratified into ever and never smokers whilst correcting for age, gender, diabetes status 
and centre specific covariates to account for population structure. 
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Table 7-1: Cohort characteristics and operational details for the studies included in the meta-analysis of lower-extremity arterial disease 
Study Go-DARTS GoDARTS-SUMMIT deCode DCCT/EDIC 
Full name of the study The Genetics of Diabetes Audit 
and Research in Tayside Scotland 
The Genetics of Diabetes 
Audit and Research in 
Tayside Scotland 
deCODE Data not yet submitted 
Reference 
225
 
225
   
Ethnicity European European European  
Region of recruitment Scotland Scotland Icelandic  
Phenotype LEAD LEAD LEAD  
Phenotype definition Full description heading 3.2.3 Full description heading 3.2.3   
Control definition Controls free of any vascular 
disease 
Controls free of any vascular 
disease 
Controls without known 
vascular disease 
 
Total sample size 
[men/women, cases/controls] 
3532 
[1906/1626,713/2819] 
2427 
[1431/996 ,332/2095] 
28456 
[11153/17303, 1458/26988] 
 
Mean age (SD) years 
[cases/controls] 
64.9 (10.7) 
[65.6(10.5)/64.7(10.8)] 
64.8 (11.8) 
[66.8(11.3/64.5(11.8)] 
50.2 (21.4) / NA  
N LEAD cases 713 332 1458  
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Study Go-DARTS GoDARTS-SUMMIT deCode DCCT/EDIC 
Mean BMI (SD) kg/m2 
[diab/nondiab, cases/controls] 
30.4 (5.5)  
[30.4 5.5)/NA,30.1(5.5)/30.5(5.5)] 
31.1 (6.1) 
[30.3(6.1)/NA,31.2 (6.1)/NA] 
26.7(4.4) / 26.9 (5.4) Data not yet submitted 
N Diabetic LEAD cases 713 332 251  
Duration diabetes[case/control] 7.2 (7.5) 
[8.9 (10.2)/6.8(6.7)] 
6.1 (6.6) 
[8.7(8.1)/5.7(6.2)] 
NA  
N current smoker LEAD cases 175 80 NA  
N ever smoker LEAD cases 385 179 886  
Genotyping centre Sanger Lund deCode  
Genotyping array Affymetrix 6.0 Illumina OmniExpress array Illumina 
HumanHap300/CNV370 
 
Calling algorithm CHIAMO Birdsuite BeadStudio  
Pre-Imputation QC - Exclusion 
criteria 
Heterozygous samples; cryptic 
relatedness and population 
outliers 
Heterozygous samples; 
cryptic relatedness and 
population outliers 
NA  
Sample call rate >=99% >=99% >98%  
SNP call rate MAF>0.01, Call rate>0.9if 
MAF>0.05, Call rate>=0.95 if 
MAF>0.01, Call rate>0.9if 
MAF>0.05, Call rate>=0.95 if 
>96%  
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Study Go-DARTS GoDARTS-SUMMIT deCode DCCT/EDIC 
MAF<0.05 MAF<0.05 
HWE 1.00E-06 1.00E-06 10-6  
Imputation software IMPUTE2 IMPUTE2 Impute  
Reference panel HapMap2 and WTCCC2 controls HapMap2 Hap Map Ceph CEU v22  
Analysis software SNPTEST SNPTEST SNPTEST  
Analysis model Logistic regression Logistic regression Logistic regression  
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7.2.3 Data cleaning steps applied before conducting the meta-analysis 
Quality control of the data was performed centrally. SNPs with a MAF lower than 1% or 
those with less than 10 minor allele homozygotes calculated as (2 x (Number of cases) x 
MAF)) were removed from individual studies. Specific quality control criteria were applied to 
directly typed and imputed SNPs separately. Directly typed SNPs with a MAF greater than 
5% were removed if the p value for the exact test for Hardy-Weinberg equilibrium (HWE) 
was less than 5.7E-07 and for SNPs with a MAF less than 1% with a less than 1E-04. Imputed 
SNPs were removed if they had an R2 value less than 0.3 if imputed with MACH and an R2 
value less than 0.4 if imputed using IMPUTE2. If imputed SNPs were analysed using SNPTEST 
then imputed SNPs were removed if the proper info value was less than 0.4. Pairwise allele 
frequency plots were drawn for each study for imputed and directly typed data separately 
to check for allele frequency outliers and strand differences amongst the summary meta-
data submitted for analysis.  
7.2.4 Statistical model checking 
The summary statistics for individual studies were checked by several procedures. These 
included plotting the beta distribution by MAF category (0-0.01, 0.01-0.05, 0.05-0.2 and 0.2-
0.5) and this was performed separately for directly typed and imputed SNPs. A deviation of 
the mean beta values from zero and scattered outliers were an indication of problems with 
the models used or low quality SNPs. To check for population stratification quantile-quantile 
plots were drawn from the p values submitted by each study and lambda was calculated.  
7.2.5 Fixed effects meta-analysis and smoking interaction 
The primary analysis comprised of an overall meta-analysis of LEAD and one sub-analysis of 
ever vs. never smokers. Our default meta-analysis used a fixed-effect model with inverse 
variance weighting and a calculation of two homogeneity statistics: Cochran's Q and I2 using 
GWAMA (http://www.well.ox.ac.uk/gwama/)252. Individual studies were corrected for 
genomic inflation using GWAMA and the overall meta-analysis was corrected for genomic 
inflation by adjusting the standard error of the estimates by the inflation factor (SE*sqrt(λ)) 
and recalculating the p values. When there was no indication for heterogeneity for a SNP 
based on a Cochran’s Q p value greater than 0.01 the fixed effect model was maintained. In 
addition to the standard meta-analysis we aimed to identify loci with heterogeneous allelic 
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effects in smokers vs. non-smokers and we applied the sex differentiation test in GWAMA to 
identify loci of interest.  
7.2.6 Random effects meta-analysis 
When heterogeneity was present (Cochran’s Q p value <0.01) the study with the most 
extreme result was excluded and the meta-analysis was repeated. If heterogeneity was still 
apparent, we adopted and reported a random-effects model246 for that SNP. The random 
effects model was applied using MetaSoft (http://genetics.cs.ucla.edu/meta/)246.  
7.2.7 Replication of known disease associations 
Two genome wide associations have been reported for LEAD in the 9p21 region for 
rs10757278 and in CHRNA3 for rs1051730. Other signals in candidate genes have been 
reported for ENNP1 rs1044498350 in non-smokers, PCSK9 rs1159114181, ACE rs1799752167 
and rs4340167, PT rs1799963186, MTTP rs1800591177, FGB rs1800591175, IL6 rs1800795169 and 
rs2069827359, F12 rs1801020174, MTHFR rs1801133176, PPARG rs1805182 and rs1805192182, 
OSBPL10 rs1902341170, NOS3 rs2070744179 and rs891512180, VSP13D rs235243170, CSMD1 
rs2554503170, MMP9 rs3918242169, AGT rs5051169 and rs699169, ITGB3 rs5918169 and F5 
rs6025169. Where the index SNPs were not available a suitable proxy was used (R2>0.80). 
Power calculations were performed in the same way as described under heading 5.2.4.6 to 
identify SNPs that which should be able to replicate in the meta-analysis given the size of 
this study and the published allelic effects. 
7.2.8 Smoking interaction 
In addition to the standard meta-analysis we aimed to identify loci with heterogeneous 
allelic effects in smokers vs. non-smokers and we applied the sex differentiation test in 
GWAMA to identify loci of interest. We also tested whether SNPs known to influence 
nicotine addiction showed heterogeneous allelic effects for SNPs in CHRNB3195, CHRNA5360, 
ANAPC1360, SLCO3A1360, CHRNA3361, CTNNA3362 and VSP13A362. 
7.3 Results 
7.3.1 Study population 
The full details of the number of cases and controls and SNPs are given in Table 7-2. Briefly a 
total of 2774 LEAD cases were included in the overall meta-analysis: 1904 had a history of 
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smoking and 614 had no record of smoking. 27177 controls were included in the meta-
analysis: 17941 had a history of smoking and 8112 had no history of smoking. 
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Table 7-2: Operational details of actual SNP numbers and final case control numbers for the different analysis subgroups 
Cohort Model Cases/Controls #SNPs Directly typed lambda #Directly typed Imputed lambda #Imputed 
GoDARTS All 713/2819 2445299 1.02 710775 1.02 1734523 
GoDARTS-SUMMIT All 332/2095 2085596 1.00 570751 1.01 1514832 
DCCT/EDIC All 256/1024 2592580 1.00  1.01 1607556 
deCode All 1473/21239 2428087 1.10 290349 1.10 2109512 
GoDARTS Smokers 432/1503 2445299 1.02 708376 1.02 1675491 
GoDARTS-SUMMIT Smokers 219/1192 2085596 1.02 597731 1.03 1718553 
deCode Smokers 1253/15246 2428087 1.09 290350 1.09 2110369 
GoDARTS Non-Smokers 281/1316 2445299 1.01 294355 1.01 1619708 
GoDARTS-SUMMIT Non-Smokers 113/903 2085596 1.02 579220 1.03 1605719 
deCode Non-Smokers 220/5993 2428087 1.02 235307 1.02 1479869 
184 
 
 
7.3.2 Genotypes and imputation 
2614480 SNPs were analysed in the meta-analysis after QC criteria had been applied, of 
these 2592552 were analysed using the fixed effects method and 21928 were analysed 
using the random effects model for the overall analysis. A total of 2592552 were included in 
the smoking interaction analysis and all were analysed using a fixed effects model. 
7.3.3 Fixed effects meta-analysis 
The fixed effects meta-analysis in all LEAD cases and controls did not detect any signals that 
reach genome wide significance (Figure 7-2) although 30 signals reaching a suggestive 
significance level (less than 1E-04) included the known LEAD signals: rs10757269 in 
CDK2NBAS (Table 7-3, Figure 7-3A and Figure 7-4) and rs1051730 (rs8034191, R2=0.93, 
D’=1.00) for CHRNA3 (Table 7-3, Figure 7-3B and Figure 7-4). The overall lambda was equal 
to one after correction and did not show a great deviation from the expected distribution of 
p values (Figure 7-1A). Suggestive signals in biologically interesting genes were found in 
HIBADH, LDB3/BMPR1A, LPHN2, GAS7, CADM2 and KAT2B (Table 7-3). 
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Figure 7-1: QQ plot of meta-analysis p values for all lower extremity arterial disease cases 
and all LEAD free controls in all individuals (A), in smokers (B) and in non-smokers (C). 
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Figure 7-2: A - Manhattan plot of meta-analysis p values from all lower extremity arterial disease cases and all LEAD free controls; B - 
Manhattan plot of meta-analysis p values from diabetic lower extremity arterial disease cases and LEAD free controls 
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Figure 7-3: Forest plots of the 9p21 region, rs10757269 (odds ratio= 1.16), CHRNAB3 rs1051730 
(Odds ratio=1.16) and ADAMTS17 rs12593235 in smokers (odds ratio=1.02) and non-smokers 
(odds ratio=0.63) 
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Figure 7-4: Locus zoom plots of rs10757269 in the 9p21 region which was the top hit 
from the meta-analysis of lower extremity arterial disease and for rs8034191 which is 
in linkage with rs1051730 in CHRNA3 a known LEAD locus 
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Table 7-3: Top hits for the overall meta-analysis for lower extremity arterial disease pruned for linkage disequilibrium 
Chromosome Position Gene SNPs 
Effect 
Allele 
Allele 
Frequency 
Odds 
Ratio 
Standard 
Error 
P value #Cases 
9 22062264 CDKN2B-AS1 rs10757269 G 0.45 1.16 0.034 1.62E-06 2768 
6 166560362 GAPDHP72 rs6931241 A 0.04 1.54 0.129 2.31E-06 2418 
10 10328165 CUX2P1 rs10218946 G 0.04 2.54 0.421 3.25E-06 969 
2 188259734 CALCRL rs16829210 T 0.02 1.79 0.200 3.43E-06 2437 
4 184744875  rs10011527 T 0.12 1.26 0.061 5.26E-06 2769 
6 19022603 
TRNAQ22/ 
RPL21P61 
rs988458 T 0.35 1.16 0.037 5.62E-06 2507 
10 129256732 DOCK1/NPS/FOX12 rs7088687 G 0.76 1.17 0.041 7.93E-06 2769 
11 119886208 ARHGEF12/GRIK4 rs2244279 G 0.57 1.18 0.043 1.08E-05 2053 
7 27532578 HIBADH rs12700813 G 0.44 0.88 0.026 1.11E-05 2769 
5 147928739 HTR4 rs7726693 G 0.66 0.87 0.027 1.14E-05 2769 
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Chromosome Position Gene SNPs 
Effect 
Allele 
Allele 
Frequency 
Odds 
Ratio 
Standard 
Error 
P value #Cases 
15 44936010 SEMA6D rs12591095 T 0.19 1.19 0.045 1.18E-05 2747 
16 77744926 WWOX rs1126183 G 0.97 0.64 0.059 1.23E-05 2437 
10 88374565 
WAPAL/OPN4/ 
LDB3/BMPR1A 
rs2355012 C 0.74 0.85 0.030 1.34E-05 2499 
14 20674429 Many genes rs10136872 T 0.28 1.21 0.052 1.36E-05 2511 
11 73715922 PGM2L1/P4HA3 rs479968 G 0.40 0.87 0.027 1.46E-05 2750 
4 83534645 ENOPH1 rs6822004 G 0.91 0.76 0.045 1.49E-05 2437 
6 17169176  rs7763738 T 0.60 0.87 0.027 1.55E-05 2768 
1 81912758 LPHN2 rs12744466 T 0.08 1.31 0.078 1.60E-05 2768 
22 23753062 KIAA1671 rs5760804 A 0.20 1.20 0.048 1.68E-05 2162 
2 28262202 BRE rs7586315 T 0.07 1.34 0.087 1.72E-05 2056 
17 9911846 GAS7 rs9913492 T 0.50 0.87 0.028 1.88E-05 2507 
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Chromosome Position Gene SNPs 
Effect 
Allele 
Allele 
Frequency 
Odds 
Ratio 
Standard 
Error 
P value #Cases 
3 85708744 CADM2 rs7617356 T 0.63 0.87 0.028 1.90E-05 2512 
14 94430979  rs1741236 T 0.19 0.85 0.032 1.93E-05 2749 
1 166436076 TIPRL rs2072776 A 0.29 1.15 0.037 1.98E-05 2744 
2 220553438  rs750894 G 0.77 0.85 0.031 2.39E-05 2513 
15 76593078 AGPHD1 rs8034191 T 0.66 0.85 0.032 2.62E-05 1798 
8 14852373 SGCZ rs17470444 G 0.29 1.19 0.047 2.68E-05 1794 
5 146651809 STK32A rs7725229 T 0.15 0.83 0.036 2.74E-05 2769 
3 20057973 KAT2B rs2929408 C 0.87 1.24 0.059 2.77E-05 2512 
*Previously associated with ankle brachial index 
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7.3.4 Random effects  
Rs4674485 in MIR4268 was the only SNP detected by the random effects model at a p<1E-
04. 
7.3.5 Replication of known signals 
The top hit for the overall meta-analysis was rs10757269 that has been reported for ankle-
brachial index and LEAD. We detected the same risk allele for the 9p21 region G with an 
odds ratio of 1.16 and the same risk allele for CHRNA3 C with an odds ratio of 1.16 which 
are both similar to published estimates(Table 7-4)169, 268. Of the 23 SNPs previously reported 
for LEAD we had information for 14 of those SNPs (Table 7-4) and detected a nominally 
significant effect for rs5051 in AGT for the published risk allele169. A power calculation 
revealed that we had 100% power to detect the effects for rs1800795 in IL6 for the 
published OR=1.44 for the major allele. 
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Table 7-4: Replication of known lower extremity arterial disease associations in the current meta-analysis for all LEAD cases and controls 
Gene SNP Proxy EA* AF** Odds 
ratio 
Lower 
95%CI 
Upper 
95%CI 
P value #Cases Published  
Odds ratio 
CDK2NBAS rs10757278/ 
rs1333049 
rs10757269 G 0.45 1.16 1.09 1.23 1.62E-06 2768 1.34 
CHRNA3 rs1051730 rs8034191 C 0.66 1.16 1.08 1.25 2.62E-05 1798 1.19 
AGT rs5051/rs699 rs2478543 C 0.41 1.06 0.89 1.00 4.57E-02 2769 1.01 
CSMD1 rs2554503 rs2554522 T 0.13 1.10 1.00 1.20 5.61E-02 2513 1.32  
ITGB3 rs5918 rs8069732 C 0.87 1.08 0.84 1.01 6.83E-02 2749 0.83 
IL6 rs2069827 rs2069827 G 0.91 1.09 0.82 1.02 1.12E-01 2494 Major risk allele 
 ENPP1 rs1044498 rs6919751 T 0.15 1.05 0.96 1.14 2.84E-01 2769 Association in non-smokers 
NOS3 rs891512 rs1808593 T 0.67 1.04 0.96 1.12 3.34E-01 2765 Major risk allele 
OSBPL10 rs1902341 rs1902344 C 0.40 1.03 0.97 1.09 3.55E-01 2768 1.31 
IL6 rs1800795 rs7808457 A 0.55 1.03 0.91 1.04 4.10E-01 2055 1.44 
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Gene SNP Proxy EA* AF** Odds 
ratio 
Lower 
95%CI 
Upper 
95%CI 
P value #Cases Published  
Odds ratio 
MTHFR rs1801133 rs1801133 A 0.45 1.03 0.91 1.04 4.19E-01 2511 0.97 
NOS3 rs2070744 rs1800783 T 0.64 1.02 0.96 1.09 4.97E-01 2766 No effect reported T ABI raising allele 
VSP13D rs235243 rs235256 A 0.08 0.97 0.87 1.09 6.32E-01 2512 1.18 
MMP9 rs3918242 rs2236416 A 0.86 1.02 0.90 1.07 7.12E-01 2769 Major risk allele 
*Effect allele; **Allele frequency 
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7.3.6 Smoking interaction analysis 
 Figure 7-5 includes the Manhattan plots for smokers (A) and non-smokers (B) which show 
different patterns of association in the two strata. Figure 7-1B shows the quantile-quantile 
plot for associations in smokers that appear slightly deflated and C shows a deviation 
outside the 95% confidence intervals in non-smokers. Two SNPs were strongly suggestive of 
a smoking interaction (p<1E06) near ADAMTS17 and UMODL1 (Figure 7-5). A forest plot of 
the effects in non-smokers vs. smokers for rs12593235 clearly illustrates the different allelic 
effects in the two strata (Figure 7-3C). 
Other interesting interactions were observed for signals in GSX1, SORBS1, ARHGAP242, 
PACRG, FRS3, TFEC, LINGO2, ZNF385B, MTAP/CDK2NBAS, SPC25 and STARD13. We did not 
detect an interaction with smoking signals in CHRNB3195, CHRNA5363, ANAPC1360, 
SLCO3A1360, CHRNA3361, CTNNA3362 and VSP13A362. A nominally insignificant interaction was 
observed for rs1051730 at p=0.08. The ratio of smokers to non-smokers LEAD cases was 3:1 
and in the LEAD controls was 2:1, so we were underpowered to detect small differences in 
allelic effects between smokers and non-smokers. ENNP1, rs1044498, was detected in non-
smokers only but we found no association between LEAD and rs1044498 in the overall 
meta-analysis and there was no interaction with smoking status. 
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7.4 Discussion 
In this study we present findings from a meta-analysis of LEAD in a total of 2774 LEAD 
cases and 17941 LEAD free controls and the first meta-analysis of a gene by smoking 
interaction for LEAD. We replicate known signals in the 9p21 region and CHRNA3 that 
are the only signals reported at genome wide significance for LEAD. We also 
investigated the published signals from candidate gene studies and detected an 
association with AGT. Two signals near ADAMTS17 and UMODL1 had large differences 
in allelic effects between smokers and non-smokers. 
The 9p21 region and CHRNA3 have both been associated with LEAD in other studies159, 
268. The 9p21 region is a locus that has been associated with different forms of 
atherosclerosis including CAD, ischaemic stroke, abdominal aortic aneurisms and 
intracranial aneurisms38, 161, 273. Loss of CDKN2B in mice led to apoptosis of the smooth 
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Figure 7-5: Manhattan plots of LEAD determinants in smokers (A) and non-smokers (B) 
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muscle cells leading to aneurism formation364. The action of genes in the 9p21 region is 
complex where MTAP has been shown to increase lesion size and knock-outs of 
CDKN2A reduce lesion size in mice285. CHRNA3 increases the risk of LEAD by 
predisposing individuals to nicotine dependence159.  
We did not detect signals for all the variants that have been associated with LEAD in 
candidate gene studies. While the effect sizes and risk alleles were consistent for most 
loci we only detected one locus at nominal significance. AGT is angiotensinogen that is 
primarily expressed in the liver where it acts through different pathways to regulate 
blood pressure. Mutations in this gene increase the susceptibility to hypertension – a 
known risk factor for LEAD365. Signals in ITGB3, MTHFR and VSP13D did not have the 
same effect allele as previously published but none of these results are significant at 
p<0.05. We did not detect an association in IL6 with the reported effect size despite 
the power to detect an association in this study. Larger studies are required to identify 
true genetic associations for LEAD. 
Other suggestive signals from the meta-analysis were in genes that may be linked to 
the disease process or may be related to risk factors for LEAD. Body mass index, 
diabetes and increased blood sugar are known risk factors for LEAD. We detected 
signals close to known BMI loci in CADM2366, in HIBADH which is upstream of JAZF1 a 
known locus for T2D367 and rs1741236 which is close a locus associated with response 
to statins368. LEAD and diabetic neuropathy are often diagnosed together so genes that 
are involved in signal transduction and cell to cell adhesion, cell growth and 
differentiation such as LPHN2 and KAT2B are good candidates for the disease process. 
Advanced stages of LEAD are often characterised by a stiffening of the arteries so 
genes that are involved in osteoblast development and matrix mineralisation such as 
GAS7369 and BMPR1A370 are also plausible associations. Large studies will be required 
to confirm these signals. 
The top association for the smoking interaction is near ADAMTS17 a metallopeptidase 
with a thrombospondin type 1 motif. Signals in ADAMTS17 have been associated with 
human height and short stature371, 372. This locus forms part of a long range 
quantitative trait locus which affects blood pressure specifically in non-smokers373. Our 
lead SNP rs1293235 shows a similar pattern of association where there is no allelic 
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effect in smokers but is 1.4 fold riskier in the non-smokers. In a study of Mexican 
Americans two SNPs in ADAMTS17 were associated with blood pressure traits: 
rs8027190 was associated with hypertension and rs2573652 was associated with 
diastolic blood pressure373. These signals were not in linkage with our top associations 
but we observe a similar association to the one that has been as previously published. 
Replication of these findings in independent samples will be required to establish this 
locus as a risk locus for LEAD specifically in non-smokers. We detected another signal 
that showed heterogeneous allelic effects downstream of ARHGAP42 another locus for 
blood pressure31.  
We did not detect any significant interactions for the nicotine associated loci and we 
believe this is due to the nicotine SNPs effect on partitioning smoking status. This 
would result in a large allele frequency difference between smokers and non-smokers. 
The effect that may be detected by an interaction analysis is the additional effect of 
the SNPs on smoking intensity within the smoking group. Taking into account the size 
of the study and the modest effect that these SNPs have on smoking intensity we 
would not expect to detect an interaction as it is likely that our study is underpowered. 
We do detect an interaction for the major allele of rs12593925 in ADAMTS17 as it has 
a large allelic effect in the non-smokers and no effect in the smokers. We did not 
detect an association with ENNP1 with LEAD in non-smokers which is the subgroup 
that it had been reported in173.  
Other interesting signals were detected in genes that modify risk factors and are 
associated with comorbidities of LEAD. Signals in UMODL1 have been associated with 
non-cardio-embolic stroke374 and myopia375. Signals in GSX1 are risk in smokers and 
protective in non-smokers, these variants are downstream of rs9512637 a known 
alcoholism variant376. We detect rs483109 close to other signals for HbA1c377. HbA1c at 
high levels may be linked to an increase in vascular calcification378. Other signals were 
found close to signals for intracranial aneurisms for rs9315202 in STARD13379 and 
myocardial infarction for rs4512473, close to MTAP. These are both known 
comorbidities and complications of LEAD. 
The main weakness of the study was lack of power to detect variants at genome wide 
significance in both the overall GWAS and the interaction analysis. The power to detect 
199 
 
 
the known signal rs10757269 in this study at p<5E-08 was 0.03 so this study is 
underpowered to detect novel signals at this significance level with similar odds ratios 
and effect allele frequencies. The main GWAS included 2774 LEAD cases and while we 
replicated both the known signals for LEAD we were unable to detect either at genome 
wide significance. We were underpowered in the interaction analysis to detect 
significant interactions as the ratio of cases in the ever smoker and never smokers was 
3:1. Despite this we did detect heterogeneous effects in a known smoking interactions 
locus.  
In this study we have detected signals for known associations in CHRNA3 and the 9p21 
region, and have identified several signals that may be associated with LEAD. We also 
report the first locus that has interactions with smoking status for LEAD. We plan to 
seek replication for this locus and to refine signals detected in both the overall meta-
analysis and the interaction analysis by including more samples in the meta-analysis. 
This study includes 3 diabetic cohorts (DCCT/EDIC, GoDARTS and GoDARTS-SUMMIT) 
where LEAD has been identified as a diabetic complication and one cohort that been 
selected as a case control study for LEAD (DeCODE). Only 30% of the deCODE cohort 
were diabetic and we hypothesize that there are probably two underlying aetiologies 
for LEAD in diabetics and LEAD in non-diabetics. Genes underlying the two distinct 
LEAD aetiologies will be detected in subgroup analyses therefore in addition to the 
smoking interaction analysis we intend to perform a diabetes-stratified analysis.  
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8. Discussion 
8.1 Main outcomes of this thesis 
In this thesis algorithms were developed to identify individuals with CAD, IS, and LEAD 
from EMR linked to the GoDARTS cohort. These algorithms were validated using data 
available from the GoDARTS cohort and known genetic associations in CDKN2BA and 
LPA regions were replicated in derived cardiovascular phenotypes. When genetic risk 
scores were associated with the cardiovascular phenotypes distinct association 
patterns with individual phenotypes were observed indicating that the derived 
cardiovascular phenotypes are distinct from each other despite an overlap in 
individuals. The genetic score for triglycerides showed an inverse association 
compared to the association serum triglyceride measures.  
The CAD phenotype was used in the largest meta-analysis of CAD to date and 
identified 15 new loci for CAD and 104 loci that passed an FDR threshold of 5%. An CAD 
genetic risk score did not improve the prediction of CAD events above serum 
cholesterol levels in GoDARTS. In a large meta-analysis of CAD in T2D individuals only 
two independent signals in ADAMTS7 which had previously been associated with CAD 
were detected at genome wide significance. There was significant allelic heterogeneity 
for the risk alleles in 6 of the known CAD loci indicating that there may be differences 
in effect between T2D and non-diabetic populations. We also detected rs944801 in the 
9p21 region was associated with T2D and CAD in T2D, and had a nominally insignificant 
interaction with T2D. The risk of CAD was increased in individuals who had co-morbid 
type 2 diabetes.  
In a Mendelian Randomisation study of CAD and vitamin D in GoDARTS, low vitamin D 
levels were associated with CAD and a genotype score for decreasing vitamin D levels 
was also found to be associated with CAD. These associations indicated that vitamin D 
was likely to be a risk factor for CAD. A meta-analysis of LEAD detected known signals 
in CHRNA3 and the 9p21 region. The smoking interaction analysis detected a new locus 
for LEAD, ADMATS17. SNPs in this locus have different allelic effects in smokers vs. 
non-smokers. 
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8.2 The value and future applications of biobanks 
Biobanks such as GoDARTS provide a platform for the study of many phenotypes for a 
relatively low cost compared to cross sectional studies. This is due to the 
comprehensive and rich data available for each study participant. In this thesis 
algorithms were developed to identify individuals with CAD, IS, and LEAD from EMR 
linked to the GoDARTS cohort. Similarly other phenotypes can be defined from the 
same group and can be investigated using the common genetic data available.  
Other studies like the UK Biobank356 and the Kaiser permanente/Genetic Epidemiology 
Research on Adult Health and Aging (GERA) cohort357 have a similar design to GoDARTS 
where DNA has been collected and linked to phenotype data. The UK BioBank has 
recruited 500,000, collected biological specimens and phenotype data for all its 
participants356. Currently the GERA cohort consists of 100,000 individuals with plans to 
genotype a further 400,000 individuals on high density SNP platforms. This cohort is 
linked to EMR data that allows for a wide range of phenotypes to be identified in a 
large population. 
These studies are extremely valuable for identifying factors that are predictive of 
future disease due to their size and longitudinal data. Cross sectional studies are 
limited in this aspect due to their design as they essentially observe one slice of patient 
time and only observe living individuals358. These studies have been very useful in 
identifying loci that are associated with CAD but the predictive value of these variants 
is lacking compared to conventional risk factors (Chapter 4). Biobanks monitor 
individuals prospectively and collect additional phenotype data regularly over an 
individual’s lifetime. Prospectively modelling changing cholesterol measures, blood 
pressure, weight, smoking status and prescribed medications is useful for designing 
predictive models for cardiovascular outcomes and for identifying genetic variants that 
predict future disease. Biobanks store a range of biological specimens from their study 
participants and these can be used to elucidate roles of SNPs in disease process and to 
identify biomarkers. Projects within SUMMIT are combining genetic data with 
proteomic and metabolomics data to identify new biomarkers for cardiovascular 
disease in diabetics. The SUMMIT study relies heavily on biobanks for suitable samples 
to analyse.  
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8.3 Explaining the missing heritability in CAD 
Loci identified in large genetic studies explain 25% of the total heritability of CAD 
which means that 75% of the genetic components that the heritability have not been 
identified. Up until now the large-scale genetic association studies for CAD have 
focussed on identifying common variants that explain the additive variance of CAD 
while investigations of the non-additive variance such as epigenetic modifications, 
epistasis or gene by environment interactions have not been attempted on a large 
scale. The contribution of rare variants to the missing heritability has also not been 
quantified in large-scale experiments.  
8.3.1 Identification of rare variants that explain the additive variance 
The large consortia have proposed a series of 1000G imputations to identify rare 
variants associated with different traits. The reference panel for imputation has been 
assembled from the 1000 genomes project (http://www.1000genomes.org/) which 
includes whole genome sequencing of individuals from different Hap Map ethnic 
groups. This reference panel includes 2000 haplotypes for 46 Million polymorphisms 
for variants, insertions and deletions and sequence polymorphisms. This reference 
panel will be used to impute polymorphisms into existing genotype data that may 
explain some of the missing heritability for CAD. Other efforts to account for the 
missing heritability in common disease include large exome array experiments. 
Similar to the CardioMetabochip, the exome chip is a custom array which includes non-
synonymous, splice, stop altering, tags for previous GWAS hits, ancestry informative 
markers for African America, European and Native American ancestry, synonymous 
SNPs, mitochondrial SNPs, Y chromosome SNPs and HLA tags 
(http://genome.sph.umich.edu/wiki/Exome_Chip_Design). Currently large populations 
are being typed on these arrays for a series of exome chip analyses that will be 
performed. The success of analyses to identify rare variants and variants that have 
modest allelic effects is greatly dependent upon large populations to analyse and 
appropriate statistical analyses. The first publication of exome array analyses has 
detected rare variants that influence glucose homeostasis380. The exome analysis for 
CAD is currently underway and should provide interesting results. 
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Other efforts to identify rare variants associated with disease traits are underway. 
Whole genome sequencing projects like UK10K are well underway with the express 
purpose of understanding the genetic architecture of rare variants that determine 
different disease traits in 10 000 individuals. Other projects like GoT2D will also whole 
genome sequence 3000 individuals and 4000 individuals for exomes to identify rare 
variants associated with T2D. Sequencing projects are useful in identifying additional 
variants that are not in linkage with variants typed on large SNP genotyping arrays or 
that are rare or private mutations that contribute toward a disease.  
8.3.2 Explaining the non-additive variance of common diseases 
Limited analysis has been conducted to identify variants that interact with 
environmental factors to modify CAD risk. Stratified analyses performed in chapter 4 
successfully identified rs16986953, a SNP that interacted with age to increase CAD risk 
in young CAD cases. Stratified analyses by risk factor have not been performed and we 
plan to perform a stratified analysis that includes non-diabetic individuals with CAD to 
build on work conducted in chapter 5. We will perform stratified analyses to identify 
loci that interact with diabetic status to modify CAD risk. GoDARTS is also taking part in 
a large smoking interaction analysis to identify variants that interact with smoking 
status to modify CAD risk.  
Other avenues to quantify the non-additive variance in CAD include experiments that 
look for changes in the cells that are not due to changes in the DNA sequence or at 
how genes interact with other genes to produce an effect on CAD. Epigenetics is the 
study of changes in gene expression or cellular phenotypes that are not due to changes 
in DNA sequence. Epigenetics includes the study of methylation, histone modification 
and micro RNA alterations. These mechanisms help the cells to rapidly respond to 
environmental changes. Epigenetic alterations have been observed for CAD in 
response to nutrition, smoking, pollution, stress and circadian rhythm. These 
modification may explain some of the missing heritability and highlight new targets for 
therapy and disease prevention381. Gene by gene interactions are also important in 
explaining the missing heritability in CAD. Polymorphisms from individual genes may 
not be individually associated with CAD but may interact with polymorphisms in other 
genes to have an effect on CAD outcome such as polymorphisms in the renin-
angiotensin system382.  
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8.4  Analyses for IS and LEAD 
In contrast with other phenotypes there are far fewer loci that have been identified for 
IS and LEAD. This may be due to smaller populations with genome wide array data for 
IS and LEAD. The stroke phenotype is also heterogeneous so the ISGC has moved its 
focus away from looking at the global IS phenotype to looking at TOAST stroke 
subtypes. Variants have been reported for large artery stroke and cardio-embolic 
stroke143, 145 and larger studies focused on more distinct phenotypes may be more 
fruitful than previous analyses. The only large-scale meta-analysis published for LEAD 
lacked power to detect SNPs with small allelic effects158 and much larger populations 
are required to identify additional variants. The meta-analysis of LEAD will be 
expanded to include more cohorts; we will also perform a diabetes-stratified analysis 
and will expand the smoking stratified analysis to include more samples. 
8.5 Challenges for predicting CAD using genetic variants 
The large CardioMetabochip replication of content contributed by large consortia is 
the first time that large populations have been typed on the same chip. As the chip 
was designed to replicate putative loci it is enriched with signals that are likely to be 
associated with targeted phenotypes. The cost of genotyping individuals on the 
CardioMetabochip allowed for more individuals to be genotyped increasing the power 
of analyses to detect SNPs with small allelic effects for individual phenotypes and to 
detect SNPs that have effects on multiple phenotypes. This provides a good resource 
for across phenotype comparisons and it is not surprising that many of the CAD 
associated SNPs were also associated with related risk factors: lipids, glycaemic traits, 
blood pressure and anthropometric measures285. Although the majority of variants 
that explain the total heritability of CAD have not been identified a large number of 
SNPs associated with CAD and related risk factors have been identified. How can we 
use the current body of known SNPs to predict CVD? 
The prediction of CAD may be greatly improved by including SNPs associated with 
common CAD risk factors in addition to those identified as SNPs solely associated with 
CAD outcome. Not all SNPs will be useful instruments for predicting CAD outcomes so 
there needs to be a process to identify key SNPs that are useful as disease predictors. 
One of the major challenges in identifying a set of predictive SNPs is that some SNPs 
have pleiotropic effects where the effect of SNPs on the intermediate phenotypes is 
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not always consistent with increasing CAD risk. Mendelian randomisation studies can 
be useful in identifying SNPs that affect the intermediate phenotypes in a manner that 
is consistent with the allelic increase in CAD risk. Creating a composite score of CAD 
associated SNPs and those that are useful predictors of CAD risk factors and CAD 
outcomes may provide a sharper instrument to predict CAD outcome.  
8.5.1 Investigating SNP pleiotropy 
In chapter 3 we combined known variants for cardiovascular risk factors into genetic 
scores that were with CAD, IS and LEAD. Despite establishing that the genetic scores 
predicted individual risk factors, the effect of the genetic score for triglycerides was in 
opposition to the effect of serum triglycerides on cardiovascular outcomes. These 
conflicting associations are likely due to pleiotropic effects of SNPs that make up the 
triglyceride score. SNP pleiotropy is observed when SNPs occur in genes that have 
effects on multiple phenotypes. 
It is important to consider that SNPs are associated with serum measures of 
triglycerides that are determined by a number of biological processes. SNPs that 
reduce serum triglyceride levels may do so by diverting triglycerides into surrounding 
tissues like the liver or the heart thus inducing lipotoxicity in vital organs of the body. 
Pleiotropy has been observed for rs1260326 (rs780094) that was included in the 
genetic score for triglycerides. The minor T-allele of rs780094 in GCKR raises 
triglyceride levels while simultaneously improving insulin sensitivity and raising HDL 
levels in individuals with metabolic syndrome267, 279-281, 383. Thus a genetic increase in 
triglycerides does not always correspond to an increase in disease risk and is not useful 
for disease prediction. 
Identifying pleiotropic SNPs and investigating the mechanism behind the pleiotropic 
effects improves our knowledge of the genetic architecture of complex traits. It also 
informs our understanding of the underlying biology and phenotypic consequences of 
SNPs identified in large genetic studies. If we want to use variants identified in large 
genetic studies to predict disease we need to fully understand how that SNP affects 
the trait directly and how it affects intermediate phenotypes. Mendelian 
randomisation studies are commonly used to infer the causal relationship between an 
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outcome and an exposure. When relationships are well established it may be used to 
detect pleiotropic genetic effects in associated SNPs.  
8.6 Mendelian randomisation studies 
8.6.1 Inferring causal relationships 
Mendelian randomisation has been applied successfully to confirming a causal 
relationship between interleukin-6168 and CAD, and disproving a relationship between 
C-reactive protein334 and CAD. In chapter 6 we applied a Mendelian randomisation 
design to determining the causal relationship between vitamin D levels and CAD. In 
GoDARTS we found a causal relationship between low vitamin D levels and CAD that 
has not been shown before. We have requested replication of these findings in other 
cohorts and have found interesting patterns in the data where the vitamin D lowering 
alleles correspond to an increase in CAD while in other cohorts closer to the equator 
the effects of the vitamin D lowering alleles tend to the null.  
Due to the source of our vitamin D data we find that the mean vitamin D levels are 
much lower than those published by other studies. This may be due to the reduced 
daylight hours and sun exposure in Scotland and vitamin D measurements were 
ordered for medical investigations. When we compared our mean measured vitamin D 
per genotype with those published we found the same reduction in vitamin D per 
additional copy of the lowering allele. This would indicate that the SNPs have the same 
effect in our population but the basal vitamin D levels are naturally lower due to the 
environment. Based on these results we hypothesised that in populations that have 
naturally lower vitamin D levels due to increasing distance from the equator the effect 
of vitamin D reduction on cardiovascular outcome would be more pronounced.  
In populations that are exposed to more sunlight and have healthy levels of vitamin D 
(70-250nmol/L)198 (Figure 1-4) a reduction of 16nmol/L of vitamin D (Table 6-3), in 
individuals who are homozygous for all four of the vitamin D reducing alleles, is 
unlikely to result in adverse health outcomes. In populations that are have naturally 
lower vitamin D levels of less than 70nmol/L, which we observe for populations at 
greater than 50° from the equator (Figure 1-4), a 16nmol/L decrease in vitamin D due 
to genotype will cause vitamin D deficiency or insufficiency. It would be in these 
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populations that you would expect to see the greatest effect of vitamin D lowering 
SNPs on health outcomes.  
These findings would provide a case for considering not just the effect of SNPs on 
intermediate phenotypes but also the context in which they are acting. These could 
include environmental or treatment factors that influence the intermediate 
phenotypes. Mendelian randomisation can be used to identify SNPs that affect an 
outcome through an intermediate phenotype. This approach was adopted by Freathy 
et al., where rs9939609 in the FTO gene was tested for association with traits affected 
by BMI and it was shown that these relationships are consistent with the effect of FTO 
variants on BMI341.  
8.6.2 Identifying variants for a global CAD score from Mendelian 
randomisation studies 
Similarly this method could be used to identify SNPs that predict CVD outcomes 
through their effects on lipid traits or other cardiovascular risk factors with the 
purpose of building a more global genetic prediction model for CAD. We could use a 
series of reductive Mendelian randomisation studies in large populations to identify 
the most suitable SNPs to be included in a predictive score for CAD. With the ultimate 
aim of predicting a lifetime risk of CAD based on carrying certain alleles. 
 In this thesis we have shown the known SNPs for CAD did not predict CAD better than 
serum lipid measures (Chapter 3). This would indicate that our current knowledge of 
CAD genetics cannot be used in a clinical setting. In order to use our knowledge to 
improve patient outcomes further studies need to be conducted to identify novel 
variants associated with CAD and follow up studies on the predictive ability for CAD 
outcomes of these variants need to be conducted. 
9. Conclusions 
Experiments, which identify the biological role and processes that these SNPs 
represent need to be conducted. A series of Mendelian randomisation studies need to 
be conducted on SNPs associated with cardiovascular risk factors to identify SNPs that 
are useful for predicting future CVD events. This thesis has highlighted how SNP x 
environment interactions need to be considered in Mendelian randomisation studies. 
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Much larger studies with focused analyses are required to detect both common and 
rare variants associated with CAD, IS and LEAD.  
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Appendices 
Appendix 1: SNPs and platforms used to calculate the genotype risk scores for type 1 
diabetes in the Go-DARTS study 
CHR BP Gene SNP Immuno 
Chip SNP 
Affymetrix 6.0 
 Illumina Dual SNP 
1 64108771 PGM1 rs2269241 rs2269241 rs2269241 
1 1.14E+08 PTPN22 rs2476601 rs2476601 rs1230666 
1 1.93E+08 RGS21 rs2816316 rs1323296 rs1323296 
1 2.07E+08 MAPKAPK2 rs3024505 rs3024505 rs3024505 
2 1.03E+08 IL18RAP rs917997 rs7559479 rs7559479 
2 1.63E+08 IFIH1 rs1990760 rs7608315 rs7608315 
2 2.05E+08 CTLA4 rs3087243 rs3087243 rs3087243 
3 46345611 CCR3 rs11711054 rs6441961 rs6441961 
4 26085511 C4orf52 rs10517086 rs932036 rs932036 
4 1.23E+08 KIAA1109 rs4505848 rs7671357 rs7671357 
5 35874575 IL7R rs6897932 rs6897932 rs6897932 
6 32408527 HLA-DRA rs9268645 rs9268645 rs9268645 
6 90958231 BACH2 rs11755527 rs4707605 rs4707605 
6 1.38E+08 BTF3L4P3 rs2327832 rs2327832 rs2327832 
7 26891665 SKAP2 rs7804356 rs10486483 rs10486483 
7 51027194 GRB10 rs4948088 rs4948088 rs4948088 
9 4291747 GLIS3 rs7020673 rs7020673 rs7020673 
10 6123495 IL2RA rs12251307 rs12251307 rs12251307 
10 6472891 PRKCQ rs11258747 rs11258747 rs11258747 
10 90023033 PTEN rs10509540 rs7068821 rs7068821 
11 2213166 MIR4686 rs7111341 rs11564708 rs11564708 
12 9910164 CD69 rs4763879 rs4763879 rs4763879 
12 56482180 ERBB3 rs2292239 rs2292239 rs2292239 
12 1.12E+08 SH2B3 rs3184504 rs653178 rs653178 
14 69263599 ZFP36L1 rs1465788 rs1465788 rs1465788 
14 98498951 C14orf64 rs4900384 rs4900384 rs4900384 
15 79235446 CTSH rs3825932 rs3825932 rs3825932 
16 11179873 CLEC16A rs12708716 rs12708716 rs12708716 
16 28539848 IL27 rs4788084 rs1074631 rs1074631 
16 75247245 CTRB2 rs7202877 rs4993971 rs4993971 
17 7633692 DNAH2 rs16956936 rs16956936 rs16956936 
17 38066240 GSDMB rs2290400 rs1008723 rs1008723 
17 38770286 CCR7 rs7221109 rs7221109 rs7221109 
18 12809340 PTPN2 rs1893217 rs2542151 rs2542151 
20 1610551 SIRPG rs2281808 rs2281808 rs2281808 
21 43836186 UBASH3A rs11203203 rs11203203 rs11203203 
22 30581722 HORMAD2 rs5753037 rs4820830 rs4820830 
22 37591318 C1QTNF6 rs229541 rs229541 rs229541 
259 
 
 
 
Appendix 2: SNPs and platforms used to calculate the genotype risk score for type 2 
diabetes in the Go-DARTS study 
CHR BP Gene SNP CardioMetabochip 
Chip SNP 
Affymetrix 6.0  
Illumina Dual SNP 
1 120517959 NOTCH2 rs10923931 rs10923931 rs10923931 
1 214154719 PROX1-AS1 rs2075423 rs2075423 rs2075423 
2 27741237 GCKR rs780094 rs780094 rs780094 
2 43690030 THADA rs10203174 rs10203174 rs10203174 
2 60568745 RNA5SP94 rs243088 rs243088 rs243090 
2 161346447 RBMS1 rs7569522 rs7569522 rs7569522 
2 165528876 COBLL1 rs13389219 rs6717858 rs6717858 
2 227093585 NYAP2 rs2943640 rs2943640 rs2943640 
3 12393125 PPARG rs1801282 rs1801282 rs1801282 
3 23454790 UBE2E2 rs1496653 rs1496653 rs1496653 
3 64090363 PRICKLE2-AS2 rs12497268 rs12497268 rs12497268 
3 64705365 ADAMTS9-AS2 rs6795735 rs6795735 rs6795735 
3 123082398 ADCY5 rs11717195 rs11717195 rs11717195 
3 185511687 IGF2BP2 rs4402960 rs4402960 rs4402960 
3 186613409 ADIPOQ rs17301514 rs17301514 rs7648806 
4 6289986 WFS1 rs4458523 rs4458523 rs4458523 
5 55806751 HMGN1P17 rs459193 rs40271 rs40271 
6 20679709 CDKAL1 rs7756992 rs7756992 rs7756992 
6 38177667 BTBD9 rs4299828 rs4299828 rs4299828 
6 39304211 KIF6 rs3734621 rs3734621 rs3734621 
7 14898282 DGKB rs17168486 rs17168486 rs17168486 
7 28196413 JAZF1 rs849135 rs864745 rs864745 
7 130437689 KLF14 rs13233731 rs13234407 rs13233731 
8 41519248 ANK1 rs516946 rs516946 rs516946 
8 95937502 NDUFAF6 rs7845219 rs7845219 rs7845219 
8 118185025 SLC30A8 rs3802177 rs3802177 rs3802177 
9 4292083 GLIS3 rs10758593 rs4237150 rs4237150 
9 8369533 PTPRD rs16927668 rs16927668 rs16927668 
9 22051670 CDKN2B-AS1 rs944801 rs7030641 rs944801 
9 22134094 CDKN2B-AS1 rs10811661 rs10811661 rs10811661 
9 81905590 MTND2P8 rs17791513 rs17791513 rs13292347 
9 84308948 TLE1 rs2796441 rs2796441 rs2796441 
10 12307894 CDC123 rs11257655 rs4747969 rs4747969 
10 70865342 SRGN rs12242953 rs12242953 rs12242953 
10 80942631 ZMIZ1 rs12571751 rs12571751 rs12571751 
10 94462882 HHEX rs1111875 rs1111875 rs1111875 
10 114758349 TCF7L2 rs7903146 rs4506565 rs4506565 
11 1696849 FAM99A rs2334499 rs2334499 rs4752781 
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CHR BP Gene SNP CardioMetabochip 
Chip SNP 
Affymetrix 6.0  
Illumina Dual SNP 
11 2691500 KCNQ1 rs231361 rs463924 rs463924 
11 2847069 KCNQ1 rs163184 rs163177 rs163177 
11 17408630 KCNJ11 rs5215 rs5215 rs5215 
11 72433098 ARAP1 rs1552224 rs17244499 rs17244499 
11 92708710 MTNR1B rs10830963 rs10830963 rs10830963 
12 4374373 PARP11 rs11063069 rs11063069 rs11063069 
12 27965150 KLHDC5 rs10842994 rs10842994 rs10842994 
12 66212318 RPSAP52 rs2261181 rs2261181 rs2261181 
12 71433293 PTPRR rs7955901 rs7138300 rs7138300 
12 121426901 HNF1A rs12427353 rs7965349 rs7965349 
13 80717156 LINC00329 rs1359790 rs1359790 rs1359790 
15 62383155 C2CD4A rs4502156 rs4502156 rs6494307 
15 77832762 HMG20A rs7177055 rs7177055 rs7177055 
15 80432222 ZFAND6 rs11634397 rs11634397 rs11634397 
15 90345335 ANPEP rs2007084 rs2007084 rs17240268 
15 91544076 VPS33B rs12899811 rs11073964 rs11073964 
16 53819169 FTO rs9936385 rs8050136 rs8050136 
16 75247245 CTRB2 rs7202877 rs3743614 rs3743614 
17 36102381 HNF1B rs11651052 rs11651755 rs11651755 
18 57884750 RPS3AP49 rs12970134 rs12970134 rs12970134 
19 19407718 SUGP1 rs10401969 rs10401969 rs10401969 
19 46158513 EML2 rs8108269 rs8108269 rs8108269 
20 42989267 HNF4A rs4812829 rs4812829 rs16988991 
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Appendix 3: SNPs and platforms used to calculate the genotype risk score for fasting glucose 
in the Go-DARTS study 
CHR BP Gene SNP CardioMetabo 
Chip SNP 
Affymetrix.6.0 
Illumina.Dual.SNP 
1 214159256 PROX1-AS1 rs340874 rs340874 rs340874 
2 27741237 GCKR rs780094 rs780094 rs780094 
2 169763148 SPC25 rs560887 rs560887 rs560887 
3 123065778 ADCY5 rs11708067 rs11708067 rs11708067 
3 170717521 SLC2A2 rs11920090 rs11924648 rs11924648 
7 15064309 DGKB rs2191349 rs4719433 rs4719433 
7 44235668 GCK rs4607517 rs2908289 rs2908289 
8 118184783 SLC30A8 rs13266634 rs13266634 rs13266634 
9 4289050 GLIS3 rs7034200 rs7024686 rs7024686 
10 113042093 ADRA2A rs10885122 rs4918635 rs4918635 
10 114758349 TCF7L2 rs7903146 rs7903146 rs7903146 
11 45873091 CRY2 rs11605924 rs6485644  rs11605924 
11 47336320 MADD rs7944584 rs7944584 rs7944584 
11 61571478 FADS1 rs174550 rs174577 rs174577 
11 92708710 MTNR1B rs10830963 rs10830963 rs10830963 
12 102875569 IGF1 rs35767 rs35767 rs35767 
15 62433962 C2CD4A rs11071657 rs12440695 rs12440695 
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Appendix 4: SNPs and platforms used to calculate the genetic risk scores for blood pressure 
in the Go-DARTS study 
CHR BP Gene SNP CardioMetabo Chip 
SNP 
Affymetrix.6.0 
Illumina.Dual.SNP 
1 11862778 MTHFR rs17367504 rs17367504 rs17367504 
1 113216543 MOV10 rs2932538 rs2932538 rs4839257 
3 27537909 SLC4A7 rs13082711 rs13082711 rs17682751 
3 41877414 ULK4 rs3774372 rs6599176 rs6599176 
3 169100886 MECOM rs419076 rs223102 rs448378 
4 81164723 PRDM8 rs1458038 rs1458038 rs1458038 
4 103188709 SLC39A8 rs13107325 rs13107325 rs13107325 
4 156645513 GUCY1A3 rs13139571 rs7698460 rs7698460 
5 32815028 NPR3 rs1173771 rs1173771 rs1173771 
5 157845402 MARK2P11 rs11953630 rs12187017 rs12187017 
6 26091179 HFE rs1799945 rs198846 rs198846 
6 31616366 BAG6 rs805303 rs805303 rs805303 
10 18419972 SLC39A12 rs4373814 rs12570727 rs12570727 
10 18707448 CACNB2 rs1813353 rs11014171 rs11014171 
10 63467553 C10orf107 rs4590817 rs2393833  rs2393833  
10 95895940 PLCE1 rs932764 rs10786152 rs10786152 
10 104846178 NT5C2 rs11191548 rs11191560 rs11191560 
11 10350538 AMPD3 rs7129220 rs7129220 rs7129220 
11 16902268 PLEKHA7 rs381815 rs11024074 rs11024074 
11 100593538 ARHGAP42 rs633185 rs604723 rs604723 
12 90060586 ATP2B1 rs17249754 rs2681472 rs2681472 
12 111884608 SH2B3 rs3184504 rs4766578 rs3184504 
12 113872179 TBX3 rs10850411s rs10850411 rs10850411 
15 75077367 CSK rs1378942 rs1378942 rs1378942 
15 91437388 FES rs2521501 rs4932370 rs4932370 
17 45013271 GOSR2 rs17608766 rs17608766 rs17608766 
17 47402807 ZNF652 rs12940887 rs12940887 rs12940887 
20 10969030 FAT1P1 rs1327235 rs1327235 rs1327235 
20 57751117 MRPS16P rs6015450 rs16982520 rs16982520 
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Appendix 5: SNPs and platforms used to calculate genotype risk scores for cholesterol, low 
density lipoprotein, high density lipoprotein and triglycerides in the Go-DARTS study. 
Gene CHR BP Lead.SNP Trait Affymetrix 
.Illumina.SNP 
CardioMetabo 
.Chip 
TMEM57 1 25775733 rs12027135 LDL rs873308 rs873308 
TMEM57 1 25775733 rs12027135 TC rs873308 rs873308 
PPIEL 1 40018509 rs4660808 TG rs17264866 rs17513135 
PABPC4 1 40028180 rs4660293 HDL rs4660293 rs4660293 
BSND 1 55504650 rs2479409 LDL rs2479409 rs2479409 
BSND 1 55504650 rs2479409 TC rs2479409 rs2479409 
DOCK7 1 63025942 rs2131925 TC rs1748195 rs1748195 
DOCK7 1 63025942 rs2131925 TG rs1748195 rs1748195 
DOCK7 1 63025942 rs2131925 LDL rs1748195 rs1748195 
EVI5 1 93009438 rs7515577 TC rs4970712 rs4970712 
CCDC18 1 93700212 rs531514 HDL rs12118262 rs12118262 
CELSR2 1 109818306 rs629301 LDL rs629301 rs629301 
CELSR2 1 109818306 rs629301 TC rs629301 rs629301 
ZNF648 1 182168885 rs1689800 HDL rs2243976 rs2243976 
 1 220973563 rs2642442 TC rs2807834 rs2807834 
 1 220973563 rs2642442 LDL rs2807834 rs2807834 
GALNT2 1 230295691 rs4846914 HDL rs4846914 rs4846914 
GALNT2 1 230295691 rs4846914 TG rs4846914 rs4846914 
LINC00184 1 234858597 rs514230 LDL rs553427 rs558971 
LINC00184 1 234858597 rs514230 TC rs684818 rs558971  
APOB 2 21225281 rs1042034 TG rs673548 rs673548 
APOB 2 21225281 rs1042034 HDL rs673548 rs673548 
APOB 2 21263900 rs1367117 LDL rs1367117 rs1367117 
APOB 2 21263900 rs1367117 TC rs1367117 rs1367117 
APOB 2 21286057 rs515135 LDL rs515135 rs515135 
APOB 2 21286057 rs515135 TC rs515135 rs515135 
APOB 2 21291529 rs668948 TG rs488507 rs488507 
GCKR 2 27730940 rs1260326 TG rs1260326 rs1260326 
GCKR 2 27730940 rs1260326 TC rs1260326 rs1260326 
ABCG8 2 44072576 rs4299376 LDL rs6544713 rs6544713 
ABCG8 2 44072576 rs4299376 TC rs6544713 rs6544713 
ABCG8 2 44074000 rs4953023 TC rs4953023 rs4953023 
ABCG8 2 44074000 rs4953023 LDL rs4953023 rs4953023 
RAB3GAP1 2 135837906 rs7570971 TC rs6730157 rs6730157 
RAB3GAP1 2 135893372 rs10445686 LDL rs16831243 rs16831243 
COBLL1 2 165513091 rs10195252 TG rs10195252 rs10195252 
COBLL1 2 165540800 rs12328675 HDL rs7607980 rs7607980 
NYAP2 2 227099180 rs2943645 TG rs2972147 rs2972147 
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Gene CHR BP Lead.SNP Trait Affymetrix 
.Illumina.SNP 
CardioMetabo 
.Chip 
NYAP2 2 227100698 rs2972146 HDL rs2972147 rs2972147 
RAF1 3 12628920 rs2290159 TC rs7956 rs11709504 
MSL2 3 135926622 rs645040 TG rs645040 rs645040 
AFF1 4 88030261 rs442177 TG rs442177 rs442177 
AFF1 4 88030261 rs442177 HDL rs442177 rs442177 
SLC39A8 4 103188709 rs13107325 HDL rs13107325 rs13107325 
ARL15 5 53298025 rs6450176 HDL rs6876198 rs4311394 
HMGN1P17 5 55861786 rs9686661 TG rs9686661 rs9686661 
HMGCR 5 74656539 rs12916 LDL rs12916 rs12916 
HMGCR 5 74656539 rs12916 TC rs12916 rs12916 
TIMD4 5 156390297 rs6882076 TC rs1501908 rs1501908 
TIMD4 5 156390297 rs6882076 LDL rs1501908 rs1501908 
HAVCR1 5 156479323 rs1553318 TG rs7724832 rs7724832 
ARPC3P5 6 16127407 rs3757354 LDL rs3757354 rs3757354 
ARPC3P5 6 16127407 rs3757354 TC rs3757354 rs3757354 
HFE 6 26093141 rs1800562 LDL rs1800562 rs1800562 
HFE 6 26093141 rs1800562 TC rs1800562 rs1800562 
WASF5P 6 31265490 rs2247056 TG rs9264602 rs2247056 
HLA-DRA 6 32412435 rs3177928 TC rs3177928 rs3177928 
HLA-DRA 6 32412435 rs3177928 LDL rs3177928 rs3177928 
HLA-DRA 6 32683961 rs12660719 TG rs12660719 rs12660719 
SPDEF 6 34546560 rs2814982 TC rs2814982 rs2814982 
SPDEF 6 34552797 rs2814944 HDL rs2814944 rs2814944 
TCP11 6 35133074 rs3800406 LDL rs3800406 rs3800406 
FRK 6 116312893 rs9488822 TC rs3798236 rs3798236 
FRK 6 116354591 rs11153594 LDL rs11153594 rs11153594 
CITED2 6 139829666 rs605066 HDL rs634869 rs634869 
CITED2 6 139843583 rs636202 TG rs628751 rs628751 
SLC22A1 6 160578860 rs1564348 LDL rs1564348 rs1564348 
SLC22A1 6 160578860 rs1564348 TC rs1564348 rs1564348 
SLC22A3 6 160774441 rs486359 TG rs487060 rs501470 
LPA 6 161010118 rs10455872 LDL rs10455872 rs10455872 
LPA 6 161010118 rs10455872 TC rs10455872 rs10455872 
LPA 6 161089817 rs1084651 HDL rs1084651 rs783149 
DNAH11 7 21607352 rs12670798 LDL rs12670798 rs12670798 
DNAH11 7 21607352 rs12670798 TC rs5008148 rs5008148 
NPC1L1 7 44579180 rs2072183 TC rs17725246 rs17725246 
NPC1L1 7 44600695 rs217386 LDL rs217381 rs217373 
BAZ1B 7 72934510 rs7811265 TG rs1178977 rs11974409 
BCL7B 7 72982874 rs17145738 HDL rs17145738 rs17145738 
KLF14 7 130433384 rs4731702 HDL rs11979110 rs11979110 
KLF14 7 130457931 rs1562398 TG rs1596972 rs1596972 
PPP1R3B 8 9183358 rs9987289 HDL rs9987289 rs2126259 
PPP1R3B 8 9185146 rs2126259 LDL rs1461729 rs2126259 
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Gene CHR BP Lead.SNP Trait Affymetrix 
.Illumina.SNP 
CardioMetabo 
.Chip 
SOX7 8 10683929 rs11776767 TG rs7000939 rs7000939 
NAT2 8 18272881 rs1495741 TC rs1495743 rs4921914 
NAT2 8 18272881 rs1495741 TG rs1495743 rs4921914 
LPL 8 19806631 rs7016529 HDL rs6586879 rs6586879 
LPL 8 19806631 rs7016529 TG rs1031045 rs7016529 
LPL 8 19844222 rs12678919 TG rs12682115 rs12678919 
LPL 8 19844222 rs12678919 HDL rs12682115 rs12678919 
FAM110B 8 59311697 rs1030431 LDL rs13277801 rs13277801 
UBXN2B 8 59388565 rs2081687 TC rs13277801 rs13277801 
TRPS1 8 116599199 rs2293889 HDL rs4599845 rs4599845 
TRPS1 8 116648565 rs2737229 TC rs2737229 rs2737252 
TRIB1 8 126490972 rs2954029 TG rs2954029 rs2954029 
TRIB1 8 126490972 rs2954029 LDL rs2954029 rs2954029 
TRIB1 8 126490972 rs2954029 TC rs2954029 rs2954029 
TRIB1 8 126495818 rs10808546 HDL rs2954029 rs2954029 
TRIB1 8 126502526 rs12677676 TC rs8180991 rs8180991 
PLEC 8 145043543 rs11136341 LDL rs7832643 rs7832643 
PLEC 8 145043543 rs11136341 TC rs7832643 rs7832643 
TTC39B 9 15296034 rs643531 HDL rs643531 rs643531 
TTC39B 9 15305378 rs581080 TC rs581080 rs585002 
ABCA1 9 107588777 rs4149311 TC rs4149311 rs4149311 
ABCA1 9 107664301 rs1883025 HDL rs1883025 rs1883025 
ABCA1 9 107664301 rs1883025 TC rs1883025 rs1883025 
ABCA1 9 107665978 rs1800978 LDL rs1800978 rs1800978 
LCN1P1 9 135144821 rs9411489 TC rs651007 rs579459 
ABO 9 136154304 rs649129 LDL rs651007 rs579459 
JMJD1C 10 65027610 rs10761731 TG rs10761741 rs10761741 
CYP26A1 10 94839642 rs2068888 TG rs2068888 rs2068888 
GPAM 10 113910721 rs1129555 LDL rs1129555 rs1129555 
GPAM 10 113933886 rs2255141 TC rs1129555 rs2255141 
AMPD3 11 10388782 rs2923084 HDL rs2923084 rs2923084 
SPTY2D1 11 18632984 rs10128711 LDL rs10128711 rs10128711 
SPTY2D1 11 18632984 rs10128711 TC rs10128711 rs10128711 
F2 11 46743247 rs3136441 HDL rs2290883 rs2290883 
FADS1 11 61569830 rs174546 LDL rs174577 rs174577 
FADS1 11 61569830 rs174546 TC rs174577 rs174577 
FADS1 11 61569830 rs174546 TG rs174577 rs174577 
FADS2 11 61623140 rs174601 HDL rs174577 rs174577 
ZNF259 11 116648917 rs964184 HDL rs964184 rs6589564 
ZNF259 11 116648917 rs964184 TC rs964184 rs6589564 
ZNF259 11 116648917 rs964184 TG rs964184 rs6589564 
ZNF259 11 116648917 rs964184 LDL rs964184 rs6589564 
APOA5 11 116665079 rs9804646 TC rs9804646 rs9804646 
SIK3 11 116728630 rs12225230 HDL rs11216162 rs11216162 
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Gene CHR BP Lead.SNP Trait Affymetrix 
.Illumina.SNP 
CardioMetabo 
.Chip 
GLULP3 11 122522375 rs7941030 TC rs7941030 rs7941030 
UBASH3B 11 122530591 rs7115089 HDL rs7941030 rs7941030 
ST3GAL4 11 126243952 rs11220462 LDL rs10893498 rs10893498 
ST3GAL4 11 126243952 rs11220462 TC rs10893498 rs10893498 
AEBP2 12 20473758 rs7134375 HDL rs7134375 rs7134375 
R3HDM2 12 57792580 rs11613352 HDL rs11613352 rs11613352 
R3HDM2 12 57792580 rs11613352 TG rs11613352 rs11613352 
MMAB 12 110000193 rs7134594 HDL rs888192 rs888192 
ATXN2 12 112072424 rs11065987 LDL rs11065987 rs11065987 
ATXN2 12 112072424 rs11065987 TC rs11065987 rs11065987 
HNF1A-AS1 12 121416650 rs1169288 TC rs2650000 rs2650000 
HNF1A-AS1 12 121416650 rs1169288 LDL rs2650000 rs2650000 
RNA5SP375 12 123773263 rs11057244 HDL rs10846513 rs10846513 
SBNO1 12 123796238 rs4759375 HDL rs10773003 rs10846509 
ZNF664 12 124460167 rs4765127 HDL rs11057408 rs11057408 
ZNF664 12 124486678 rs12310367 TG rs7975482 rs7975482 
NCOR2 12 125261593 rs838880 HDL rs838880 rs838880 
NYNRIN 14 24872209 rs6573778 TC rs6573778 rs6573778 
NYNRIN 14 24883887 rs8017377 LDL  rs8017377   rs8017377  
CAPN3 15 42683787 rs2412710 TG rs2412710 rs2412710 
FRMD5 15 44245931 rs2929282 TG rs492571 rs492571 
ALDH1A2 15 58683366 rs1532085 HDL rs1532085 rs1532085 
ALDH1A2 15 58683366 rs1532085 TC rs1532085 rs1532085 
ALDH1A2 15 58723939 rs2070895 HDL rs2070895 rs1077834 
ALDH1A2 15 58726744 rs261334 TG rs261332 rs588136 
ALDH1A2 15 58731153 rs261342 TC rs261342 rs588136 
ALDH1A2 15 58731153 rs261342 TG rs261342 rs588136 
TPM1 15 63396867 rs2652834 HDL rs2729783 rs2652834 
CTF2P 16 30918487 rs11649653 TG rs11649653 rs4889606 
HERPUD1 16 56989590 rs247616 LDL rs247617 rs247617 
HERPUD1 16 56993324 rs3764261 TC rs247617 rs247617 
HERPUD1 16 56993324 rs3764261 HDL rs247617 rs247617 
CETP 16 57002732 rs9939224 HDL rs9939224 rs7499892 
CETP 16 57004889 rs7205804 TG rs1532625 rs1532625 
PSKH1 16 67928042 rs16942887 HDL rs1124324 rs1124324 
HPR 16 72108093 rs2000999 TC rs2000999 rs2000999 
HPR 16 72108093 rs2000999 LDL rs2000999 rs2000999 
CMIP 16 81534790 rs2925979 HDL rs2925979 rs2925979 
STARD3 17 37813856 rs11869286 HDL rs931992  rs931992  
ITGB3 17 45391804 rs7225700 LDL rs7225700 rs7225700 
EFCAB13 17 45425115 rs7206971 TC rs12452315 rs12452315 
ABCA8 17 66875294 rs4148008 HDL rs4148005 rs4148005 
PGS1 17 76403984 rs4129767 HDL rs2376583 rs4366775 
LIPG 18 47160953 rs7241918 HDL rs7240405 rs7240405 
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Gene CHR BP Lead.SNP Trait Affymetrix 
.Illumina.SNP 
CardioMetabo 
.Chip 
LIPG 18 47160953 rs7241918 TC rs7240405 rs7240405 
LIPG 18 47278345 rs2040293 HDL rs7241641 rs7241641 
RPS3AP49 18 57849023 rs12967135 HDL rs476828 rs476828 
ANGPTL4 19 8433196 rs7255436 HDL rs2278236 rs2278236 
LDLR 19 11202306 rs6511720 LDL rs6511720 rs6511720 
LDLR 19 11202306 rs6511720 TC rs6511720 rs6511720 
LDLR 19 11224265 rs5930 LDL rs5930 rs5930 
LDLR 19 11227602 rs688 TC rs688 rs688 
DOCK6 19 11347493 rs737337 HDL rs737337 rs737337 
SUGP1 19 19407718 rs10401969 LDL rs10401969 rs10401969 
SUGP1 19 19407718 rs10401969 TG rs10401969 rs10401969 
SUGP1 19 19407718 rs10401969 TC rs10401969 rs10401969 
APOE 19 45414451 rs439401 TG rs439401 rs439401 
APOE 19 45415640 rs445925 LDL rs7412 rs7412 
APOC1 19 45422946 rs4420638 HDL rs4420638 rs4420638 
APOC1 19 45422946 rs4420638 LDL rs4420638 rs4420638 
APOC1 19 45422946 rs4420638 TC rs4420638 rs4420638 
APOC4 19 45448465 rs5167 HDL rs5167 rs5167 
FUT2 19 49206417 rs492602 LDL rs492602 rs492602 
FUT2 19 49206417 rs492602 TC rs516316 rs516246 
MIR4752 19 54792761 rs386000 HDL rs103294  rs103294  
FER1L4 20 34152782 rs2277862 TC rs2277862 rs2277862 
ATG3P1 20 39091487 rs2902940 TC rs2902940 rs2902940 
ATG3P1 20 39091514 rs2902941 LDL rs2902940 rs2902941 
ATG3P1 20 39181246 rs6016382 LDL rs6016382 rs6016381 
ATG3P1 20 39181246 rs6016382 TC rs6016382 rs6016381 
TOP1 20 39672618 rs6029526 TC rs760762 rs6065311 
ZHX3 20 39936815 rs909802 LDL rs6029609 rs6029609 
HNF4A 20 43042364 rs1800961 HDL rs1800961 rs1800961 
HNF4A 20 43042364 rs1800961 TC rs1800961 rs1800961 
PLTP 20 44554015 rs6065906 HDL rs7679 rs7679 
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Appendix 6: Table of SNPs that have been previously associated with coronary artery 
disease that were used in the genotypic risk score calculation 
Gene CHR BP SNP Affymetrix.Illumina.SNP CardioMetabo.Chip Reference 
BSND 1 55496039 rs11206510 rs11206510 rs11206510 48  
CELSR2 1 109818530 rs646776 rs646776 rs646776 32  
MIA3 1 222823529 rs17465637 rs17465637 rs17465637 38 
48 
WDR12 2 203745885 rs6725887 rs6725887 rs6725887 48  
NYAP2 2 227068080 rs2943634 rs2943634 rs2943634 38  
INPP5D 2 233998481 rs10933436 rs10933436 rs10933436 48  
BTD 3 15648004 rs7651039 rs7651039 rs7651039 48  
MRAS 3 138122122 rs9818870 rs9818870 rs9818870 41  
PHACTR1 6 12927544 rs12526453 rs12526453 rs12526453 48  
ANKS1A 6 35034800 rs17609940 rs17609940 rs2077750 48  
VEGFA 6 43758873 rs6905288 rs6905288 rs6905288 384  
FAM46A 6 82515315 rs16893526 rs16893526 rs16893526 385  
TCF21 6 134214525 rs12190287 rs12190287 rs12190287 48  
MTHFD1L 6 151252985 rs6922269 rs6922269 rs6922269 38  
FNDC1 6 159646333 rs365302 rs365302 rs2782552 385  
LPA 6 160961137 rs3798220 rs3798220 rs3798220 50  
LPA 6 161010118 rs10455872 directly typed rs10455872 50  
BCAP29 7 107244545 rs10953541 rs10953541 rs12539895 49  
ASZ1 7 117067822 rs7808424 rs7808424 rs4148709 48  
ZC3HC1 7 129663496 rs11556924 rs11556924 rs11556924 48  
CDKN2B-AS1 9 22031005 rs7865618 rs7865618 rs7865618 385  
CDKN2B-AS1 9 22125503 rs1333049 rs1333049 rs1333049 38 
385 
47 
386 
ABO 9 136142203 rs514659 rs514659 rs514659 43  
ABO 9 136154168 rs579459 rs579459 rs579459 48  
KIAA1462 10 30316072 rs3739998 rs3739998 rs2487927 387  
KIAA1462 10 30335122 rs2505083 rs2505083 rs2505083 32  
LINC00619 10 44775824 rs1746048 rs1746048 rs1746048 48  
LIPA 10 91002927 rs1412444 rs1412444 rs2246833 385 
32 
CNNM2 10 104719096 rs12413409 rs12413409 rs12413409 48  
DYNC2H1 11 103660567 rs974819 rs974819 rs974819 32  
ZNF259 11 116648917 rs964184 rs964184 rs6589564 48  
ST3GAL4 11 126281897 rs4937126 rs4937126 rs7933887 48  
SH2B3 12 111884608 rs3184504 rs3184504 rs10774625 48  
HNF1A 12 121435587 rs2259816 rs2259816 rs2259816 41  
COL4A2 13 110960712 rs4773144 rs4773144 rs4773144 48  
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Gene CHR BP SNP Affymetrix.Illumina.SNP CardioMetabo.Chip Reference 
HHIPL1 14 100133942 rs2895811 rs2895811 rs2895811 48  
SMAD3 15 67458639 rs17228212 rs17228212 rs17228212 38  
MORF4L1 15 79111093 rs4380028 rs4380028 rs4380028 32  
SMG6 17 2125605 rs1231206 rs1231206 rs143499 48  
SMG6 17 2126504 rs216172 rs216172 rs143499 48  
PEMT 17 17543722 rs12936587 rs12936587 rs12936587 48  
UBE2Z 17 46988597 rs46522 rs46522 rs15563 48  
SMARCA4 19 11163601 rs1122608 rs1122608 rs1122608 48  
LINC00310 21 35599128 rs9982601 rs9982601 rs9982601 48  
SEZ6L 22 26689635 rs688034 rs688034 rs653361 47  
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Appendix 8: 153 SNPs included in the coronary artery disease gene score 
SNP CHR Position Nearest gene Risk 
allele 
Allele 
frequency 
Weight 
rs10965228 9 22072380 9p21 A 0.92 0.09 
rs11238956 10 44069860 CXCL12 C 0.3 0.04 
rs11617955 13 109616103 COL4A1/COL4A2 T 0.87 0.08 
rs11619057 13 109806392 COL4A2 T 0.13 0.05 
rs12127701 1 109639787 MYBPHL A 0.94 0.07 
rs12526453 6 13035530 PHACTR1/RPEL C 0.68 0.08 
rs12873154 13 109718853 COL4A1/COL4A2 G 0.12 0.07 
rs16905599 9 22059144 9p21 G 0.89 0.08 
rs17062853 6 134142738 BC041459 T 0.7 0.05 
rs17155842 10 44072639 CXCL12 C 0.97 0.1 
rs17465637 1 220890152 MIA3 C 0.72 0.05 
rs17630235 12 111076069 SH2B3/TRAFD1 A 0.39 0.06 
rs2244608 12 119901371 HNF1A G 0.34 0.04 
rs2288911 19 50141124 APOC4/APOC2 T 0.51 0.03 
rs2521501 15 89238392 FES T 0.31 0.06 
rs2891403 12 111621955 SH2B3/RPH3A A 0.26 0.05 
rs3809274 12 110528716 ATXN2 G 0.78 0.06 
rs4268379 1 109579760 SARS T 0.49 0.04 
rs6490029 12 110182840 CUX2 G 0.73 0.05 
rs7139492 13 109713796 COL4A1/COL4A2 C 0.75 0.05 
rs7181240 15 76932181 MRG15 G 0.15 0.05 
rs7515901 1 109641419 MYBPHL C 0.83 0.06 
rs883947 6 12895700 PHACTR1/RPEL C 0.67 0.04 
rs892115 19 11124650 SPC24 G 0.32 0.04 
rs9472428 6 12830159 PHACTR1/RPEL A 0.41 0.04 
rs9515201 13 109838799 COL4A1/COL4A2 A 0.3 0.05 
rs11072794 15 76793637 ADAMTS7/DQ582071 T 0.28 0.07 
rs11191447 10 104642313 CYP17A1/CNNM2/NT5C2 C 0.9 0.09 
rs11203042 10 90979089 LIPA T 0.45 0.04 
rs11206510 1 55268627 PCSK9 T 0.82 0.06 
rs1122608 19 11024601 LDLR/SMARCA4 G 0.76 0.09 
rs11556924 7 129450732 ZC3HC1 C 0.64 0.08 
rs12190287 6 134256218 TCF21 C 0.61 0.07 
rs12205331 6 35006433 ANKS1A C 0.79 0.04 
rs12936587 17 17484447 RAI1/PEMT/RASD1 G 0.58 0.05 
rs13211739 6 13070981 PHACTR1 G 0.25 0.06 
rs1333049 9 22115503 9p21 C 0.47 0.21 
rs15563 17 44360192 UBE2Z G 0.53 0.04 
rs17114036 1 56735409 PPAP2B A 0.91 0.11 
rs2047009 10 43859919 CXCL12/AX747950 G 0.5 0.05 
rs2048327 6 160783522 SLC22A3/LPAL2/LPA C 0.37 0.06 
rs2075650 19 50087459 APOE/APOC1/TOMM40 G 0.14 0.11 
rs2246833 10 90995834 LIPA T 0.37 0.05 
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SNP CHR Position Nearest gene Risk 
allele 
Allele 
frequency 
Weight 
rs2281727 17 2064695 SMG6 G 0.36 0.05 
rs2306374 3 139602642 MRAS C 0.16 0.07 
rs2351524 2 203589237 WDR12/ALS2CR16 T 0.12 0.12 
rs2505083 10 30375128 KIAA1462 C 0.42 0.06 
rs2895811 14 99203695 HHIPL1 C 0.43 0.06 
rs3184504 12 110368991 SH2B3 T 0.42 0.07 
rs3217992 9 21993223 CDKN2BAS/MTAP/CDKN2B T 0.38 0.15 
rs445925 19 50107480 APOE/APOC1/TOMM40 G 0.9 0.12 
rs4773144 13 109758713 COL4A1/COL4A2 G 0.43 0.07 
rs495828 9 135144688 ABO T 0.2 0.07 
rs501120 10 44073873 CXCL12 T 0.84 0.07 
rs602633 1 109623034 PSRC1/SORT1 G 0.78 0.12 
rs7173743 15 76928839 ADAMTS7/MRG15 T 0.57 0.07 
rs9326246 11 116116943 ZNF259/APO5A/APOA1 C 0.1 0.09 
rs9515203 13 109847624 COL4A1/COL4A2 T 0.73 0.08 
rs974819 11 103165777 PDGFD T 0.29 0.06 
rs9982601 21 34520998 KCNE2/C21orf82 T 0.14 0.12 
rs10051876 5 87300520 TMEM161B C 0.82 0.05 
rs10237377 7 139403605 PARP12/MST109 G 0.66 0.05 
rs1034565 22 18364211 ARVCF T 0.31 0.04 
rs10495907 2 43852230 DYNC2LI1 A 0.16 0.05 
rs10507753 13 68180277 BC042673 T 0.06 0.07 
rs10797416 1 2172202 SKI T 0.62 0.04 
rs10962774 9 16958831 BNC2 G 0.52 0.03 
rs11204666 1 148809752 MCL1 C 0.82 0.05 
rs1167800 7 75014132 HIP1 A 0.58 0.04 
rs11710224 3 46561282 LRRC2 C 0.72 0.04 
rs11718455 3 44031902 DQ592230 C 0.75 0.04 
rs12125501 1 167540432 NME7 G 0.65 0.04 
rs12663498 6 151045533 PLEKHG1 C 0.91 0.07 
rs12801636 11 65147893 PCNXL3 G 0.77 0.05 
rs1321309 6 36746614 CDKN1A A 0.51 0.04 
rs1393786 3 137336725 PPP2R3A A 0.28 0.04 
rs1490738 1 88910193 PKN2 A 0.39 0.03 
rs16948048 17 44795465 ZNF652 G 0.35 0.03 
rs17083481 4 54351705 PDGFRA T 0.21 0.04 
rs17087335 4 57533340 C4orf14 T 0.2 0.05 
rs17318596 19 46628935 ATP5SL A 0.38 0.04 
rs17485781 8 27943481 C8orf80 C 0.94 0.1 
rs17655141 4 44814329 GNPDA2 A 0.92 0.06 
rs2071167 17 39643045 UBTF C 0.76 0.04 
rs217 7 27917546 JAZF1 T 0.64 0.04 
rs2292096 1 199093392 CAMSAP1L1 G 0.12 0.06 
rs2294461 6 6559500 BC031936/AX746739/LY86 C 0.1 0.06 
283 
 
 
SNP CHR Position Nearest gene Risk 
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rs2395858 7 106751669 COG5 G 0.1 0.07 
rs2571445 2 218391399 TNS1 A 0.4 0.04 
rs2681472 12 88533090 ATP2B1 G 0.18 0.04 
rs2736100 5 1339516 TERT A 0.48 0.04 
rs2832227 21 29454947 C21orf7/DKFZp564A247 G 0.16 0.05 
rs2880765 15 83857466 AKAP13 A 0.48 0.04 
rs4149033 12 21209077 SLCO1B1 G 0.77 0.04 
rs4301033 3 151525308 TSC22D2 A 0.09 0.06 
rs4410190 18 18274198 CTAGE1 T 0.47 0.03 
rs4469055 4 148605171 EDNRA G 0.84 0.05 
rs4566357 2 227630259 COL4A4 A 0.38 0.04 
rs4591971 7 130996735 PODXL A 0.26 0.04 
rs4690974 4 156613091 MAP9 C 0.48 0.04 
rs4762911 12 20052013 PDE3A A 0.74 0.04 
rs4793721 17 47166312 CA10 C 0.45 0.03 
rs6088638 20 32934175 ACSS2 C 0.16 0.05 
rs683800 11 125688966 DCPS T 0.56 0.03 
rs6926458 6 160939856 LPA A 0.75 0.05 
rs7074064 10 88673102 BMPR1A C 0.27 0.04 
rs7116641 11 43653493 HSD17B12 G 0.31 0.04 
rs7356185 4 120386559 USP53 T 0.23 0.04 
rs7496815 15 89862501 BC036442 A 0.44 0.04 
rs7561273 2 24101018 LOC388931 A 0.46 0.03 
rs7642590 3 48074754 MAP4/FKSG52 A 0.68 0.04 
rs816889 2 151033541 RND3 G 0.82 0.05 
rs93139 11 9716184 SWAP70 C 0.59 0.04 
rs972158 7 26301532 SNX10 T 0.57 0.04 
rs10947789 6 39282900 KCNK5 T 0.76 0.06 
rs1429141 4 148507517 EDNRA T 0.81 0.07 
rs1561198 2 85663500 GGCX/VAMP10/VAMP8 T 0.45 0.05 
rs16986953 2 19805954 AK097927 A 0.09 0.1 
rs17514846 15 89217554 FES/FURIN A 0.44 0.06 
rs2023938 7 19003300 HDAC9 C 0.11 0.07 
rs2252641 2 145517931 ZEB2-AC074093.1 C 0.45 0.05 
rs264 8 19857460 LPL G 0.85 0.07 
rs273909 5 131695252 SLC22A4/SLC22A5 G 0.13 0.08 
rs2954029 8 126560154 TRIB1 A 0.54 0.05 
rs4252120 6 161063598 PLG T 0.72 0.06 
rs4845625 1 152688691 IL6R T 0.44 0.05 
rs515135 2 21139562 APOB C 0.83 0.07 
rs6544713 2 43927385 ABCG5/ABCG8 T 0.29 0.06 
rs7692387 4 156854759 GUCY1A3 G 0.8 0.07 
rs9319428 13 27871621 FLT1 A 0.32 0.06 
rs11057841 12 123882696 SCARB1 T 0.15 0.07 
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rs11806316 1 115555005 NGF G 0.63 0.04 
rs11916151 3 88363366 C3orf38 T 0.92 0.11 
rs1247351 6 161283909 PLG/MAP3K4 C 0.3 0.05 
rs12765878 10 105659612 OBFC1 C 0.5 0.04 
rs2070783 17 59760703 PECAM1 G 0.54 0.04 
rs2146238 14 99242482 CYP46A1 G 0.84 0.06 
rs246600 5 142497090 ARHGAP26 T 0.48 0.05 
rs2820315 1 200138887 LMOD1 T 0.31 0.05 
rs3748242 10 81904767 ANXA11 T 0.24 0.05 
rs3778448 6 39271179 KCNK5 G 0.33 0.05 
rs4299203 17 17818884 TOM1L2/LRRC48/ATPAF2 G 0.37 0.05 
rs4613862 6 82668990 BC038576 A 0.53 0.04 
rs590121 11 74951798 SERPINH1 T 0.3 0.05 
rs606452 11 74953826 SERPINH1 C 0.86 0.06 
rs6494488 15 62811257 RBPMS2 A 0.82 0.06 
rs6700559 1 198912696 DDX59 C 0.54 0.04 
rs6841581 4 148620640 EDNRA A 0.16 0.07 
rs6984210 8 22089560 BMP1 G 0.07 0.1 
rs8111989 19 50501048 MARK4/CKM C 0.31 0.05 
rs867186 20 33228215 PROCR A 0.89 0.07 
rs9316753 13 54365930 BC044614 C 0.63 0.04 
rs9608859 22 28997277 OSM C 0.58 0.05 
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Appendix 9. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE 
Collaboration): meta-analysis of genome-wide association studies 
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Appendix 10. Candidate Gene Association Study for Diabetic Retinopathy in Persons with 
Type 2 Diabetes: The Candidate Gene Association Resource (CARe) 
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